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Abstract 
Autophagy is a catabolic mechanism by which cytoplasmic components are 
sequestered and transported by a double-membrane vesicle called an autophagosome to 
the lysosome for degradation.  This recycling of organelles and macromolecules 
provides the cell with amino acids in times of nutrient deprivation though we do not 
fully know how the process is triggered or controlled.  It is a highly regulated process in 
mammalian cells and its deregulation has been shown to contribute to multiple diseases. 
In order to find new regulators of mammalian autophagy, I performed a 
genome-wide screen using the Dharmacon human siRNA library in a stable human cell 
line expressing GFP-LC3, a specific marker for autophagosomal membranes.  First I 
incubated the cells with the siRNA pools then I starved the cells of amino acids.  This 
initiated the formation of GFP-LC3-labelled autophagosomes that I quantified using the 
Cellomics VTiScan microscope and accompanying software.  I measured the effect of 
specific siRNA-mediated knock-down on multiple parameters including spot count.  
Accounting for cell death and normalising the data, I generated a Z-score for each 
siRNA pool and retested the best 500 autophagy-increasing and 500 autophagy-
decreasing siRNAs as above.  The 190 strongest siRNA pools were deconvoluted 
leaving 20 hits that reproduced the phenotype with three or four out of four duplexes.  
These 20 hits were then assayed for endogenous LC3 lipidation in a different cell line 
and the ability of their siRNA to reduce mRNA levels was determined. 
Four increasers of GFP-LC3 spots increased endogenous LC3 lipidation, 
suggesting that these proteins are either negative regulators of autophagy or inhibit the 
maturation or degradation of autophagosomes.  Five decreasers of GFP-LC3 spots also 
inhibited endogenous LC3 lipidation and I have characterised two of these proteins 
required for autophagy.  SCOC colocalises with early autophagy markers and may be 
providing a scaffold for autophagy machinery.  WAC, through its reported binding 
partners, may be playing a role in both the autophagic and ubiquitin/proteasome 
pathways. 
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UBL  ubiquitin-like 
UBQ  ubiquitin homologue domain 
µg  microgram 
µL  microlitre 
ULK   unc-51-like kinase 
µM  micromolar 
UPS  ubiquitin-proteasome system 
Vps  vacuolar protein sorting 
WAC  WW domain containing adaptor with coiled-coil 
WD  WD40 repeat domain 
WW  WW domain 
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Chapter 1. Introduction 
1.1 Degradative pathways 
There are two major degradative pathways in mammalian cells: macroautophagy 
and the ubiquitin-proteasome pathway.  Macroautophagy is a catabolic, mostly 
unselective pathway that channels bulk portions of the cytoplasm to the lysosome to 
generate amino acids and macromolecules and is generally responsible for degrading 
long-lived proteins and large cellular structures.  A selective version of autophagy, 
chaperone-mediated autophagy, also uses the lysosome for degradation and responds to 
prolonged nutrient deprivation by recycling a subset of cytosolic proteins.  The 
ubiquitin-proteasome system is responsible for degrading damaged proteins in the 
proteasome and is specific in its selection of proteins and protein aggregates.  By 
balancing these degradative pathways with new protein synthesis, cells are able to 
survive development, grow and maintain equilibrium. 
1.1.1 Macroautophagy 
Macroautophagy, hereafter referred to as autophagy, is a term generated from 
the Greek words, ‘phagy,’ meaning to eat and ‘auto,’ for self.  It is a highly conserved 
intracellular membrane trafficking pathway that is exhibited in all eukaryotes from 
yeast to humans.  It responds to nutrient deprivation as its most evolutionarily 
conserved function but is also triggered by cellular stress and the accumulation of 
protein aggregates and damaged organelles, especially in higher organisms.  Autophagy 
generates the means for survival by degrading cytosolic proteins and whole organelles 
and recycling these back to the cytosol as amino acids and macromolecules.  As a 
result, autophagy maintains cellular homeostasis by clearing the cell of misfolded or 
long-lived proteins and damaged parts and has also developed to rid the cell of invading 
microorganisms. 
Autophagy is characterised by the formation of double-membrane vesicles, 
called autophagosomes that travel to the lysosome where they fuse and the contents of 
which are degraded by hydrolases.  The autophagosome was originally observed using 
microscopy in the late 1950s and was first characterised by de Duve in 1966 when he 
described degradative vesicles that were seen to contain both cytoplasmic components 
and mitochondria (De Duve and Wattiaux, 1966).  He saw the vesicles merge with 
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lysosomes and called the process of ‘nonspecific bulk segregation and digestion’ 
autophagy.  Since a massive resurgence of research into the process of autophagy 
beginning in the early 1990s, cell biologists have dissected the progression of the 
autophagosome from its formation or nucleation, its expansion, its maturation including 
fusion with components of the endocytic pathway and its eventual degradation by the 
lysosome.  Also, great strides have been made to determine how the process is triggered 
and how the autophagy machinery is initiated.  Many autophagy-specific proteins, 
called Atg proteins, have been discovered in yeast through to humans and we know that 
the process requires these components as well as other cytosolic proteins and 
intracellular organelles such as the endoplasmic reticulum (ER) and Golgi apparatus, in 
addition to the endosome-lysosome system. 
During autophagy, cytoplasmic components are sequestered in a growing 
phagophore or isolation membrane (IM) in mammals, called the pre-autophagosomal 
structure, or PAS in yeast (Figure 1.1).  This double-membrane structure expands 
around portions of the cytoplasm containing proteins, aggregated proteins and 
organelles and then closes, forming the autophagic vesicle (AV) or autophagosome.  
Most mature autophagosomes are approximately 0.5 to 1µm in diameter; they can fuse 
with endocytic pathway vesicles including early endosomes, multivesicular bodies 
(MVBs), and late endosomes thus forming amphisomes.  Eventually, the AV fuses with 
the lysosome, becoming an autolysosome, and the acidic hydrolases within break down 
the captured components to macromolecules and amino acids that are released back to 
the cytosol by transporters and permeases delivered with the lysosomal membrane.  
After degradation by autophagy, the recycled products can be used to maintain the cell 
processes whose compromising initiated the entire pathway (Xie and Klionsky, 2007). 
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Figure 1.1 Mammalian autophagy  
During mammalian autophagy, first an isolation membrane (IM), also known as a phagophore is formed 
or nucleated.  The IM engulfs portions of the cytoplasm and can take up mitochondria (blue), misfolded 
proteins and various vesicles in a step called expansion. During maturation, the autophagosome can fuse 
with endocytic vesicles to become an amphisome. The mature autophagosome or amphisome fuses with 
the lysosome and becomes degradative. Adapted from Simonsen and Tooze, (Simonsen and Tooze, 
2009). 
 
Autophagy is responsible for clearing the cell of large structures such as 
organelles and protein aggregates and in this way functions as a sort-of cellular garbage 
disposal.  In yeast, the cytoplasm-to-vacuole (CVT) pathway, which shares many of the 
core components with autophagy, and both pexophagy and mitophagy (the specific 
autophagic degradation of peroxisomes and mitochondria respectively) are considered 
selective forms of yeast autophagy.  Until quite recently mammalian autophagy was 
believed to be an unspecific process, capturing random parts of the cell, but now it is 
believed to also specifically engulf protein aggregates, organelles and bacteria as cargo 
as these have been seen to selectively and exclusively incorporate into autophagosomes. 
The organelle-specific pathways of pexophagy, mitophagy and even ER-phagy have 
been observed in human cells though how these organelles are recognised and targeted 
by the autophagosome is unknown.  In addition, the source of the membrane is a subject 
of intense research and great debate.  In most cases, autophagy allows for cellular 
survival in times of stress such as hypoxia, infection, and starvation though much of the 
pre-nucleation process and the steps leading to its initiation remain to be elucidated.  
Autophagy in mammals is highly evolved and has become a tightly regulated process.  
In turn, its misregulation is associated with many diseases. 
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1.1.2 Chaperone-mediated autophagy 
Chaperone-mediated autophagy (CMA), like macroautophagy, uses the 
lysosome for degradation of cytosolic proteins, but is induced after prolonged nutrient 
deprivation or oxidative stress (Dice, 2007).  CMA is stimulated by molecular 
chaperones such as hsc70 and hsp90 that not only activate the pathway by recognising a 
consensus motif on the proteins that are targeted for degradation, but also unfold the 
substrates.  Then, by directly associating with the lysosomal membrane through 
lysosome-associated membrane protein type 2A (LAMP-2A), proteins are translocated 
into the degradative vesicle.  Levels of LAMP-2A control CMA activity and in turn, 
CMA activity has been suggested to be a factor of ageing.  Like macroautophagy, when 
CMA is compromised it can contribute to disease.  Recently discovered regulators of 
CMA, GFAP and EF1α respond to GTP and explain how CMA is regulated by energy 
levels (Bandyopadhyay et al., 2010), implicating GTP levels as a potential switch 
between CMA and macroautophagy. 
1.1.3 Ubiquitin-proteasome system 
Cellular stress leads to damaged proteins and these accumulate; in order that 
these do not become toxic to the cell, the proteins are unfolded, ubiquitinated and taken 
to the proteasome for degradation.  The ubiquitin-proteasome system (UPS) is a 
selective mechanism that works on abnormal short-lived proteins and sometimes 
organelles and, unlike autophagy, degrades nuclear proteins and misfolded ER proteins.  
Though the previous view was that the UPS and autophagy act in a mutually exclusive 
way, recent work has shown that the two pathways are linked through their common 
modulator, p62/SQSTM1 (Korolchuk et al., 2009). 
1.2 Autophagy core machinery 
The molecular machinery responsible for autophagy initiation and autophagosome 
nucleation and expansion was discovered first in S. cerevisiae through genetic screens 
that identified essential autophagy proteins that respond to amino acid starvation 
(Takeshige et al., 1992), (Tsukada and Ohsumi, 1993).  Currently, there are 34 known 
Atg proteins involved in both autophagy and the CVT pathway in yeast and most, if not 
all, human counterparts of the autophagy-specific proteins have been discovered 
(Klionsky et al., 2003).  In mammals, there are twenty core autophagy proteins (sixteen 
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if one does not consider family members) and multiple auxiliary proteins that contribute 
to and control autophagy.  The human Atg proteins can be divided into four groups 
listed in the order that they are thought to act: the ULK1 kinase complex, the 
Vps34/class III PI3-kinase complexes, the ubiquitin-like proteins Atg12 and Atg8/LC3 
and their conjugation systems, and the Atg9 cycling complex, including WIPI2.  Also, a 
set of proteins is responsible for transferring degraded material back into the cytoplasm.  
The four protein groups act early on in the autophagy pathway and are recruited to the 
isolation membrane and the recent explosion of autophagy research has lead to a 
somewhat comprehensive idea of how they operate to form the autophagosome. 
1.2.1 ULK1 (and ULK2) kinase complex 
The first-identified yeast autophagy gene was ATG1 (Matsuura et al., 1997).  It 
transcribes a serine/threonine kinase that was shown to initiate autophagy directly 
downstream of the amino-acid sensor and the negative regulator of autophagy, TOR 
kinase.  Atg1 initiates both starvation-induced autophagy and the CVT pathway in yeast 
and does so through interactions with at least seven other Atg proteins.  Autophagy is 
initiated through the starvation-dependent dephosphorylation of the interacting partner 
Atg13 that causes it and the third member of the complex, Atg17, to bind Atg1 tightly, 
activating its kinase activity (Kabeya et al., 2005).  This occurs directly as a result of the 
inhibition of TOR either by amino-acid deprivation or treatment with the TOR inhibitor 
rapamycin.  But it is Atg17, not Atg1 or Atg13 that is at the top of the hierarchy of Atg 
proteins, as determined by systematic analysis of yeast mutants (Suzuki et al., 2007).  
Atg1 also seems to play a kinase-independent, structural role in autophagy in that it 
provides a scaffold for and recruits other proteins to the PAS to aid nucleation (for 
review see (Chan and Tooze, 2009)). 
Atg1 in Drosophila and C. elegans (in which it is called UNC-51) together with 
Atg13 and Atg17 are also critical in these organisms’ control of autophagy but Atg1 is 
also involved in apoptosis and development through multiple non-Atg binding partners 
(Chan and Tooze, 2009).  In addition, Atg1/UNC-51 is required for neuronal vesicular 
trafficking and development possibly through its indirect interaction with microtubule 
motors (Toda et al., 2008).  As in yeast, Drosophila Atg13 binds more strongly to Atg1 
during autophagy but opposite to yeast, induction of autophagy upon nutrient 
deprivation in flies is characterised by increased phosphorylation of Atg13 and a loss of 
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phosphorylation of Atg1 by TOR (Chang and Neufeld, 2009).  Also, TOR remains 
complexed with Atg1 in both nutrient-rich and starvation conditions. 
Two of the mammalian homologues of Atg1, called unc-51-like kinase 1 and 2 
(ULK1 and 2) were first discovered to be involved in autophagy by our laboratory in 
2007 (Chan et al., 2007).  The discovery of the Atg17 orthologue came shortly after and 
though it shares little sequence homology to the yeast protein, FIP200, also known as 
RB1CC1 for RB-1inducible coiled-coil 1, shares a functional role as an autophagy 
scaffolding protein (Hara et al., 2008).  FIP200 has been shown to bind ULK1 in both 
nutrient-rich and amino acid-free conditions (Ganley et al., 2009), but ULK1 
phosphorylates FIP200 in starvation (Figure 1.2) and they then travel together to the site 
of autophagosome formation (Jung et al., 2009).  Our lab also uncovered the Atg13 
homologue through sequence analysis and showed that it not only binds both ULK1 and 
ULK2 but is also a substrate for both kinases (Chan et al., 2009).  Atg13 itself binds 
FIP200 (Hosokawa et al., 2009) (Jung et al., 2009) and it is proposed that Atg13 serves 
to stabilise the interaction of ULK1 and FIP200.  Again, ULK1 kinase activity is 
highest when it is complexed together with Atg13 (or FIP200) and Atg13 is seen to go 
to the IM upon starvation (Chan et al., 2009), (Ganley et al., 2009), (Hosokawa et al., 
2009). 
Exciting new research has shown that the mammalian TOR kinase complex, 
mTORC1 directly binds to the ULK1-Atg13-FIP200 complex and that Raptor and 
ULK1 bind in nutrient-rich conditions but dissociate upon starvation (Hosokawa et al., 
2009).  In addition, multiple groups have shown that mTOR directly phosphorylates 
ULK1/2 and also Atg13 (Ganley et al., 2009), (Hosokawa et al., 2009), (Jung et al., 
2009).  Atg101, a fourth Atg13-binding protein that is not conserved in yeast was seen 
to interact with the Atg13-ULK1-FIP200 complex in an Atg13-dependent manner and 
is required for and possibly promotes autophagy by stabilising Atg13 (Mercer et al., 
2009).  Corroborating evidence of the importance of ULK1 and its interactions with its 
adaptor proteins and mTOR itself for the initiation of autophagy, a recent study of the 
hierarchy of mammalian autophagy proteins places ULK1 and FIP200 as the most 
upstream at the site of autophagosome formation (Itakura and Mizushima, 2010). 
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Figure 1.2 ULK1 kinase complex 
In nutrient-rich conditions ULK1 binds to partners Atg13 and FIP200 and also raptor of the mTORC1 
kinase complex. ULK1 autophosphorylates and phosphorylates Atg13. mTORC1 phosphorylates ULK1 
and Atg13. In amino-acid starvation conditions, mTORC1 dissociates from the ULK1 kinase complex 
and no longer phosphorylates ULK1 or Atg13.  ULK1 still autophosphorylates but phosphorylates Atg13 
less. ULK1 also now phosphorylates FIP200. Modified from Chan and Tooze (Chan and Tooze, 2009). 
 
There are five potential paralogues in the ULK family, ULK1, ULK2, ULK3, 
ULK4 and STK36 also known as Fused (Chan and Tooze, 2009).  ULK1 and ULK2 
show the most homology to Atg1 of other species and thus to each other.  ULK3, 
ULK4, and Fused exhibit homology to Atg1 only in their kinase domains.  Being most 
similar, ULK1 and ULK2 share functionality during development in mammals and 
though ULK1 and ULK2 are very similar it is only ULK1 knock-down that inhibits 
starvation-induced autophagy in HEK293 cells; ULK2 is not required (Chan et al., 
2007).  It has been shown that ULK2 binds Atg13 and FIP200 with different efficiency 
to ULK1 (Jung et al., 2009) suggesting that ULK2 cannot be exchanged for ULK1 in 
the model above (Figure 1.2).  We have shown that though overexpression of kinase-
dead versions of both ULK1 and ULK2 blocks autophagy, acting as dominant-
negatives, overexpression of wild-type ULK1 and ULK2 has differential effects (Chan 
et al., 2009).  Confounding, mice with a targeted deletion of ULK1 develop normally 
and exhibit generally functional autophagy, though they do show defects in autophagic 
mitochondrial clearance (Kundu et al., 2008).  The most likely theory to explain the 
discrepancy between the actions of ULK1 and ULK2 is that ULK2 compensates for 
ULK1 during long-term deletion experiments but not short-term siRNA-based knock-
downs.  Recently, a role for ULK3 in autophagy-mediated oncogene induced 
senescence has been described suggesting this paralogue has specific non-starvation-
induced functions (Young et al., 2009). 
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1.2.2 PI3-kinase complexes 
The action of the autophagy-regulating class III PI3-kinase complex, like the 
ULK1 complex, acts early in the process and is required for nucleation of the isolation 
membrane.  It was discovered very early on that treatment with 3-methyladenine (3-
MA), an inhibitor of the PI3-kinases, inhibits autophagy (Seglen and Gordon, 1982).  
Since then, it has emerged that the production of Phosphatidylinositol(3)P, also known 
as PtdIns(3)P or PI(3)P, is essential for the formation of the autophagosome and it is the 
class III phosphatidylinositol (PI) 3-kinase Vps34 that is responsible through its 
phosphorylation of phosphoinositides (PIs) at position 3 on their inositol ring to produce 
PI(3)P (Simonsen and Tooze, 2009).  3-MA also inhibits the class I PI3-kinase that 
produces PI(3,4,5)P3 that in turn activates mTOR by way of Akt/PKB, thereby 
signalling to inhibit autophagy.  However, the effect of inhibition of Vps34 wins out 
over the Akt pathway as the class III PI3-kinase, also known as PI3KC3, and production 
of PI(3)P are both essential requirements for autophagy. 
The lipid kinase vacuolar protein sorting (Vps) 34 and its complex, including the 
Vps15 regulatory subunit and the accessory autophagy proteins Atg14 and Atg6 were 
first described as requirements for autophagy in yeast (Kihara et al., 2001b).  The 
mammalian homologue of Vps15 is p150 and is also called PIK3R4 for 
phosphoinositied-3-kinase, regulatory subunit 4; this protein anchors the Vps34 
complex to membranes (Figure 1.3).  The mammalian homologue of Atg6 is Beclin 1 or 
BECN, a coiled-coil protein, and together with the newly identified human orthologue 
of Atg14, they form the mammalian PI3K Complex 1 (Figure 1.3). 
Human Atg14 was only recently identified and was also called BARKOR, 
standing for beclin 1-associated autophagy-related key regulator (Itakura et al., 2008), 
(Sun et al., 2008).  Atg14 has since been shown to be required for autophagosome 
formation and more specifically for the recruitment of Atg16 and LC3, essential 
proteins of the isolation membrane to be discussed below, to the site of autophagosome 
formation (Itakura et al., 2008), (Zhong et al., 2009), (Matsunaga et al., 2009).  Unique 
as a member of the PI3-K complex, Atg14 interacts with both Beclin 1 and Vps34 and 
its coiled-coil domain is key for its binding.  Atg14 itself is recruited to Atg16-positive 
and LC3-positive IM structures but Atg14 is found on these structures without Beclin 1 
and Vps34 and the kinase activity of Vps34 is not required, suggesting it is Atg14 that 
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dictates when and where autophagosome nucleation occurs possibly by recruiting 
Vps34 to this site and even stimulating its activity (Matsunaga et al., 2009).  
Overexpression of Atg14 increases autophagosome formation and it is required for the 
autophagy-mediated elimination of salmonella (Sun et al., 2008). 
Another coiled-coil protein UVRAG (UV radiation resistance associated gene) 
binds to Beclin 1 (Liang et al., 2006) and UVRAG does not associate directly with 
Vps34 Complex 1 but actually forms a distinct complex containing p150, Vps34 and 
Beclin 1, but not Atg14 (Itakura et al., 2008), (Figure 1.3).  Though Itakura et al claim it 
is not required for autophagy,  Liang et al show that UVRAG directly associates with 
Beclin 1 and is in turn required for autophagy (Liang et al., 2008).  UVRAG seems to 
compete with Atg14 for Beclin 1 binding leading to two mutually exclusive complexes 
(Sun et al., 2008), though the role of the UVRAG complex in autophagy is still 
unknown.  The protein Bif-1, also called SH3GLB1 or SH3-domain GRB2-like 
endophilin B1 may provide some insight; Bif-1 is required for autophagy (Takahashi et 
al., 2007).   Like many others, it has a coiled-coil domain and interacts with Beclin 1 
through a direct interaction with UVRAG.  Bif-1 has other roles in membrane traffic 
and is required for fission of Golgi carriers; it is suggested that Bif-1 may be required 
for autophagosome membrane expansion and curvature through its N-BAR membrane 
curvature domain and its binding to the tethering factor ARF-GAP (Simonsen and 
Tooze, 2009).  Following on, recently Bif-1 was shown not to act on autophagy 
initiation but to regulate degradative endocytic traffic and in turn, autophagosome 
maturation (Thoresen et al., 2010). 
Among the recent eruption of research surrounding the Vps34 kinase complex is 
data describing yet-another Beclin 1-binding protein, RUBICON (an acronym for run 
domain Beclin-1 interacting and cysteine-rich containing protein, still annotated as 
KIAA0226) (Matsunaga et al., 2009), (Zhong et al., 2009).  Rubicon resides in a 
separate complex to UVRAG and binds Atg14, complexing with Beclin 1 and Vps34 to 
form the Rubicon complex (Figure 1.3).  Opposite to Atg14, RUBICON knock-down 
increases autophagy by inhibiting fusion of the autophagosome with the lysosome and 
also the maturation of endosomal vesicles to lysosomes (Matsunaga et al., 2009).  GFP-
tagged RUBICON is found on endosomes and lysosomes and over-expression of 
RUBICON inhibits autophagosome turnover confirming its role as a negative regulator 
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of fusion.  Zhong et al also show that over-expression of the protein causes aberrant 
expansion of late endosomes and lysosomes (Zhong et al., 2009). 
A sixth Beclin 1-binding protein, Ambra1 also contributes to a distinct Vps34 
complex (Fimia et al., 2007), (Figure 1.3).  The WD-repeat-containing protein is not 
only a positive regulator of Beclin 1 but is also required for starvation-induced 
autophagy.  The role of the Ambra1 complex in autophagy initiation is not known. 
 
Figure 1.3 PI3-kinase complexes that control autophagy 
Four distinct PI3-Kinase complexes, Complex 1, the UVRAG Complex including UVRAG-binding 
protein Bif-1, the Rubicon Complex and the Ambra1 complex are shown. The complexes all share the 
components p150, Vps34, and Beclin 1 (BECN).  Complex 1 and the Ambra1 complex are positive 
regulators of autophagy while the Rubicon complex is a negative regulator. Contrasting roles of the 
UVRAG complex are reported. Adapted from Simonsen and Tooze (Simonsen and Tooze, 2009). 
 
Though p150 is a shared regulatory component of the complex and Vps34 is the 
essential kinase, Beclin 1 is the protein that mediates the interactions of the auxiliary 
proteins that distinguish the four known complexes.  Through its differential binding, 
Beclin 1 may act as a switch between the complexes in order to coordinate the 
regulation of autophagy in highly evolved species.  As a master regulator, Beclin 1 may 
balance autophagosome nucleation and maturation by toggling between Complex1 and 
the UVRAG complex and also the RUBICON complex.  Beclin 1 also plays a role in 
apoptosis through its binding to the anti-apoptotic protein Bcl-2 (Pattingre et al., 2005).  
Bcl-2 negatively regulates Beclin 1 by keeping it away from its PI3-kinase complex 
partners and thereby preventing autophagy.  Beclin 1 may not only be important for the 
balance of autophagosome formation and maturation but sits between autophagy and 
apoptosis, making it an important modulator of cell death versus survival. 
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1.2.3 Ubiquitin-like conjugation systems 
Two ubiquitin-like conjugation reactions produce the Atg5-Atg12-Atg16 
complex and lipidated Atg8 and are essential for the formation and elongation of the 
autophagosome.  Many detailed studies have resulted in a thorough understanding of 
how these critical autophagy proteins contribute to the expansion of the double-
membrane vesicle (Klionsky, 2005). 
1.2.3.1 Atg12 conjugation reaction 
In mammalian cells, Atg12, a ubiquitin-like (UBL) protein is conjugated to Atg5 
through a multi-step conjugation reaction that requires the enzymatic activities of E1-
like and E2-like proteins.  First Atg12 is activated by the E1-like enzyme Atg7 and then 
transferred to the E2-like enzyme Atg10 which then catalyses the conjugation of Atg5 
to Atg12 (Mizushima et al., 1998b), (Figure 1.4).  Subsequently, the Atg5-Atg12 
complex is covalently bound to Atg16 and this trimeric complex homodimerises to 
become a large, 800 kDa complex (Mizushima et al., 2003).  Mammalian Atg5 is an 
important marker for early autophagosome formation and GFP-tagged Atg5 localises to 
the isolation membrane (Mizushima et al., 2001).  Atg5 is an essential gene and is 
required for survival in the post-natal starvation period (Kuma et al., 2004).  
Mammalian Atg16 differs from yeast in that it contains a C-terminal WD40 repeat 
domain for multi-protein complex assembly and, as mentioned above, is recruited to the 
isolation membrane, most likely by Atg14. 
 
 
Figure 1.4 Atg5-Atg12 conjugation system 
Atg5 is conjugated to a C-terminal glycine on the UBL Atg12 through the actions of the E1-like Atg7 and 
E2-like Atg10. Atg16 is added to the complex which then homodimerises. 
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1.2.3.2 Atg8/LC3 conjugation reaction 
Atg8, the yeast UBL protein that is lipidated and integrated into the 
autophagosomal membrane has multiple homologues in mammals grouped into LC3-
like and GABARAP-like subgroups.  LC3, short for microtubule-associated protein 1 
light chain 3 beta, is the best characterised Atg8 homologue and was the first to be 
shown to localise to the autophagosome with electron microscopy (EM) (Kabeya et al., 
2000).  To begin the LC3 lipidation reaction, LC3 is primed by the cysteine 
endopeptidase Atg4, exposing a C-terminal glycine (Hemelaar et al., 2003), referred to 
as the LC3I form.  Next, Atg7, which serves as the E1-like enzyme for both conjugation 
reactions, activates LC3 and then the E2-like enzyme Atg3 facilitates the conjugation of 
phosphatidylethanolamine (PE) to LC3 (Tanida et al., 2002), (Figure 1.5).  In the same 
way, GABARAP and GABARAPL2 (also known as GATE16) can be post-
translationally processed and bound to PE (Kabeya et al., 2004).  It has been 
demonstrated that phosphatidylserine (PS) can also be conjugated to LC3 in vitro (Sou 
et al., 2006) but it has been shown that factors such as the pH of the cytosol in vivo 
dictate the preferential lipidation of LC3 with PE (Oh-oka et al., 2008).  Once LC3 is 
lipidated and becomes part of the autophagosome, it remains membrane-bound and can 
be followed from isolation membrane expansion until fusion with and degradation by 
the lysosome.  As a result, LC3 and GFP-tagged LC3 are bone fide markers of the AV 
(Rubinsztein et al., 2009), and we can measure LC3’s flux through the pathway visually 
or by western blot analysis in order to monitor autophagy (Klionsky et al., 2008). 
After closure of the autophagosome, Atg4 cleaves LC3 from PE thereby 
removing LC3 from the mature autophagosome (Tanida et al., 2004), a step that is 
critical for its fusion with endosomes and lysosomes.  Experiments with an Atg4 mutant 
have shown that priming LC3 is critical for the early Atg7-mediated step of the 
conjugation pathway but the Atg4 mutant also led to defects in the closure of the 
expanded autophagosome, suggesting that the lipidated, or LC3II form of the protein is 
needed for the membrane curvature required to close the vesicle (Fujita et al., 2008). 
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Figure 1.5 LC3 is conjugated to PE 
Atg4 cleaves a C-terminal cysteine on LC3, exposing a glycine to which Atg7 is added then replaced by 
Atg3, which catalyses the conjugation of the phospholipid, phosphatidylethanolamine (PE) to LC3. The 
unlipidated form of LC3 is referred to as LC3I and the lipidated as LC3II. Adapted from Sou et al, (Sou 
et al., 2006). 
 
1.2.3.3 Cross-talk between the two ubiquitin-like pathways 
Current evidence points to an interplay between the ubiquitin-like conjugation 
pathways, beyond sharing their E1-like enzyme Atg7.  It is generally believed that the 
Atg5-Atg12 reaction occurs upstream of the LC3 lipidation pathway and a recent paper 
solidifies the notion that the Atg5-Atg12-Atg16 complex lies before LC3 lipidation in 
that the trimeric complex is required for the recruitment of LC3II to the site of 
autophagosome formation (Fujita et al., 2008).  The authors, by artificially forcing 
Atg16 to the plasma membrane, captured lipidated LC3 on the PM where it is normally 
not seen.  Because LC3 has no localisation signal of any kind, they suggest that Atg16 
defines the site of vesicle formation.  In addition, exciting evidence shows, at least in 
vitro, that the Atg5-Atg12 complex acts as an E3-like enzyme, conferring specificity to 
the conjugation of LC3 to PE (Hanada et al., 2007).  Conversely, overexpressed Atg3 
enhances Atg5-Atg12 conjugation (Tanida et al., 2002) and it has been shown that LC3 
conjugation is important for the formation of the Atg5-Atg12 complex using Atg3 
negative mouse embryonic fibroblasts (MEFs), which are impaired for Atg5-Atg12 
conjugation (Sou et al., 2008).  Supporting the role for lipidated LC3 in membrane 
fusion or closure, these Atg3 negative cells also show a distinct reduction of 
autolysosomes.  Solidifying the evidence for cross-talk between the two pathways, 
Atg3, the E2-like enzyme for LC3 lipidation is also a substrate for Atg12 conjugation 
(Radoshevich et al., 2010).  Though this novel Atg3-Atg12 conjugate is not required for 
starvation-induced autophagy it does seem to regulate mitochondrial homeostasis 
Chapter 1. Introduction 
 32 
because without it, mitochondria were seen to swell and mitochondrial-mediated cell 
death was compromised. 
1.2.4 Atg9 recycling complex and WIPI2 
The only membrane-spanning autophagy core complex protein is Atg9.  It has 
six trans-membrane spanning domains and its association with membrane and 
extrapolation from yeast studies suggests that mammalian Atg9 (mAtg9) may deliver 
membrane to forming autophagosomes; but as of now, there is no known function 
designated to Atg9.  In yeast, Atg9 is seen to cycle between the PAS and a peripheral 
pool that has recently been shown to comprise of clusters of vesicles and tubules often 
found close to mitochondria (Mari et al., 2010).  Atg1 is required for this cycling but 
Atg9’s movement is not dependent on Atg1 kinase activity (Reggiori et al., 2004).  The 
localisation of Atg9 to the PAS depends on a small set of proteins: Atg2, Atg8, Atg14, 
and Atg18 (Suzuki et al., 2007), and retrieval from the PAS, which occurs prior to 
autophagosome formation requires Atg1, Atg2, Atg18, which localises Atg2 and PI3-
kinase (Reggiori et al., 2004).  The mammalian homologue of Atg2 has been annotated 
but to this date, has not been characterised. 
Mammalian Atg9 is required for autophagy and is an essential gene for survival; 
Atg9 knock-out mice cannot survive past P0 much like Atg3, Atg5 and Atg7 knock-out 
mice (Saitoh et al., 2009).  Similar to yeast Atg9, mAtg9 cycles between two pools, 
residing in a juxta-nuclear Golgi pool in full medium but dispersing to a peripheral, 
perhaps endosomal, pool upon amino-acid withdrawal (Young et al., 2006).  As in 
yeast, this translocation requires ULK1 and we recently showed that it also requires 
Atg13 (Chan et al., 2009).  Regulation of autophagy was recently linked to the p38 
MAP kinase pathway through Atg9, for it was demonstrated that the cycling of Atg9 
requires the Atg9- and p38-interacting protein p38IP and through these interactions, 
p38α acts as a negative regulator of autophagy (Webber and Tooze, 2010). 
Atg18 interacts with Atg9 in yeast and recently the mammalian homologues of 
Atg18, WIPI (WD-repeat protein Interacting with PhosphoInosides) family proteins, 
have been characterised (Proikas-Cezanne et al., 2004), (Polson et al., 2010).  WIPI2 is 
contains a non-canonical PI(3)P binding region and WIPI2, as well as being required for 
autophagy, forms puncta upon starvation that partially localise with Atg16, GFP-LC3 
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and ULK1, placing it very early in the hierarchy of autophagy proteins.  As it is not 
seen to bind endosomes, WIPI2 is thought to be a specific effector of the autophagy-
specific cellular pool of PI(3)P. 
 
Figure 1.6 Putative mammalian Atg9 recycling complex 
Mammalian Atg9, with its six transmembrane-spanning regions, is shown. Atg9-interacting protein p38IP 
and putative interacting partners Atg2 and WIPI2, the mammalian homologue of Atg18, are shown. 
ULK1 is required for the relocalising of Atg9 from the Trans-Golgi network (TGN) to a peripheral pool. 
 
 
1.2.5 Summary of mammalian and yeast Atg proteins 
Mammalian 
name 
Mammalian 
reference 
Function Yeast name Yeast 
reference 
ULK1 (Chan et al., 2007) Serine/threonine kinase ATG1 (Matsuura et al., 
1997) 
ULK2 (Chan et al., 2007) Serine/threonine kinase N/A N/A 
ULK3 (Young et al., 
2009) 
Serine/threonine kinase N/A N/A 
ATG2 x Interacts with ATG18 ATG2 (Reggiori et al., 
2004) 
ATG3 (Tanida et al., 
2002) 
E2-like enzyme for LC3 
lipidation 
ATG3 (Schlumpberger 
et al., 1997) 
ATG4 (Hemelaar et al., 
2003) 
Cysteine protease primes 
Atg8/LC3 
ATG4 (Lang et al., 
1998) 
ATG5 (Mizushima et al., 
2001) 
Conjugated to Atg12 ATG5 (Mizushima et 
al., 1998a) 
BECN1 (Liang et al., 
1999) 
Core component of the 
Vps34 PI3-kinase complex 
ATG6/VPS30 (Kihara et al., 
2001b) 
ATG7 (Tanida et al., 
2002) 
E1-like enzyme ATG7 (Tanida et al., 
1999) 
MAP1LC3B (Kabeya et al., 
2000) 
UBL conjugated to PE; 
incorporated into AV 
membrane 
ATG8 (Lang et al., 
1998) 
GABARAP (Kabeya et al., 
2004) 
UBL conjugated to PE N/A N/A 
GABARAPL2 (Kabeya et al., 
2004) 
UBL conjugated to PE N/A N/A 
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ATG9 (Young et al., 
2006) 
Integral membrane protein ATG9 (Noda et al., 
2000) 
ATG10 (Mizushima et al., 
1998b) 
E2-like enzyme for Atg5-
Atg12 conjugation 
ATG10 (Mizushima et 
al., 1998a) 
ATG12 (Mizushima et al., 
1998b) 
Ubiquitin-like protein 
conjugated to Atg5 
ATG12 (Mizushima et 
al., 1998a) 
ATG13 (Chan et al., 2009) Phosphoprotein; part of 
ULK1 kinase complex 
ATG13 (Funakoshi et 
al., 1997) 
ATG14 (Itakura et al., 
2008), (Sun et al., 
2008) 
Protein binder; accessory to 
the Vps34 PI3-kinase 
complex 
ATG14 (Kihara et al., 
2001b) 
ATG16 (Mizushima et al., 
2003) 
Atg5-Atg12 super complex 
component 
ATG16 (Mizushima et 
al., 1999) 
FIP200 (Hara et al., 2008) Scaffolding protein ATG17 (Kamada et al., 
2000) 
WIPI2 (Polson et al., 
2010) 
Mammals: PI(3)P-binding 
protein. Yeast: membrane 
protein that localises Atg2 
ATG18 (Barth et al., 
2001) 
Table 1.1 Summary of the mammalian autophagy genes 
The mammalian name, yeast name and function and corresponding references for 20 autophagy genes are 
listed. Adapted from Klionsky et al (Klionsky et al., 2003). 
 
 
1.3 Autophagy signalling/regulation of autophagy 
In yeast, autophagy is directly activated by the loss of negative regulation by TOR 
through amino acid starvation or TOR inhibition with rapamycin (Noda and Ohsumi, 
1998).  In mammalian cells, the mTOR kinase complex mTORC1 also acts as the key 
negative regulator of autophagy as well a positive regulator of cell growth and 
autophagy is activated by inhibition of TOR with drugs such as rapamycin (Figure 1.7).  
Amino acids stimulate TOR and promote the phosphorylation of ribosomal S6 protein 
(RS6) by p70S6 kinase and a decrease in phosphorylated RS6 reflects an induction of 
autophagy by starvation or rapamycin (Blommaart et al., 1995).  Recently, Rag 
GTPases and three proteins in a complex called the ‘Ragulator’ have been shown to 
signal mTOR in response to amino acid starvation and also translocate mTOR to the 
lysosome membrane (Sancak et al., 2010).  mTOR loss stimulates autophagy by directly 
affecting ULK1, but adding complexity, ULK1 and ULK2 have been shown to 
feedback to the mTOR-p70S6 kinase pathway (for review, see (Chan and Tooze, 
2009)).  In fact, in Drosophila autophagy inhibits cell growth and Atg1 itself can 
directly inhibit Tor signalling suggesting positive feedback (Neufeld, 2007).   
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Nutrients like amino acids can directly signal mTOR through the Rag-Ragulator 
complex but a lack of amino acids can also activate autophagy independently from 
mTOR.  For instance, amino acids inhibit the Raf-1-MEK1/2-ERK1/2 signalling 
cascade that in turn inhibits autophagy (Ogier-Denis et al., 2000).  Other TOR-
independent autophagy activation pathways have been reported including that induced 
by lithium chloride, which appears to act through modulation of myo-inositol-1,4,5 
triphosphate (IP3) levels (Sarkar et al., 2005).  Although conflicting data does exist, one 
group reports that resveratrol also drives autophagy independent of TOR by activating 
sirtuins that deacetylate autophagy proteins which activates autophagy (Morselli et al., 
2010). 
As previously discussed, 3-MA and also wortmannin inhibit autophagy through 
the inhibition of the class III PI3-K product PI(3)P; but 3-MA also inhibits class I PI3-K 
which is a negative regulator of autophagy through the Akt-TSC1/2-Rheb-mTOR 
signalling pathway (Petiot et al., 2000).  Growth factor (insulin) signalling inhibits 
autophagy through stimulation of IRS1 and IRS2, which activate the class I PI3-kinase.  
Alternately, overexpression of PTEN stimulates autophagy by inhibiting the inhibitory 
Akt pathway (Arico et al., 2001).  The anti-apoptotic protein Bcl-2 inhibits autophagy 
by sequestering Beclin 1 away from Vps34 and it was recently demonstrated that 
starvation removes Bcl-2, through direct phosphorylation by JNK1, from the class III 
PI3-kinase complex 1 (Wei et al., 2008).  In addition, energy inhibits LKB1, a positive 
regulator of autophagy that activates AMPK (which also senses reduced ATP levels 
itself), and this pathway is activated in stress conditions (Liang et al., 2007).  
Autophagy is also influenced by p53, a master regulator of cell cycle progression and 
apoptosis, in opposing ways.  Basal levels of the cytoplasmic form of the protein inhibit 
autophagy and its degradation leads to the induction of autophagy (Tasdemir et al., 
2008a) but in times of cellular stress, p53 can activate both autophagy and apoptosis 
(Vousden and Ryan, 2009). 
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Figure 1.7 Mammalian autophagy signalling 
Inhibitory (red) and activating (blue) autophagy signalling proteins. Nutrients (amino acids, glucose) and 
insulin and other growth factors inhibit autophagy through multiple pathways. 3-MA is 3-methyladenine, 
rapa is rapamycin.  Adapted from Yang and Klionsky (Yang and Klionsky, 2010). 
 
1.4  Source of the autophagosome membrane 
Though many of the essential proteins and machinery required for autophagosome 
nucleation and expansion are known (as discussed above), the source of the membrane 
and the mechanism for IM formation are mostly unknown.  The origin of the membrane 
has been in question since the discovery of the double membraned vesicle and is 
recently the subject of intense debate and concentrated research.  Autophagy scientists 
strive to determine whether the membrane forms de novo from localised lipid synthesis 
or is derived from a pre-existing organelle or organelles.  In yeast it is perhaps more 
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simple, as autophagosomes always form at the PAS and next to the vacuole.  But in 
mammalian cells, autophagosomes seem to be able to form anywhere in the cytoplasm 
and a distinct place of origin, like the PAS, does not exist.  Isolation membranes may 
form from a PAS-like structure or the IM itself could be the mammalian equivalent of 
the PAS, but this is not known.  Perhaps the difficulty arises from a lack of protein 
markers, both for the autophagosome and of other membrane sources found in the 
autophagosomal membrane (Overbye et al., 2007).  Using current methods, it is difficult 
to differentiate between the autophagosome membrane and the membrane of the 
organelles it engulfs and our two primary marker proteins, Atg5 and LC3 associate with 
the isolation membrane only after it begins to form so earlier markers and non-transient 
markers are needed (Tooze and Yoshimori, 2010).  Multiple recent studies have 
increased our knowledge of the origin of the autophagosome and point to the ER, 
mitochondria and even the plasma membrane as possible sources of the membrane 
(Hayashi-Nishino et al., 2009), (Yla-Anttila et al., 2009), (Hailey et al., 2010), 
(Ravikumar et al., 2010). 
1.4.1 De novo formation of autophagosomes 
The autophagosome membrane is unique in many ways.  Containing two lipid 
bilayers, the organelle requires a large amount of membrane, but a distinct lack of 
organelle markers obtained from purified fractions of the mammalian autophagosomes 
is remarkable (Stromhaug et al., 1998).  In addition, the autophagosome membrane is 
for the most part devoid of transmembrane proteins and, in general, the membrane is 
relatively protein-poor (Fengsrud et al., 2000).  These findings suggest that 
autophagosomes are distinct from other membrane-bound vesicles, supporting a de 
novo mechanism of lipid synthesis and construction in unspecified locations throughout 
the cell.  To this date, however, no lipid synthesising enzymes have been found at the 
phagophore assembly site. 
1.4.2 Golgi apparatus as a source of the autophagosomes 
In yeast, the Golgi apparatus is the only organelle with evidence to support its 
donation to the autophagosome membrane.  The essential membrane-bound protein 
Atg9, as discussed previously, cycles between the Golgi and various cytoplasmic 
punctate structures and is hypothesised to be involved in supplying membrane to the 
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PAS.  Upon starvation, Atg9 disperses and the peripheral Atg9-containing structures are 
essential for the generation of the PAS and have been shown to be derived from the 
Golgi (van der Vaart and Reggiori, 2010).  Recently, multiple Golgi proteins have been 
shown to play a role in autophagy in yeast.  Golgi-localising Sec7 and guanine 
nucleotide exchange factors (GEFs) Gea1 and Gea2 control autophagy by activating 
GTPases Arf1 and Arf2 (van der Vaart et al., 2010).  The GEFs normally control exit 
from the Golgi but their function is also required for autophagy; interestingly, they seem 
to be required not for PAS localisation but for expansion of the phagophore.  
Independently, Dan Klionsky’s group have shown that the post-Golgi proteins Sec2 (a 
GEF) and downstream GTPase Sec4 are also required for autophagy perhaps by 
diverting membrane to the Golgi to expand the autophagosome (Geng et al., 2010).  
Last, the TRAPP complex 3, which serves as a Golgi tethering factor has been shown to 
localise to the PAS (Yen et al., 2010).  The subunits of the conserved oligomeric Golgi 
(COG) are involved in autophagosome formation and are speculated to fuse together 
Golgi-derived membranes and the PAS.  Perhaps Atg9 is also acting as a Golgi-derived 
regulator of this process, helping to tether together the Golgi and the PAS because Atg9 
directly interacts with the COG subunits and Sec7 mutants show a blockage of transport 
of Atg9 membranes to the PAS, thereby inhibiting autophagosome formation (van der 
Vaart et al., 2010). 
Extrapolating to mammalian cells, Atg9 could also shuttle membrane to the 
growing phagophore and Atg9 is recruited to the forming autophagosome from the 
TGN where it localises in nutrient-rich conditions.  Although more evidence for the role 
of Atg9 in vesicle expansion is needed, its subcellular localisations support a role for 
both the juxta nuclear Golgi region and endosomal compartments.  Like Atg9, Beclin 1 
localises to the TGN in full growth conditions (Kihara et al., 2001a) and is essential for 
IM nucleation.  Bif-1 is another Golgi-resident protein (it is also associated with 
mitochondria) and it activates class III PI3-kinase to induce autophagy (Takahashi et al., 
2007) and more recently is linked to autophagosome expansion and maturation 
(discussed above).  Together, these proteins support a role for a post-ER Golgi 
compartment in the formation of the autophagosome. 
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1.4.3 Endoplasmic reticulum (ER) as a source for the autophagosome 
Original observations of mammalian autophagosome lead De Duve to believe 
that the autophagic vesicles’ membrane came from pre-existing membrane like the ER 
(De Duve and Wattiaux, 1966), though it has been difficult to distinguish between the 
autophagic degradation of the ER (ER-phagy), a process that was discovered early on in 
autophagy research (Bolender and Weibel, 1973), and the use of the ER membrane for 
the formation of the autophagosome. 
Recent exciting data illustrates how the endoplasmic reticulum forms a platform 
for autophagosome formation.  The discovery of the ER protein DFCP-1 links the ER to 
autophagosome formation (Axe et al., 2008).  Through its double FYVE-domain, 
DFCP-1 binds the autophagic pool of PI(3)P and translocates from the Golgi to sites 
close to ER membrane where it congregates in response to amino acid starvation.  
These sites, called omegasomes, are rich in PI(3)P and autophagosomes are seen to 
emerge from the omegasome.  Though knock-down of DFCP-1 does not inhibit 
starvation-induced autophagy, the recruitment of ULK1, Atg14 and also the PI(3)P 
effector protein WIPI2 to the omegasome is essential (Axe et al., 2008), (Polson et al., 
2010).  The ER membrane is not rich in PI(3)P and so it is critical that the PI(3)P-
binding protein WIPI2 translocates to omegasomes in order bring the phospholipid so 
that omegasomes progress to autophagosomes.  DFCP-1-containing omegasomes serve 
as ER platforms for the recruitment of the Atg5 and then LC3 and in turn, 
autophagosome formation, though the physical properties that anchor the omegasome to 
the ER and then allow the autophagosomes to bud off from the omegasome remain to 
be discovered. 
Two complementary tomography studies have demonstrated physical 
interactions between the isolation membrane and the ER (Hayashi-Nishino et al., 2009), 
(Yla-Anttila et al., 2009). Tomatsu Yoshimori’s group show in NIH3T3 cells and 
MEFs, that the IM and the ER are interconnected.  They demonstrate isolation 
membranes sandwiched between two ER membranes, labelled with DFCP-1; the ER-
juxtaposed phagophores suggest a “cradle” model where enwrapped isolation 
membranes grow out of omegasomes.  Eeva-Liisa Eskelinen’s tomography work on 
normal rat kidney cells also reveals connections between the ER and phagophore and 
they show enriched ER membranes within the budding autophagosomes. 
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As mentioned, the ER is not an ample source of PI(3)P and thus this lipid must 
be recruited to omegasomes in order for autophagy to proceed.  Most recently, it was 
uncovered that Atg14 targets the PI3-kinase complex to the ER leading to the 
production of PI(3)P and the recruitment of autophagy proteins (Matsunaga et al., 
2010).  Knock-down of Atg14 abolishes the omegasome, suggesting that Atg14 anchors 
to the ER and recruits DFCP-1 and the ER localisation of Atg14 is critical for 
autophagosome formation.  Atg14 localises to the ER in nutrient-rich conditions, 
contains an ER-targeting domain and is enriched in the organelle upon starvation, a 
process that requires ULK1. 
1.4.4 Mitochondria as a source for the autophagosome 
One artificial marker of the mitochondrial outer membrane has lately been 
shown to also colocalise with the autophagy proteins Atg5 and LC3 (Hailey et al., 
2010).  Experiments suggest that the colocalisation of tagged LC3 and an outer leaflet-
anchored protein is not due to selective autophagic degradation of the mitochondria 
(mitophagy) and the authors believe that this phenomenon has been underreported 
because people ascribe similar findings to mitophagy.  Using high-resolution imaging, 
the group shows that autophagosomes colocalise with mitochondria but also establish 
that mitochondrial membrane proteins are sterically excluded from the forming 
autophagosomes.  A protein that connects the ER to the mitochondria, mitofusin2, is 
critical for autophagy induction suggesting that interplay between the two organelles is 
important.  Also, the ER and the mitochondria have recently been shown to connect 
through the ERMES protein complex (Kornmann, 2010).  Mitochondria are more 
enriched for PE than the ER and could supply newly synthesised lipid for forming 
autophagosomes. 
1.4.5 Plasma membrane as a source for the autophagosome 
LC3 can also be recruited to plasma membrane (PM)-derived membranes 
(Sanjuan et al., 2007) and recent evidence suggests that endocytic clathrin coated 
vesicles (CCVs) derived from the PM contribute to the formation of isolation 
membranes (Ravikumar et al., 2010).  David Rubinsztein’s group discovered that Atg16 
interacts with clathrin heavy chain (CHC) and AP2 which are required for vesicle 
budding from the PM and sorting endosomes and cargo recruitment to CCVs onto the 
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PM and early endosomes respectively.  Knock-down of CHC and AP2 significantly 
decreased basal autophagy and blocking clathrin-dependent endocytosis inhibited the 
number of newly formed autophagosomes, though marginally, suggesting that the PM is 
not the only source of the membrane.  Atg16 was found on IM precursor structures 
close to the plasma membrane and marking these membranes with cholera toxin lead to 
the incorporation of the toxin in the autophagosomal membrane.  The plasma membrane 
is highly dynamic and contains a large amount of lipid bilayer that may be utilised when 
a drastic increase in the number of autophagosomes is required, like during amino-acid 
starvation. 
Taken together, these results suggest that the Golgi, ER and mitochondria are 
important for autophagosome formation.  In addition, it has been demonstrated that 
endosomes are required for autophagy (for review, see (Longatti and Tooze, 2009)).  
Together with the plasma membrane, all of these could be sources of lipid for the 
autophagosomes.  The origin of the isolation membrane is difficult to determine 
because it seems that ER or mitochondrial membrane proteins are excluded from newly 
formed autophagosomes.  It is conceivable that there are multiple sources of the AV 
membrane and that different inductions of autophagy exploit different membranes, 
especially basal versus starvation-inducing conditions, and even different cargos may 
dictate membrane recruitment.  In addition, supply of the membrane could depend on 
the organism or cell or tissue type.  Overall, the diverse nature of the formation of the 
autophagosome supports the notion that autophagy is critical but adaptable. 
1.5 Role of p62 in autophagy 
Autophagy is responsible for the degradation of long-lived proteins but also 
degrades damaged or unfolded proteins.  These short-lived proteins become 
polyubiquitinated and are targeted to the UPS but can also be sent to the autophagy 
pathway.  p62, also known as sequestosome 1 (SQSTM1) is responsible for directing 
these proteins to the autophagosome; it is a multi-functional adaptor protein that binds 
polyubiquitinated proteins and aggregates by oligomerisation (Wooten et al., 2008). 
Though p62 is not required for starvation-induced autophagy, it is a specific substrate 
for the process and its autophagy-induced degradation can be used as a read-out for 
autophagy function (Pankiv et al., 2007).  In addition to binding ubiquitin (Ub), it also 
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binds to LC3 thereby recruiting the ubiquitinated proteins to the autophagosome (Shvets 
et al., 2008b), (Ichimura et al., 2008).  Even large p62-positive inclusions can be 
degraded by basal constitutive autophagy making it an important neuroprotective 
process and the p62-dependent formation and degradation of polyubiquitin-containing 
bodies by autophagy maintains cell health.  Together with LC3, p62 forms a casing 
around aggregates of mutant huntingtin thereby protecting the cell against Huntingtin-
induced cell death (Bjorkoy et al., 2005).  p62 has recently been demonstrated to 
translocate into the nucleus where it colocalises with promyelocytic leukaemia (PML) 
bodies and the nucleoplasm to cytoplasm shuffling of p62, which is possibly controlled 
by phosphorylation events, may serve as a regulatory mechanism for its role in 
autophagy (Pankiv et al., 2010). 
Another LC3- and Ub-binding protein, neighbour of BRCA1 gene 1 (NBR1), also 
serves as autophagic receptor for ubiquitinated targets (Kirkin et al., 2009).  Like p62, 
NBR1 contains an LC3-interacting region (LIR) and this motif is required for NBR1’s 
degradation by autophagy, though p62 is not required.  It seems that NBR1 cooperates 
with p62 to direct autophagic degradation of ubiquitinated targets and both can serve as 
markers of pathological inclusions.  The clearance of these inclusions is an important 
homeostatic function that autophagy has gained in higher organisms, although the exact 
mechanism of how autophagy selectively degrades these substrates is not known. 
1.6 Autophagy in Disease 
Autophagy serves a critical purpose by regenerating macromolecules and amino 
acids to be used for the maintenance of vital cellular functions after conditions of 
cellular stress such as hypoxia, starvation and infection.  Autophagy is also required 
during poor growth conditions directly after birth when nutrient supply from the 
placenta is disrupted.  These are all normal situations cells or organisms will face and 
autophagy has adapted to maintain cellular house-keeping and protects against 
pathogens and aggregate-prone proteins; but when autophagy is disrupted multiple 
diseases can occur (Mizushima et al., 2008).  In addition, the cell may use autophagy to 
fight xenobiotic invasion and other diseases.  Thus, efficient autophagy is essential for 
cell heath and contributes to normal ageing and immunity as well as disease and cell 
death. 
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1.6.1 Crohn’s Disease 
A direct link between autophagy and inflammatory bowel disease was found as 
mutations in two autophagy genes are associated with increased Crohn’s disease risk.  A 
single Thymine to Adenine mutation of ATG16 confers increased risk and highlights 
the importance of autophagy in intestinal homeostasis and also immunity, both of which 
are involved in Crohn’s disease (Hampe et al., 2007), (Rioux et al., 2007).  It was 
shown that ATG16 is broadly expressed in the intestinal system as well as in immune 
cells.  The T300A mutation is in the C-terminal WD repeat of the protein, a region not 
conserved in yeast, and neither the WD domain nor the mutated Thymine are required 
for canonical autophagy (Fujita et al., 2009).  Instead, this region may be important for 
the stability of the Atg16 protein as the level of Atg16 is important for autophagy and 
Fujita et al suggest the levels are tightly maintained by the UPS.  A mutation in the 
immunity-related GTPase family, M (IRGM) gene is also implicated in Crohn disease 
risk (Parkes et al., 2007).  IRGM activates autophagy and clears intracellular 
mycobacteria through the induction of large autolysosomes (Singh et al., 2006).  
Together with other studies on the role of autophagy in both innate and adaptive 
immune responses (reviewed in (Levine and Deretic, 2007)), (Munz, 2010), these 
findings show that autophagy can capture and eliminate intracellular bacteria, process 
antigens for presentation, enhance innate immune responses and even control epithelial 
and immune cell fate thereby playing a critical role in cellular defence against 
pathogens. 
1.6.2 Cancer 
The cytoprotective functions of autophagy including the removal of damaged 
proteins and organelles and its response to cellular stress to mitigate damage caused by 
genotoxic stress not only restore balance but also protect the cell from cancer.  In turn, 
multiple autophagy proteins are known tumour suppressors.  Beclin 1 is a 
haploinsufficient tumour suppressor and the deletion of one Beclin 1 allele occurs in 40-
75% of human breast, prostate, and ovarian cancer (Liang et al., 1999), (Aita et al., 
1999).  Beclin 1+/- mice develop spontaneous tumours (Yue et al., 2003) and, as 
discussed above, Beclin 1 not only plays a critical role in autophagy but is also involved 
in apoptosis with Beclin 1 and the Bcl-2 antiapoptotic proteins controlling the balance 
between the two systems.  UVRAG is also a tumour suppressor and overexpression of 
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the gene in a colon cancer cell line with a UVRAG mutation rescued autophagy (Liang 
et al., 2006).  Mice lacking Atg4C show increased tumourigenesis due to impaired 
autophagy (Marino et al., 2007) and hypermethylation of Atg16 is associated with 
poorer prognosis in response to anti-cancer treatments (Dunwell et al., 2010) and as in 
Crohn’s disease, the levels of Atg16 protein may dictate autophagy function.  Also, the 
loss of PTEN function in cancer cells inhibits autophagy suggesting that autophagy 
contributes to the important tumour suppressor properties of PTEN (Arico et al., 2001).  
The role of the classic tumour suppressor p53 in autophagy is more complicated most 
likely due to the diverse cellular functions it controls including apoptosis, senescence, 
DNA repair and even metabolism (Vousden and Ryan, 2009).  As mentioned above, 
basal cytoplasmic p53 inhibits autophagy and it does so in a cell-cycle-dependent 
fashion and deletion or inhibition of p53 induces autophagy (Tasdemir et al., 2008c), 
(Tasdemir et al., 2008b).  But activation of p53 by DNA damage and cellular stress 
causes p53 to translocate into the nucleus and stimulate autophagy-inducing genes, thus 
acting as a tumour suppressor; one of these p53 target genes, DRAM, is a lysosomal 
protein with roles in both autophagy and apoptosis (Crighton et al., 2006).  Autophagy 
protects the cell from and DNA damage (Mathew et al., 2007) and ROS, which have 
been shown to directly activate autophagy by oxidation of Atg4 (Scherz-Shouval et al., 
2007).  A mechanism for how autophagy suppresses tumourigenesis has recently been 
described: metabolic stress induces p62 to accumulate thus activating the DNA damage 
response (Mathew et al., 2009). 
During cancer, autophagy can also protect through its function as a non-
apoptotic, or type II cell death pathway.  When apoptosis is not functioning, cells 
trigger autophagic cell death and thereby do not undergo necrosis that can result in local 
inflammation, which can promote tumour growth (Degenhardt et al., 2006).  But 
autophagy in cancer is often referred to as a double-edged sword, as young, nutrient-
hungry tumours can hijack the autophagy pathway in order to sustain rapid growth 
before they can recruit sustenance-supplying blood vessels through angiogenesis.  In 
this way, autophagy acts as a cancer cell survival pathway (Mizushima et al., 2008).  
mTOR inhibitors are used to treat many cancers as they inhibit cell growth but mTOR 
inhibition also activates metabolism and autophagy, promoting tumour survival.  Eileen 
White has shown promising new data suggesting that the combination of an mTOR 
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inhibitor with an autophagy inhibitor may shrink tumour xenographs in mice (White et 
al., 2010). 
1.6.3 Neurodegeneration 
Neurons are especially sensitive to the accumulation of damaged or aggregated 
cytosolic proteins or membranes and constitutive basal autophagy protects cells from 
this damage thereby preventing neurodegeneration (Tooze and Schiavo, 2008).  
Suppression of basal autophagy through the loss of the autophagy genes Atg5 or Atg7 
causes neurodegeneration in mice (Komatsu et al., 2006), (Hara et al., 2006) and Atg7 
is essential for the maintenance of axonal homeostasis; without it, intracellular proteins 
accumulate to toxic levels and axons degenerate (Komatsu et al., 2007).  As discussed 
before, autophagy as well as the proteasome degrade misfolded proteins but p62 seems 
to distinguish when to direct these aggregates to the lysosome thereby preventing cell 
death (Bjorkoy et al., 2005). 
Alterations of autophagy have been observed in many protein conformation 
diseases and one neurodegenerative disease with which it is associated is Huntington’s 
disease (HD), caused by a polyglutamine expansion mutation in the huntingtin protein 
(htt) that confers a toxic gain-of-function.  Autophagy degrades aggregate-prone mutant 
huntingtin (Ravikumar et al., 2002) and this is mTOR dependent (Ravikumar et al., 
2004).  In turn, the promotion of autophagy by rapamycin decreases these aggregates 
and it is proposed that combining rapamycin with another autophagy-inducing drug, 
lithium provides synergistic protection against neurodegeneration in HD animal models 
(Sarkar et al., 2008).  A new small molecule was shown to upregulate neuronal 
autophagy in an mTOR-independent way (Tsvetkov et al., 2010); it is an exciting 
potential treatment against protein folding disease without the known side-effects of 
mTOR-inhibiting drugs.  Giving further evidence for the role of autophagy in HD, 
recently it was found that an Atg7 polymorphism influences the age of onset and those 
with the mutation showed symptoms earlier (Metzger et al., 2010). 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are protein folding 
diseases associated with protein aggregates called inclusions in the brain.  The toxic 
proteolytic product β-ameloid accumulates in AD brains causing dystrophic neurites 
and the aggregates are not fully degraded when autophagy is impaired perhaps leading 
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to further propagation (Yu et al., 2005).  Most recently it was revealed that the AD-
related transmembrane protein presenilin-1 is itself required for acidification of 
lysosomes and thus autophagy (Lee et al., 2010).  This may provide a mechanism for 
the early-onset form of AD that is linked to mutations in the presenilin-1 gene.  Both 
autophagy and CMA contribute to the degradation of α-synuclein-inclusions associated 
with Parkinson’s disease but the inability of CMA to specifically degrade mutant α-
synuclein contributes to its pathogenesis (Cuervo et al., 2004).  Lysosome impairment 
has also been recently linked to PD and explains why an increased number of 
autophagosomes is seen in the brains of PD patients (Dehay et al., 2010).  Other 
neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), which is 
characterised by the presence of intracellular aggregates within motor neurons, and even 
prion disease are associated with impaired autophagy. 
Despite the recent surge of publications delving into the molecular mechanisms 
of autophagic function, there are many remaining questions.  Of critical importance is to 
determine how and where the isolation membrane forms in mammalian cells and what 
other proteins are required to act at this site.  Perhaps this would get us closer to 
understanding the origin of the autophagosome membrane.  What confers specificity to 
cargo and how p62 and other Ub- and LC3-interacting proteins differentially send 
protein aggregates to the lysosome or proteasome are also interesting subjects.  
Autophagy is critical for maintaining proper cell wellbeing and is involved in multiple 
diseases.  Striving to uncover the mysteries of the process, autophagy scientists will find 
new drug targets that may provide the framework for therapies for multiple conditions 
and diseases, including ageing, cancer and neurodegeneration.  During my PhD 
studentship, I performed a genome-wide siRNA-based screen in order to find new 
modulators of mammalian autophagy that may possibly shed light on some of the 
questions put forth in this summary of autophagy. 
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Chapter 2. Materials and Methods 
2.1 Cell culture 
HEK293A cells were obtained from Cell Services, Clare Hall, LRI.  HeLa cells 
were obtained from Eeva-Liisa Eskelinen University of Helsinki, Helsinki, Finland.  
GFP-LC3-HEK cells were made and characterised by Edmond Chan (Chan et al., 
2007). 
All cells were cultured at 37º Celsius, with 10% CO2. 
Full medium is: Dulbecco’s Modified Eagle Medium 1x (DMEM) (GIBCO, 
2169), 9% Foetal Bovine Serum (FBS) (SIGMA, F7524), 1.5% L-glutamine, 
Pen./Strep.  Starvation (amino-acid free) medium is Earle’s Buffered Salt Solution 
(EBSS): NaCl (0.2grams/litre), NaHCO3 (1.1gram/litre), KCl, CaCl2, MgSO4, 
NaH2PO4, D-Glucose (1gram/litre), 1% Phenol red, Pen./Strep. 
EBSS, L-glutamine, PBS, Trypsin, Versene, Pen/strep were supplied by LRI 
laboratory services. 
2.2 Intein reporter assay experiments 
2.2.1 Cloning intein constructs 
I received intein constructs (containing Ssp. Staphylococcus inteins) from Kanno 
et al: pX8luc, pcmLV, pDcV, and pmLDn (in pcDNA3.1(-)), (Kanno et al., 2006).  
Received human ATG3, ATG7, ATG7CS, LC3 and LC3ΔG from Isei Tanida (National 
Institute of Infectious Diseases, Tokyo, Japan): Tag2B-LC3 wt, Tag2B-LC3ΔG, 
Tag2B-hAtg3, Tag2B-hAtg3CS, 3xMyc-hAtg7 WT, 3xMyc-hAtg7 CS.  Received 
RasV12 and Raf from Julian Downward (LRI): mRaf pEFH PLINK (a pEF PLINK2 
derivative with an H6 and myc tag at N-terminus) and V12H-Ras (cloned into 
pcDNA3).  The following primers were used to clone the intein constructs: 
Construct Restriction 
enzymes (N-
terminal, C-
terminal) 
Forward primer sequence     
(5’-3’) 
Reverse primer sequence   
(5’-3’) 
Atg3 pDcV XhoI, XbaI ctcgaggccaccatgcagaatgtgattaat  atctagacccattgtgaagtgtcttgt 
Atg7 pDcV NotI, XbaI taggcggccgcgccaccatggcggcagctacgggg  atctagaccgatggtctcatcgtcgct 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Atg7CS pDcV NotI, XbaI taggcggccgcgccaccatggcggcagctacgggg  atctagaccgatggtctcatcgtcgct 
LC3 pDcV XhoI,  XbaI ctcgaggccaccatgccgtcggagaagacc  atctagacccactgacaatttcatccc 
LC3ΔG pDcV XhoI, XbaI ctcgaggccaccatgccgtcggagaagacc  atctagacccactgacaatttcatgaa 
pmLDn Atg3 BamHI, EcoRI tagggatcccagaatgtgattaatact  aatgaattcttacattgtgaagtgtct 
pmLDn Atg7 EcoRI, NotI taggaattcagcggcagctacgggggat  aatgcggccgctcagatggtctcatcgtc 
pmLDn LC3 BamHI, EcoRI tagggatccccgtcggagaagaccttc  aatgaattcttacactgacaatttcat 
pmLDn LC3ΔG  BamHI, EcoRI tagggatccccgtcggagaagaccttc  aatgaattcttacactgacaatttcat 
Raf pDcV XhoI, XbaI ctcgaggccaccatggagcacatacaggga  atctagaccgaagacaggcagcctcgg 
pmLDnRasV12 BamHI, EcoRI tagggatccaccgaatacaagcttgtt aatgaattctcaggaaagcacacactt 
Table 2.1 Intein construct cloning enzymes and primers 
Intein construct name, N-terminal and C-terminal restriction enzymes, N-terminal and C-terminal primer 
sequences (both shown 5’ to 3’) are shown. 
 
Accuprime Pfx DNA polymerase is from Invitrogen. T4 DNA ligase (reactions 
done at 16ºC overnight, typical 1:3 plasmid:insert), XhoI, XbaI, NotI, BamHI, EcoRI, 
and restriction enzyme buffers are from New England Biolabs. 
Plasmids were transformed into DH5α chemical competent bacteria 
(Invitrogen), grown in Luria broth (LB) medium (2% Tryptone, 0.5% Yeast extract, 
10mM NaCl)(LRI laboratory services). 
PCR Purification Kit, QIAquick Gel Extraction Kit, Miniprep Kit, DyeEx 2.0 
Spin Kit, Endo-free Plasmid DNA Maxiprep Kit all from Qiagen. DNA sequencing was 
preformed using BigDye terminator (BDT) on the ABI Prism 377 DNA sequencer 
(Applied Biosystems) by the LRI sequencing service. 
2.2.2 Overexpression of intein-containing constructs 
For the luciferase assay, HEK or HeLa cells were plated typically at 1250 
cells/well in 96-well Plates, Polystyrene, White, Tissue Culture Treated (Matrix, 4934) 
in 100µL full medium without antibiotics and grown overnight.  On day 2 a 
conventional transfection was performed: typically, 0.1µg pX8luc, 0.1µg pGL4.74 
luciferase (Promega, E6921), 0.25µg pDcV construct and 0.25µg pmLDn construct (or 
0.25µg pcmLV and 0.25µg pcDNA3.1) were mixed in 10µL OPTI-MEM I (GIBCO, 
31958); 0.4µL Lipofectamine2000 (Invitrogen) were mixed in 10µL OPTI-MEM.  The 
DNA-containing and transfection reagent-containing liquids were mixed for 20 minutes 
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following manufacturer’s recommendations (Invitrogen).  20µL of medium was 
removed from each well and 20µL of transfection mix is added to each well and cells 
were incubated overnight.  On day 3, cells are treated and luciferase activity was 
measured. 
For measuring expression, HEK or HeLa cells were plated typically at 2500 
cells/well in 24-well clear, tissue culture treated plates.  On day 2, 1µg DNA was 
transfected with 2µL Lipofectamine2000 as described above.  On day 3, expression is 
measured by western blot. 
2.2.3 Luciferase Assay 
Transfected cells were dosed with 0.2µM rapamycin (Calbiochem) or 10mM 
lithium chloride (Sigma) for 24 hours or 11.0µM rapamycin for 2 hours.  An equal 
volume to medium (75µL) of Dual-Glo Luciferase Reagent (Dual-Glo Luciferase Assay 
System, Promega E2920) was added, incubated for 10 minutes, and firefly 
luminescence was read on the EnVision 2102 Multilabel Reader (Perkin Elmer).  75µL 
of Dual-Glo Stop&Glo Reagent was added, incubated for 10 minutes, and renilla 
luminescence was read.  Luciferase firefly luminescence values were corrected for 
renilla luminescence values, triplicate corrected values were averaged and sometimes 
further corrected by dividing by the corresponding values for full medium. 
2.2.4 Western blotting 
2.2.4.1 Checking expression 
Cells were washed with PBS and lysed in 100µL NP40 buffer (50mM TRIS, 
150mM NaCl, 1.0% NP-40, pH 8.0) plus Complete, EDTA-free protease inhibitors 
(Roche, 11873580001).  A Bradford Assay was performed to determine protein 
concentration compared to IgG standards (Protein Assay, BIO-RAD 500-0006). 
Samples were mixed with NuPAGE Sample buffer (Invitrogen) and run on 
SDS-PAGE NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) and transferred onto 
Immobilon PVDF Transfer Membrane (Millipore) (PVDF was activated with methanol) 
using a semi-dry transfer cell (BIO-RAD).  Membranes were stained with PonceauS 
and probed with anti-myc 9B11 (Cell Signaling, 2276) or anti-LexA (Invitrogen, R990-
25) primary antibodies.  Blots were washed in TBS with 0.05% Tween and probed with 
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ECL anti-mouse IgG, HRP-linked whole antibody (from sheep) (GE Healthcare, 
NA931V) or ECL Anti-rabbit IgG, HRP-linked whole antibody (from donkey) (GE 
Healthcare, NA934V).  Membranes were incubated with ECL (GE Healthcare, 
RPN2106VI) and exposed onto film. 
2.2.4.2 Endogenous LC3 lipidation assay 
Cells were transfected in a 24-well plate as described above.  Autophagy is 
induced with lithium chloride or rapamycin as described above.  Cells were washed 
with PBS, lysed in 50µL cold TNTE (20mM Tris-HCl, 150mM NaCl, 0.3% TX-100, 
5mM EDTA, pH 7.5) plus protease inhibitors on ice and spun for 5 minutes at 11,000 
rpm at 4ºC.  Supernatant was added to 5x SDS Laemmli sample buffer (15%SDS (w/v), 
312.5mM Tris-HCl (v/v) pH 6.8, 50% glycerol (w/v), 16% β-mercaptoethanol, 
bromophenol blue; all Sigma), incubated for 10 minutes at 65ºC and loaded onto a 
hand-poured 12% gel (4% stack). The gel was transferred onto PVDF as above and 
blotted with anti-LC3 5F10 monoclonal (Nanotools, 0231-100/LC3-5F10) or anti-β -
tubulin polyclonal (Cell Signaling). 
2.2.5 Co-immunoprecipitation 
Cells were transfected for 24 hours as above (scaled-up as appropriate) in 6cm 
or 10cm dishes so that cells were grown to 80%-90% confluency at the time of 
transfection.  Cells were washed in cold PBS, lysed in cold TNTE supplemented with 
protease inhibitors and PhosSTOP phosphatase inhibitors (Roche 04906837001) and 
spun for 5 minutes at 4ºC at 12000rpm.  40µL Protein A bead slurry (Protein A 
sepharose in PBS, Sigma) or Protein G bead slurry (Protein G sepharose in PBS, Sigma) 
were washed 2 times with cold TNTE and once with cold TNTE plus protease 
inhibitors.  Anti-myc 9E10 antibody (LRI Cell services) was added to the beads (or not 
for ‘no antibody’ control).  50µL of supernatant (input) was held from each lysate.  
Lysate is added to each tube (or not for ‘no lysate’ control).  IPs were incubated 
overnight at 4ºC. 50µL of supernatant (unbound supernatant) was held from each IP.  
Beads were washed three times with TNTE plus protease and eluted in 25-50µL 3x 
sample buffer and heated to 95ºC for 5 minutes. Samples were run on SDS-PAGE 
NuPAGE Novex 4-12% Bis-Tris gels, transferred onto PVDF, stained with PonceauS 
and probed with anti-LexA antibody. 
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2.2.6 Making stable cell lines 
Low-passage HeLa cells were transfected with pX8luc and selected with 1ug/mL 
G418.  Clones were picked and measured for luciferase activity as above after 
transfection with pcmLV control. 
2.3 Image-based screen optimisation and primary, secondary 
and deconvolution screen 
GFP-LC3-HEK cells were generated by Edmond Chan with an eGFP-LC3 
construct obtained from Y. Kabeya.  Rat LC3 was cloned into pEGFP-CI (Clontech) 
using BamHI and EcoRI.  
2.3.1 Imaging GFP-LC3-HEK cells 
GFP-LC3-HEK cells were plated on the following: Microtest 96-well Assay 
Plate, Optilux, Black/Clear Bottom, TC Surface Sterile, With lid (BD Falcon, REF 
353948) or Imaging plate, Flat bottom (BD Falcon, REF 353219).  Plates were coated 
with Poly-D-lysine hydrobromide (Sigma, P0899).  Of note, if the Poly-D-lysine was 
not adequately washed off the plates before the cells were added and subsequently 
transfected using lipid transfection reagents such as Lipofectamine2000 then the cells 
would suffer from toxicity (data not shown).  Thus, the plates needed to be washed well 
after treatment with Poly-D-Lysine or alternatively a lower concentration or a higher 
quality of reagent was also used. 
During optimisation, autophagy was induced in GFP-LC3-HEK cells using the 
following conditions or chemicals: 50µM vinblastine (Sigma Aldrich V1377) 2 hours, 2 
hour incubation in EBSS, 2 hour incubation in EBSS plus 0.25mg/mL leupeptin 
(Roche, 1529048) or 11µM rapamycin for 2 hours.  The GFP-LC3-HEK cell line was 
derived from HEK293A cells, where the ‘A’ stands for adherent.  The HEK293A cells, 
despite their name, do not stick as well as other adherent cells such as HeLa cells and 
tend to become detached from the plate when manipulated.  This posed a challenge for 
me because, in order to induce autophagy by culturing the cells in EBSS, all the full 
medium needed to be washed off.  For cells in 96-well plates this required washing two 
to three times with EBSS or PBS before the addition of fresh EBSS or EBSS with 
leupeptin and this had to be done slowly and carefully when attempting to do so by 
hand.  I minimised cell loss by gently pipetting with a multi-channel pipette. 
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After induction of autophagy, cells were washed 1x in room temperature PBS, 
fixed with 3% para-formaldehyde (Pfa) for 20 minutes, washed 1x in PBS, incubated in 
5µg/mL Hoechst B226 in PBS (1:200 from 1mg/mL stock, Sigma, 33258), incubated 
for 20 minutes, washed 1x in PBS and changed into 100uL fresh PBS.  The plate is 
sealed and kept at 4ºC. 
Plates were processed in the Cellomics ArrayScan VTI HCS Reader (Thermo 
Scientific) using a 20X 0.45NA lens (of note, capturing at 20x is about 196 fields per 
well; 40x is about 400 fields per well).  Images were analysed on-the-fly using the 
Cellomics SpotDetector V3 Bioapplication.  The GFP channel (GFP-LC3 spots) was 
used to set the focus with fixed illumination time and spots were defined as having the 
following broad characteristics: SpotArea 1.75-18, SpotShapeBFR 0.33-1.4, 
SpotShapeBAR 1-3, SpotAvgInten 44-888, SpotTotalInten 250-13000, in an area 22 
microns surrounding and external to the nuclear region as defined by the DAPI stain 
(i.e. excluding any contribution from nuclear spots) thereby restricting the analysis to 
perinuclear and cytoplasmic GFP-LC3 spots.  Several parameters were recorded 
including the number of nuclei (object count; OC) from the DAPI channel, the number 
of GFP-LC3 spots per cell (spot count per object; SCPO), the total intensity of GFP-
LC3 spots per cell (spot total intensity per object; STIPO), and the total area covered by 
GFP-LC3 spots per cell (spot total area per object; STAPO). 
2.3.2 Reverse transfection for siRNA knock-down 
2.3.2.1 Transfection reagents tested 
The 20 cationic lipid transfection reagents tested are as follows:(1) siPORT 
NeoFX Transfection Agent, (2) siPORT Amine Transfection Agent (Ambion); (3) 
Metafectene (Bionex); (4) Dharmafect 1 (Dharmacon), (5) GeneSilencer (GTS); (6) 
Lipofect RNAiMax, (7) Oligofectamine, (8) Lipofectamine2000, (9) Lipofectamine 
(Invitrogen);  (10) TransIT-siQuest, (11) TransIT-TKO (Mirus);  (12) TransPassR1 
(New England Biolabs); (13) DreamfectGold, (14) Lullaby (OZ Bioscience); (15) 
HiPerFect (Qiagen); (16) Interferin (PolyPlus); (17) CodeBreaker (Promega); (18) 
siRNA transfection reagent (Santa Cruz); (19) NTER nanoparticles (Sigma); (20) 
siIMPORTER (Upstate). 
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The eight transfection reagents tested with a more-specified range of 
concentrations (shown in µL per well) are as follows: (1) siPORT NeoFX Transfection 
Agent (Ambion) 0.4, 0.5, 0.6; (2) siPORT Amine Transfection Agent (Ambion) 0.3, 
0.4, 0.5; (3) Metafectene (Biomex) 0.25, 0.3, 0.35; (5) GeneSilencer (GTS) 0.15, 0.2, 
0.25; (6) Lipofect RNAiMax (Invitrogen), 0.3, 0.5, 0.7; (8) Lipofectamine2000 
(Invitrogen) 0.3, 0.45, 0.6; (13) DreamfectGold (OZ Bioscience), 0.1, 0.2, 0.3; (15) 
HiPerFect (Qiagen) 0.1, 0.25, 0.4. 
Western blot analysis with three transfection reagents was done using reverse 
transfection (see below) with 0.4µL transfection reagent and 50nM siRNA.  siRNA 
used was: COPB1 siGenome duplex-03 siRNA (Dharmacon, D-017940-03) and 
western blots were probed with an anti-COPB1 serum produced in rabbits immunised 
with COPB1 peptide. 
2.3.2.2 Optimised reverse transfection protocol 
Optilux 96-well plates were coated with poly-D-lysine and washed with water 
three times.  0.4µL Lipofectamine2000 was added to 10µL OPTI-MEM; 37.5nM siRNA 
was added to 10µL OPTI-MEM; these two were mixed together by inverting five times 
and then incubated for 20 minutes.  GFP-LC3-HEK cells were trypsinised, brought up 
in 10mL full medium (with antibiotics), and counted.  4000 cells were resuspended in 
80µL of full medium (with antibiotics).  20µL of transfection mix was added to each 
well and 4000 cells in 80µL full medium was added to each well.  Cells were incubated 
for 48 hours.  On day 3, the medium was replaced with fresh full medium.  On day 4, 
autophagy was induced and the cells were fixed or lysed as appropriate. 
2.3.3 The primary screen 
2.3.3.1 Materials 
I sent the GFP-LC3-HEK cells away to our cell services facility where they 
underwent testing for mycoplasm infection, the result of which was negative. I also 
created a stock of frozen cells in case something went wrong with the cells that were 
expanded for the screen and a large amount were needed quickly.  I expanded a large 
amount of cells and froze down 50 vials of cells at passage 12. 
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The following materials were used during the primary screen after their 
batches/lots had been tested: Lipofectamine2000 (Invitrogen, 11668019, 1.5mL, Lot 
394876) (note: I needed 23 1.5mL vials and negotiated a discounted price ultimately 
receiving £204 off of each); Leupeptin (Roche, 1529048, batch no. 70122530 and 
70138029) (note: I also negotiated a discounted price for the 1.4 grams required), Poly-
D-lysine hydrobromide suitable for cell culture (Sigma, P6407), OPTI-MEM, and 
HBSS (GIBCO, 14170). 
I obtained siRNA for the negative and positive controls to fill the two empty 
columns on each plate.  These were tested to ensure that the siRNA Smartpools were 
performing as before.  The siRNA negative and positive controls were as follows: 
RISCfree: siControl RISC-free siRNA #1, D-001220-01-05 
siControl: siCONTROL Non-targeting siRNA pool #1, D-001206-13-05  
siULK1: siGENOME Smartpool, M-005049-00 
siATG7: siGENOME Smartpool, M-020112-01 
siATG13: KIAA0652 siGENOME Smartpool, M-020765-01 
siNRBP2: LOC340371 siGENOME duplex-01, D-005340-01 
(GGAGAUGGCUGUACUGGAAUU) 
I prepared a large amount of medium for the screen.  I ordered 20 litres of full 
growth medium to which I added FBS, penicillin and streptomycin and supplemental L-
glutamine, assuring that the FBS that I added was the same batch that I had been using 
during optimisation.  I ordered 10 litres of EBSS for the starvation incubation and tested 
this batch to assure that autophagy induction was achieved. 
I prepared the plates for the screen.  A small number of plates were coated with 
Poly-D-lysine and tested.  These plates were sufficient as the GFP-LC3-HEK cells 
remained attached during washing and no Poly-D-lysine seemed to remain, causing 
toxicity.  The remaining plates were then coated with Poly-D-lysine and washed and 
barcodes were added (1.4 to 267.6).  The siRNA library was aliquoted onto the coated 
plates (at 375nM in 10 µL HBSS), resealed, and kept at -20ºC until day 1 of the screen. 
I prepared the cells for the screen.  The GFP-LC3-HEK cells to be used in the 
screen were thawed from their lowest passage available (from their original freeze after 
stable GFP-LC3 expression was obtained) and these cells, at passage seven, were tested 
for their ability to be induced for autophagy.  I then tested that the cells survived 
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transfection as described above and measured the effect of positive and negative control 
siRNA on these cells, now at passage 9.  These cells responded as before and were 
expanded in order to have enough cells for the screen.  The cells used in the primary 
screen were at passage 11. 
The Dharmacon siGenome library consists of four sub-libraries: Plates 1-10, 
Protein Kinase (Cat No: G-003500); Plates 11-17, G Protein-Coupled Receptors (Cat 
No: G-003600); Plates 18-93, Human Druggable Set (Cat No: G-004600) Plates 94-
267, Human Genome Set (Cat No: G-005000). 
The screen was performed in four batches of 200 cells.  These batches by bar 
codes are as follows: Batch 1, 2.4-66.6; Batch 2, 67.4-132.6; Batch 3, 133-198.6; Batch 
4, 199.4-267.6. 
The following robots were used during the screen: Matrix WellMate 8-channel 
Microplate Dispenser (Thermo Scientific) and ELx405 Microplate Washer (BioTek). 
2.3.3.2 Primary screen protocol 
Day 1: 
First I prepared the positive and negative siRNA controls for the sixteen empty wells on 
each plate.  The siRNA was resuspended in HBSS to achieve a concentration of 375nM 
10µL so that the final concentration would be 37.5nM in 100µL total volume of each 
well.  This was done only once in the morning before the screen began.  The plates 
containing 10µL of siGENOME siRNA in HBSS in each well were thawed and spun.  
The foil was removed and the control siRNA was added by hand.  I prepared the cells to 
be added; I trypsinised twelve 175cm flasks, counted the cells with a Haemocytometer, 
and resuspended the cells so that there would be 4000 cells in 80µL of full growth 
medium.  Meanwhile, 0.4µL of Lipofectamine2000 diluted in 10µL Opti-MEM medium 
was added to each well of each plate using one of two Thermo Scientific Matrix 
WellMate 8-channel Microplate Dispensers in two tissue culture hoods.  The 20µL 
siRNA/transfection reagent was left to mix on the plate for 20 minutes and then 80µL of 
cells in full growth medium was added.  The plates were stacked and placed in one of 
three incubators and left for 48 hours.  This process was then repeated three times over 
the course of the day. 
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Day 2. 
A selection of wells from a selection of plates from each of the three incubators were 
examined to check the density and viability of the cells. 
Day 3. 
The transfection medium was removed using a BioTek Microplate Washer and 100µL 
fresh full medium was added using the Matrix WellMate Microplate Dispenser at slow 
speeds in order to cause as little disruption to the cells as possible.  This was done in 
sterile conditions. 
Day 4. 
The plates were again processed in four batches of 200 plates and the induction step 
again required the efforts of four people.  The full growth medium was removed and the 
plates were washed by dunking the plates, two at a time, in a large tub filled with PBS 
and then excess PBS was removed.  60µL of EBSS with 0.25mg/mL leupeptin was 
immediately added to each well using a WellMate Microplate Dispenser and the plates 
were placed back into the incubator for two hours.  The cells were then fixed by the 
addition of 60µL 8% formaldehyde and incubated in this 4% formaldehyde solution for 
at least 20 minutes at room temperature, sealed and kept over-night at 4°C.  On day 5, 
the plates were de-sealed, 100µL of PBS was added and plates were kept at 4°C. 
Dapi staining. 
Batches of plates to be read were stained with DAPI the day of image acquisition. Fixed 
cells were treated with 1µg/mL DAPI (Sigma) for 20 minutes, the stain was removed, 
100µL of PBS was added and plates were sealed. 
Image acquisition. 
The 16 wells containing positive and negative control siRNA were compared to a plate 
that was treated with full medium, not EBSS with leupeptin in order to optimise the 
Cellomics SpotDetector parameters for the screen.  Of note, the parameters that gave the 
most accurate spot calling and best fold induction between the uninduced plate and the 
RISCfree negative control wells on the induced plates were set so that the least number 
of spots were counted on the uninduced plate.  We set the thresholds for spots were set 
quite high and only big, bright spots of GFP-LC3 intensity were counted as ‘spots.’ 
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2.3.3.3 Data normalisation 
Further details of the B-score and Z-score normalisation can be found in the Appendix 
section 9.1. 
2.3.4 The secondary screen 
The cells, siRNA controls and all other reagents were re-tested before the secondary 
screen.  The secondary screen was performed as the primary screen. 
2.3.5 The deconvolution screen 
A custom order of 190 deconvoluted siGenome Smartpools was made to Dharmacon.  I 
arranged the sets of 4 siRNA duplexes on 10 plates, leaving the first two columns free 
for siRNA controls as before using Dharmacon’s custom order template. The cells, 
siRNA controls and all other reagents were re-tested before the deconvolution screen.  
The deconvolution screen was performed as the primary screen. 
2.4 Gene annotation 
Candidate genes were annotated using the following databases: 
Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene 
Human Protein Reference Database (HPRD): http://www.hprd.org/query 
Online Mendelian Inheritance in Man (OMIM): 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim 
UniProtKB: http://www.uniprot.org 
The 51 ‘validated-by-deconvolution’ hits were analysed for GO term annotations using 
the Generic GO term Mapper and generic GO slim terms (http://go.princeton.edu/), 
(http://go.princeton.edu/GOTermMapper/goSlimFiles/goslim_generic.obo) and 
analysed using Panther annotation for protein class (http://www.pantherdb.org). 
2.5 Further validation 
2.5.1 siRNA duplexes 
The two best siRNA duplexes for the 20 ‘three-out-of-four’ hits were chosen 
from the deconvolution screen.  2.0 nmol was ordered for each of the following: 
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Gene 
symbol 
siGENOME 
siRNA number 
Target sequence duplex A Target sequence duplex B 
CDH19 D-013105-02,-03 GAUAAUGGUACAAUCACUA GCUGAGGAGUAGUACCAUA 
SUPT5H D-016234-01,-04 CGGAAGGGCUUUCUGUUCA GCGAGUAUUACAUGAAGAA 
C1orf198 D-015001-02,-03 GCGCUUCACUUACUUCUCG GGUCUUGCCUCCCUGCUAC 
GHSR D-005513-01,-03 GGGUGAAGCUGGUCAUCUU GGACCAGAACCACAAGCAA 
LARP1 D-027187-01,-04 GCACCGAGCUUUACAGUGU UGAACAACAUCACCUACUA 
NAA25 D-014530-01,-02 GACCGGAGUUAGUUACAAA CCAAUGUUGUGGAUCAUAU 
SCOC D-014916-02,-03 CAGAUGACAUAGACCAUUC GAACUCCAACACACACUUG 
PAFAH1B2 D-008797-03,-04 GUGAGAAACCCAAUCCUUU GAUCGAGGCCAUUGUACAA 
WAC D-013325-03,-04 GAGACAAACCCGUAUCACA CGAUCCACGUGUUCAUUAA 
TLK2 D-005389-03,-04 CCAAAGAUCUCAAAUAAAG GCAUGGAGCUAACAUCACA 
RBM12 D-010094-03,-04 GGAAUGGAUUGGUUAAGUU CCACCUAGCUCAGGAAUGA 
CNOT1 D-015369-02,-04 CAAGUUAGCACUAUGGUAA GCAAUAUAAUCGUGCAGUU 
FBXL14 D-015718-01,-04 GCCAGAAGCUCACAGAUCU GCUCAACAUUGGACAGUGU 
KIF25 D-010082-01,-03 GGAAGAGGAGGCCGGAUUG CCUACUCACUUCUCUCUUG 
STAT2 D-012064-01,-04 GGACUGAGUUGCCUGGUUA CUGCUAGGCCGAUUAACUA 
ADHFE1 D-008453-03,-04 GAGCAGCAGUUACAAAGGA GAAGCAAGGUCUCAUAUGC 
RASIP1 D-020794-03,-04 GGACUUCGAUCAGUUGACU CGACAUUGCCACUGAGUUC 
WDR6 D-013085-02,-03 CAAGGAACGUUGUCGGUAC GCAGGAUUCUGGGCGGAUU 
RASGRF2 D-024516-04,-06 GAAGGAACACCAAACUUUA GCACAGUACUUGCUUGACA 
SNX20 D-016514-01,-03 GCACUUAGACACACACAGU GCACGUCAAACUGCUCUUU 
Table 2.2 siRNA duplexes acquired for each of the 20 validated-by-deconvolution 
hits 
The gene symbol, siGENOME siRNA order numbers and sequences for the two duplexes are shown. 
 
2.5.2 Induction screen 
The induction screen was performed on the following plates:  
Plates 1, 2, 3:  full medium + 0.25mg/mL leupeptin 24 hours 
Plates 4, 5, 6: full medium + 10mM LiCl 24 hours 
Plates 7, 8, 9:  full medium + 0.25mg/mL leupeptin 2 hours 
Plates 10, 11, 12: EBSS 2 hours 
Plates 13, 14, 15: EBSS + 0.25mg/mL leupeptin 2 hours 
Plates 16, 17, 18: full medium + 250nM Torin + 0.25mg/mL leupeptin 2 hours 
Plates 19, 20, 21: full medium + 128µM Resveratrol + 0.25mg/mL leupeptin 2 hours 
Plate 22: NO siRNA, just Lipofectamine 2000, fresh full medium 2 hours 
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Torin is from D.M. Sabatini, (MIT, Boston, USA); Resveratrol is from Sigma. 
2.5.3 24 well knock-down of GFP-LC3-HEK cells 
The 96-well reverse transfection was scaled up to a 24-well format: 24-well 
plates were coated with poly-D-lysine and washed well. 37.5nM siRNA in 50µL OPTI-
MEM was mixed with 1.25µL Lipofectamine 2000 in 50µL OPTIMEM and incubated 
for 20 minutes.  100µL of transfection mix was added to plates.  7 x 104 GFP-LC3-HEK 
cells in 400µL in full growth medium were added to each well, incubated for 48 hours; 
the media was changed to 500µL full growth medium; incubate for 24 hours (total: 72 
hours).  Autophagy was induced (after washing 3 times) with EBSS plus 0.25mg/mL 
leupeptin for hours. 
2.5.3.1 Confocal images 
Glass coverslips were placed in 24-well plates, coated with poly-D-lysine, 
washed and transfection mix then GFP-LC3-HEK cells were added on top of the 
coverslips and the reverse transfection procedure was followed, as above.  Negative 
control siRNA was RISCfree control siRNA, and single duplexes were used for siULK1 
and siNRBP2: siGenome ULK1 siRNA duplex-04 (Dharmacon, D-005049-04, 
UGUAGGUGUUUAAGAAUUGUU); siGenome LOC340371 siRNA duplex-01 
(Dharmacon, D-005340-01, GGAGAUGGCUGUACUGGAAUU).  RISCfree cells 
were treated with either full medium or EBSS plus 0.25mg/mL leupeptin for two hours 
and siULK1, siNRBP2, and all test siRNA duplexes were treated with EBSS plus 
0.25mg/mL leupeptin for two hours.  Cells were fixed with 3% PFA (Sigma) for 20 
minutes, quenched with 50nM NH4Cl/PBS for 10 minutes, washed in PBS, incubated in 
Hoechst in PBS for 20 minutes, washed and mounted with moviol onto glass slides.  
Cells were imaged with an LSM 510 laser scanning confocal microscope at 63x with a 
1.4NA, Plan Apochromat oil-immersion objective (Carl Zeiss MicroImaging, Inc.).  
Laser and all intensity settings were identical when capturing every image.  Images 
were processed using LSM 510 software. 
2.5.3.2 Measuring mRNA levels by qRTPCR 
Side-by-side to the knock-downs performed on coverslips, two wells of a 24-
well plate were transfected with each siRNA duplex above.  On day 4, GFP-LC3-HEK 
Chapter 2. Materials and Methods 
 60 
cells were not induced for autophagy.  Instead, total RNA was isolated from cells in two 
wells using the RNeasy mini kit (Qiagen).  The RNA was eluted in 30µL RNAase-free 
water and the RNA concentration was measured using a NanoDrop spectrophotometer 
(Thermo Scientific).  All RNA was stored at -80ºC. 
cDNA was reverse transcribed from the 1.0µg RNA using Superscript RTII and 
oligo dT (Invitrogen).  mRNA levels were determined by quantive real-time polymerase 
chain reaction (qRTPCR) using SYBRGreen PCR Master Mix (Applied Biosystems 
4309155) in a 20µL reaction (2.5µL of cDNA (in 50µL RNAse-free water), 5.5µL 
water, 10µL SYBRGreen and 2µL QuantiTect Primer).  Cycles were performed on a 
7900HT Fast Real-Time PCR System (Applied Biosystems) and data was normalised to 
β-actin control (Qiagen, ACTB QT00095431).  Qiagen QuantiTect Primer Assays 
(“containing a mix of lyophilized forward and reverse primers for a specific target”) 
were used for the 20 candidate hits: 
Gene symbol Gene ID Accession 
number 
Qiagen QuantiTect 
primer number 
CDH19 28513 NM_021153 QT00009359 
SUPT5H 6829 NM_003169 QT00059423 
C1orf198 84886 NM_032800 QT00090293 
GHSR 2693 NM_004122 QT01666217 
LARP1 23367 NM_015315 QT00043701 
C12orf30/NAA25 80018 NM_024953 QT00099834 
SCOC 60592 NM_032547 QT00069846 
PAFAH1B2 5049 NM_002572 QT01845550 
WAC 51322 NM_016628 QT00060480 
TLK2 11011 NM_006852 QT01666518 
RBM12 10137 NM_006047 QT00214004 
CNOT1 23019 NM_016284 QT00080136 
FBXL14 144699 NM_152441 QT01031184 
KIF25 3834 NM_005355 QT00024934 
STAT2 6773 NM_005419 QT00095704 
ADHFE1 137872 NM_144650 QT00040999 
RASIP1 54922 NM_017805 QT00035637 
WDR6 11180 NM_018031 QT01841056 
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RASGRF2 5924 NM_006909 QT00028462 
SNX20 124460 NM_153337 QT01671334 
Table 2.3 qRTPCR primers for the 20 validated-by-deconvolution hits 
Gene symbol, GeneID, Accession number and Qiagen QuantiTect primer assay catalogue number for 
each of the 20 hits. 
 
2.5.4 LC3 lipidation assay in HeLa cells with Licor 
The 24-well reverse transfection protocol was performed as described for 
monitoring GFP-LC3 spot formation in GFP-LC3-HEK cells (section 1.5.3.1 above) 
except that HeLa cells were plated at a higher concentration of 1.5 x 105 cells per well.  
On day 4, duplicate test wells were transferred to fresh full medium, EBSS, or EBSS 
plus 0.25mg/mL leupeptin for two hours (as before, the cells were washed three times 
before the addition of starvation medium). 
Cells that received full medium were washed with cold PBS and all cells were 
lysed with 50µL cold TNTE supplemented with protease inhibitors.  Cells were then 
spun at 12,000 for five mintes at at 4°C.  20µL of lysate was transferred to a fresh tube 
and 5µL of 5x Laemmli sample buffer was added.  Tubes were heated at 65°C for 10 
minutes and loaded onto NuPAGE Novex 4-12% Bis-Tris Midi Gels (20 well) 
(Invitrogen, WG1403) and run in MES running buffer.  The gels were transferred onto 
(methanol-activated) Immobilon-FL PVDF Transfer Membrane (Millipore, IPFL0010, 
pore size 0.45µm) using a semi-dry transfer cell.  After transfer, membranes were 
stained with PonceauS and blocked with a 50% solution of Licor Blocking Buffer 
(Odyssey, 927-40000) in PBS for one hour.  Membranes were probed with anti-Actin 
AC40 monoclonal (Sigma)  at 1:1000 in PBS or anti-LC3 5F10 monoclonal (Nanotools) 
at 1:250 in PBS overnight at 4°C.  Membranes were washed with PBS plus 0.05% 
Tween (5 x 12minutes).  The secondary antibody was Alexa Fluor 680 goat anti-mouse 
IgG (H+L) (Invitrogen, A21058) and membranes were again washed with PBS-Tween 
and scanned on the LI-COR Odyssey Infrared Imager.  Protein band strength was 
quantified using Metamorph software by drawing narrow boxes around the band 
thereby recording average pixel intensity and then background intensity was subtracted. 
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2.6 SCOC experiments 
2.6.1 SCOC annotation 
SCOC homologues were determined using tBLASTn (performed by Richard 
Mitter, LRI): 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=tblastn&BLAST_PROGRAMS=tb
lastn&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome) 
and BLASTp (performed by me): 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST_PROGRAMS=bl
astp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome).
The isoform schematic was built using UniProt: (UniProtKB: http://www.uniprot.org).  
Molecular weights were predicted using ExPASy compute pI/Mw tool 
(expasy.org/tools/pi_tool.html). 
2.6.2 SCOC immunoprecipitation 
SCOC-myc and the affinity purified anti-SCOC rabbit polyclonal antibody were 
obtained from Richard Kahn (Emory University).  Cloning and generation of the 
antibody are described in Van Valkenburgh et al (Van Valkenburgh et al., 2001). 
To perform the endogenous immunoprecipitation, HEK cells were plated on a 
6cm dish and the next day were washed in cold PBS and lysed in 750 µL TNTE plus 
protease inhibitors plus phosphatase inhibitors.  40µL of protein A bead slurry was 
washed three times in TNTE plus protease inhibitors.  1µL of anti-SCOC was added to 
the beads and then lysate was added.  The tubes were rotated on a spinning wheel 
overnight at 4°C.  The tubes were spun slowly at 3000 rpm at 4°C and lysate was to 
load as unbound supernatant.  Beads were washed 3 times in TNTE plus protease 
inhibitors and beads were boiled for 10 minutes at 95°C.  1.3% input and unbound post-
IP supernatant were loaded as well as bead eluate.  The gel was transferred to PVDF as 
above and probed with anti-SCOC antibody at 1:400 and anti-rabbit HRP secondary at 
1:1000.  The film was developed using ECL reagents as described above and exposed 
over the weekend. 
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2.6.3 GFP-LC3 confocal images, pRTPCR and LC3 lipidation 
GFP-LC3-HEK cell confocal imaging and qRTPCR were performed as described 
above (1.5.3).  LC3 lipidation was performed as described above (1.5.4).  Additional 
siRNA duplexes used are as follows: 
siRNA 
duplex 
siRNA number Target sequence 
SCOC-01 Dharmacon D-014916-01 CAUGUCAGCUUCUAGUGUU 
SCOC-41 Ambion s34141 (cat no 4427037) AGAUCUCUCUGCAAGAGUAtt 
SCOC-42 Ambion s34142 CCAAAAGUUUGUUACCCAAtt 
SCOC-43 Ambion s34143 ACAUUUCUCUUGCAGAUGAtt 
Amb siC#1 Silencer® Select Negative 
Control #1 Cat#: 4390843 
 
Amb siC#2 Silencer® Select Negative 
Control #2 Cat#: 4390846 
 
Table 2.4 Additional siRNA duplexes for SCOC and Ambion siRNA controls 
One Dharmacon siRNA duplex and three Ambion siRNA duplexes targeting SCOC additionally ordered 
are described above.  Also, Ambion siRNA controls are shown 
 
2.6.4 p62 degradation assay 
The p62 degradation assay was performed with GFP-LC3-HEK cells.  8x104 
cells were knocked down using siSCOC-01,-02,-03, siULK-04 or RISCfree control 
using the 24-well reverse transfection protocol described above.  On day 4, cells were 
starved in EBSS for four hours without leupeptin.  Cells were lysed in 50µL TNTE plus 
protease inhibitors, spun for 5 minutes at 10,000 rpm, and run on NuPAGE 4-12% Bis-
Tris gels, transferred to PVDF-FL and blotted following the Licor protocol described 
above.  The membranes were probed with anti-p62 monoclonal antibody at 1:500 
(SQSTM, BD Translabs) and anti-actin AC40 monoclonal antibody.  Gels were scanned 
using the Licor imager and quantified using metamorph as described above.  Cells for 
qRTPCR were knocked down side-by-side with the cells used for p62 blotting and 
SCOC mRNA levels were determined as described above. 
2.6.5 Cloning SCOC-GFP and GFP-SCOC 
SCOC isoform Q9UIL1-3 was cloned into pEGFP-N1 (Clontech) to create N1-
SCOC-GFP (aka SCOC-GFP) and into pEGFP-C1 (Clontech) to create C1-GFP-SCOC 
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(aka GFP-SCOC).  The open reading frame of SCOC isoform PCR’ed from the IMAGE 
clone BC062684 using Sal1 and BamHI the following primers: 
N1 Sal1 forward 5’ ATATGTCGACGGACGGGTCCAGGAAAGAG 
N1 BamHI reverse 5’ TATAGGATCCTTACTTTCTTTTGCTTTTTGT 
C1 Sal1 forward 5’ ATATGTCGACGACGGGTCCAGGAAAGAG 
C1 BamHI reverse 5’ TATAGGATCCTTACTTTCTTTTGCTTTTTGT 
2.6.6 Knock-down then overexpression of SCOC 
HEK cells were knocked down with the seven SCOC siRNA duplexes as above 
(24-well plate, 37.5nM siRNA, 1.25µL Lipofectamine 2000, 8x105 cells).  On day 3, 
cells were washed with full medium minus Pen./Strep. and transfected for 
overexpression.  3.2µL Lipofectamine/mL and 0.8µg of DNA (N1, SCOC-GFP or 
SCOC-myc) were combined in 300µL OPTI-MEM, incubated for 20minutes and added 
to the cells.  The cells were incubated in this 300µL for 3 to 6 hours and then the 
medium was changed to full medium minus Pen./Strep.  Membranes were probed with 
anti-Actin AC40 (Sigma), anti-GFP 3E10 monoclonal (LRI Cell Services), or anti-myc 
9E10 monoclonal (LRI Cell Services) and scanned using Licor or probed with anti-
SCOC polyclonal and developed using ECL as described above. 
For rescue experiments the protocol above was followed but 1.5x105 HeLa cells 
per well were plated.  Endogenous LC3 lipidation was assessed as above using the 
Licor protocol and SCOC-myc expression was assessed using anti-myc 9E10. 
2.6.7 SCOC immunofluorescence 
Endogenous SCOC staining was performed with the anti-SCOC polyclonal 
antibody using the following protocol adapted from Van Valkenberg et al (Van 
Valkenburgh et al., 2001): HEK cells, GFP-LC3-HEK cells or GFP-DFCP1-HEK cells 
(obtained from Nicolas Ktistakis (Babraham Institute, Cambridge, UK)) were fixed in 
3% paraformaldehyde for 20 minutes, quenched with 50nM NH4Cl/PBS for 10 minutes, 
permeabilised in 0.2% saponin for 3 minutes, and blocked with 10% goat serum in PBS.  
All antibody incubations were done in 10% goat serum and coverslips were washed 
with 5% goat serum then PBS and finally mounted using moviol onto glass slides.  
Overexpressed SCOC (SCOC-myc or GFP-SCOC) immunofluorescence was performed 
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using the following protocol: HEK cells were fixed in 3% paraformaldehyde for 20 
minutes, quenched with 50nM NH4Cl/PBS for 10 minutes, permeabilised in 0.2% 
Triton for 3 minutes, and blocked with 0.2% gelatin in PBS.  All antibody incubations 
were done in 0.2% gelatin in PBS and coverslips were washed with 0.2% gelatin in PBS 
then PBS and finally mounted using moviol onto glass slides. 
The following antibodies were used for immunofluorescence: 
Antibody Antigen Species Dilution Supplier 
anti-SCOC SCOC Rabbit 1:200 R. Kahn 
anti-mAtg9 mAtg9 Armenian 
hamster 
1:1000 LRI 
anti-TGN46 TGN46 Sheep 1:500 AbD Serotec 
anti-GM130 GM130 Mouse 1:500 BD Transduction 
anti-Atg12 Atg12 Mouse 1:100 Abgent (AM1816) 
anti-LC3 LC3B Mouse 1:200 MBL 
anti-9E10 myc Mouse 1:500 Sigma 
anti-ULK1 ULK1 Rabbit 1:250 Santa Cruz 
anti-Atg16 Atg16 Rabbit 1:400 Cosmo Bio 
STO 285* Atg16 Rabbit 1:200 LRI (affinity 
purified by S.Tooze) 
anti-HA.11 HA-tag Mouse 1:1000 Covance 
Alexa Fluor 
488, 555 
anti-rabbit 2º Goat  1:1000 Molecular Probes 
(Invitrogen) 
Alexa Fluor 
488, 555 
anti-mouse 2º Goat 1:1000 Molecular Probes 
(Invitrogen) 
Cy3 anti-armenian 
hamster 2º 
Goat 1:1000 Jackson 
Immunoresearch 
Alexa Fluor 
555 
anti-sheep 2º Donkey 1:1000 Molecular Probes 
(Invitrogen) 
Table 2.5 Antibodies used for SCOC immunofluorescence 
Antigen, organism in which the antigen was produced, concentration used and the supplier of the 
antibodies used during SCOC immunofluoresence experiments are shown. 
 
*This anti-Atg16 antibody was made against a peptide in Atg16 and affinity 
purified by Sharon Tooze (N-term peptide SSGLRAADFDRWKRHISEQ(c)).  Knock-
down of Atg16 with the ON-TARGET plus siRNA Smartpool (Dharmacon, L-021033-
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01) decreases Atg16 levels as detected by IF and westernblot (Figure2.1).  Knock-down 
of Atg16 also inhibits GFP-LC3 spots and LC3 lipidation (Figure 2.1). 
 
Figure 2.1 Atg16 affinity purified rabbit antibody 
a. GFP-LC3-HEK cells were transfected with RISCfree control or siAtg16 siRNA, starved for 2 hours in 
EBSS, fixed and stained with anti-STO285 antibody. b. Anti-STO285, -actin, and –LC3 blots after 
indicated siRNA treatment (RF is RISCfree, 16 is siATG16) and mediua conditions in GFP-LC3-HEK 
cells. 
2.6.8 Co-immunoprecipitations 
GFP-FEZ1 was provided by Caroline Whitehouse (King’s College London, 
UK). HEK cells were grown on 6cm dishes and transfected with 1µg SCOC-myc and 
1µg GFP-FEZ1, incubated in full medium or EBSS for two hours.  Cells were lysed and 
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incubated with protein G beads and 1.5µL anti-GFP 4E12 as described above (1.6.2).  
Blots were probed with anti-SCOC polyclonal and anti-FEZ1 goat polyclonal (Abcam, 
ab53562) primary antibodies and anti-rabbit and anti-Goat (Dako, P0449) secondary 
antibodies.  Note that the anti-FEZ1 Abcam goat polyclonal antibody shows a 
nonspecific band that is not reduced by siRNA against FEZ1 (Figure 2.2).  Endogenous 
FEZ1 is not detected but overexpressed GFP-FEZ1 is detected by this antibody. 
 
Figure 2.2 Anti-FEZ1 detects overexpressed GFP-FEZ1 but not endogenous FEZ1 
Anti-FEZ1 blot (using Abcam anti-FEZ1 goat polyclonal). HEK cells were transfected with indicated 
siRNA or overxpressed with indicated construct. 
 
HA-TLK2 was provided by Tamara Gruener and Richard Treisman (LRI). HEK 
cells were grown on 6cm dishes and transfected with 1µg SCOC-myc and 1µg HA-
TLK2 and incubated with protein G beads and 2.0µL anti-HA.11 monoclonal (as 
described above (1.6.2)).  Blots were probed with anti-SCOC polyclonal antibody and 
anti-HA polyconal (1:1000). 
2.6.9 FEZ1 and ARL1 experiments 
The siRNA pool against FEZ1 was generated by combining the siGenome 
siRNA duplexes-01, -02, and -04. mRNA levels were determined using a QuantiTect 
primer (Qiagen, QT00034447). 
The siRNA pool against ARL1 was generated by combineing the siGenome 
siRNA duplexes -01 (gcaauggaaugguuaguug), -03 (uagagacggugacguacaa), -04 
(gaacucgggaaaugagaau) (Dharmacon, D-019265). mRNA levels were determined using 
a QuantiTect primer (Qiagen, QT00044303). 
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2.7 WAC experiments 
2.7.1 WAC annotation 
WAC disease associations were determined by Richard Mitter using EMBL-EBI 
ATLAS (E-GEOD-1751: (Borovecki et al., 2005)); (E-GEOD-3790: (Hodges et al., 
2006)).  WAC and SCOC disease associations were also determinted using Ingenuity 
curated findings.  WAC conservation was determined using Homologene (NCBI).  
WAC isoforms were determined using UniProt.  The NLS of WAC was determined 
using ExPaSy tools: http://expasy.org/tools/.  The predicted WAC phosphorylation sites 
were obtained from HPRD (HPRD:18291). 
2.7.2 Assesing the effect of WAC knock-down 
The following additional siRNA duplexes targeting WAC were obtained: 
siRNA 
duplex 
siRNA number Target sequence 
WAC-01 Dharmacon D-013325-01 CAACAUAACGUCUCUGAUU 
WAC-02 Dharmacon D-013325-02 UAAGCACACCUCAAACUAA 
WAC-53 Ambion s27953 GCACUUAAGUAUUCAUCGAtt 
WAC-54 Ambion s27954 CAGUAGCGGUGAUCACAGAtt 
WAC-55 Ambion s27955 GUACUCCAGUAGUUAAGCAtt 
Table 2.6 Additional WAC duplexes used 
Two Dharmacon siRNA duplexes and three Ambion siRNA duplexes targeting WAC additionally 
ordered are described above. 
 
All GFP-LC3-HEK cell knock-downs for qRTPCR and confocal analysis and all 
HeLa LC3 lipidation experiments were performed as SCOC experiments as explained 
above (1.6.3).  The WAC p62 degradation experiemnts were performed as above 
(1.6.4).  p62 mRNA levels were determined using a QuantiTect primer assay for p62 
(Qiagen). 
2.7.3 WAC cloning 
WAC cloning was performed using an IMAGE clone obtained for the WAC 
isoform NM_016628. (NBRC, AK290174).  This ORF was subcloned into  
Chapter 2. Materials and Methods 
 69 
pcDNA3.1(-) adding a myc tag to either the N- and C-terminals or a FLAG tag to the C-
terminal of the WAC ORF using the following primers: 
WAC NT myc: 
EcoRVNtermMycWAC 5’ 
TAGAGATATCACCACCATGGAGCAAAAGCTCATTTCTGAGGAAGATCTCAA
TGGTGTAATGTATGCGAGGAAA 
WAC BamHI rev: 5’ TCTAGGATCCTCACACCATGAAGGAATT 
 
WAC CT myc: 
EcoRV WAC for: 5’ TAGAGATATCACCACCATGGTAATGTATGCGAGG 
WAC Cterm myc BamHI rev: 5’ 
TCTAGGATCCCTAACCATTGAGATCTTCCTCAGAAATGAGCTTTTGCTCCAC
CATGAAGGAATTCTG 
 
WAC CT Flag: 
EcoRV WAC for: 5’ TAGAGATATCACCACCATGGTAATGTATGCGAGG 
Wac Cterm flag BamHI rev: 5’ 
TCTAGGATCCCTACTTGTCATCGTCATCCTTGTAGTCCACCATGAAGGAATT
CTG 
 
2.7.4 WAC antibody 
Rabbit polyclonal antibodies were generated using peptides listed below.  The 
serum from Bleed 4 of rabbit STO296 was affinity purified by Sharon Tooze. 
STO 293/294 WAC NT1 MVMYARKQQELSDG(C) 
STO 295/296 WAC NT2 SKSHPSSGDHRHEKMRDAG(C) 
STO 297/298 WAC CT (C)LRQQIKELEKLKNQNSFMV 
2.7.5 WAC immunofluorescence 
WAC immunofluorescence was performed as follows: HEK cells were fixed in 
3% paraformaldehyde for 20 minutes, quenched with 50nM NH4Cl/PBS for 10 minutes, 
permeabilised in 0.2% Triton for 3 minutes, and blocked with 0.2% gelatin in PBS.  All 
antibody incubations were done in 0.2% gelatin in PBS and coverslips were washed 
with 0.2% gelatin in PBS then PBS and finally mounted using moviol onto glass slides. 
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Antibody Antigen Species Dilution Supplier 
anti-WAC 
(STO296) 
WAC Rabbit 1:200 LRI 
Anti-p62 P62 Mouse 1:250 BD 
anti-GABARAP GABARAP Sheep* use 
with donkey 2º 
1:100 Abcam (AP1821) 
anti-Atg12 Atg12 Mouse 1:100 Abgent (AM1816) 
Anti-A1Up UBQLN4 Mouse 1:50 Santa Cruz 
Alexa Fluor 
488, 555 
anti-rabbit 2º Goat  1:1000 Molecular Probes 
(Invitrogen) 
Alexa Fluor 
488, 555 
anti-mouse 2º Goat 1:1000 Molecular Probes 
(Invitrogen) 
Alexa Fluor 
555 
anti-sheep 2º Donkey 1:1000 Molecular Probes 
(Invitrogen) 
Table 2.7 Additional Antibodies  
Antibodies used during WAC immunofluorescence experiements are described. 
 
pEGFP-Htt-Q80 was received from Elizabeth Sztul (Tower et al., 2010). 
2.7.6 WAC and ULK1 western blotting 
Western blotting for ULK1 and WAC was done using the ECL proceedure 
above.  Affinity purified WAC antibody was used at 1:1000 and anti-ULK1 (Santa 
Cruz) was used at 1:250, both in 5% milk/TBS. 
2.7.7 WAC UPS reporter assays 
The UbG76V-GFP HeLa cells were obtained from Florian Salomons at the KI 
(Karolinska Institute, Stockholm, Sweeden), (Dantuma et al., 2000), and the MelJuso 
UbG76V-YFP cells were received from Nico Dantuma (Karolinska Institute, 
Stockholm, Sweeden), (Menendez-Benito et al., 2005).  MG132 was obtained from 
Sigma and used at at concentration of 10µM MG132 treatment.  Anti-GFP, -p62 and -
actin blots were produced using the Licor protocol above. 
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Chapter 3. Screen Optimisation 
 
3.1 High content siRNA screening 
In order to discover new modulators of mammalian autophagy, I performed a 
genome-wide siRNA-based screen.  RNA interference (RNAi) is a powerful tool that 
allows researchers to pinpoint the function of a single gene in the context of a living 
cell.  By promoting the specific degradation of a target gene’s mRNA, small interfering 
RNA (siRNA) oligonucleotide duplexes inhibit that gene’s protein production (Hannon, 
2002).  If this induces a loss-of-function or a gain-of-function in terms of a certain 
biological process (in this case, autophagy) then one can hypothesise that the target 
gene is a modulator of this process.  Commercially available libraries consisting of 
pools of siRNA duplexes targeting the approximately 21,000 currently annotated human 
genes can be combined with high-throughput screening (HTS) assays in order to probe 
the human genome with a given question.  Recently, developments in microscopy have 
made it a robust platform for high-content screening (HCS) and large-scale image 
acquisition can be combined with on-the-fly quantification to generate large amounts of 
data (Krausz, 2007).  Measuring the physiology of intact cells allows researchers to 
determine the effect of an siRNA pool on a whole cell and not just a single gene, a 
caveat of reporter gene assays.  In addition, it potentially allows the researcher to 
control for the biological heterogeneity within cell populations and eliminate outliers. 
Many HCS projects have increased our knowledge of multiple cellular 
processes.  An image-based siRNA screen of the human kinome for both clathrin- and 
raft-mediated endocytosis has greatly expanded the knowledge of the signalling 
pathways and mechanisms involved in this key cellular process (Pelkmans et al., 2005).  
More recently, a genome-wide siRNA screen of macrophages infected with virulent 
Mycobacterium tuberculosis implicated a large number of required host factors many of 
which are involved in the regulation of autophagy (Kumar et al., 2010).  siRNA screens 
are made even more powerful when combined with gene array and proteomics data in 
order to determine expression patterns of target genes.  Recently a combined gene array 
and siRNA-based screen identified the insulin-signalling pathway as a modulator of 
autophagy-mediated clearance of huntingtin aggregates (Yamamoto et al., 2006).  An 
Chapter 3. Screen Optimisation 
 72 
image-based screen of a small compound library (480 compounds) illustrated that GFP-
tagged LC3 can be visually analysed as a marker for autophagosome formation and 
provides proof-of-principle for my genome-wide siRNA screen for starvation-induced 
autophagy (Zhang et al., 2007b). 
 
3.2 Intein-Mediated Luciferase Assay as a basis for the screen 
3.2.1 Intein-Mediated Luciferase Reporter Gene Assay 
When I began my PhD studentship, the London Research Institute (LRI) did not 
possess a microscopy system capable of such high-content screening.  In order to 
perform a genome-wide siRNA-based screen to find novel regulators of autophagy, I 
attempted to create a new assay for autophagy that would utilise the protein-protein 
interactions that are required for autophagy induction.  In early 2006, Kanno et al 
described a novel luciferase-based assay that can monitor cytosolic protein-protein 
interactions in living mammalian cells.  The assay exploits the ability of inteins, or 
protein “introns,” to create a fusion protein that can in turn drive luciferase activity 
(Kanno et al., 2006).  One interacting protein is fused to DnaEn, the N-terminal half of a 
bacterial DnaE intein, and modified LexA (mLexA) (pmLDn) and the other interacting 
protein is fused to a DnaEc, the C-terminal half of the protein splicing element and the 
transcriptional activation domain of VP16 (VP16AD) (pDcV).  mLexA is a DNA 
binding protein modified in order to keep the mLexA/DnaEn fusion protein out of the 
nucleus constitutively by deletion of its intrinsic NLS.  VP16AD is the transcriptional 
activation domain from a herpes simplex virus and it activates transcription of a reporter 
gene whenVP16AD and mLexA are spliced together.  The reporter assay was based on 
the ability of inteins, or protein “introns” to post-translationally catalyze, excise and 
ligate proteins through their autocatalytic endonuclease activity (Chong et al., 1996) so 
that when the two over-expressed fusion proteins come together in the cell the inteins 
are in close enough proximity to fold and induce protein splicing, creating a new fusion 
product of the mLexA and VP16AD (Figure 3.1).  The intein-mediated splicing reaction 
creates a stable peptide bond between the DNA binding protein and the transcriptional-
activating protein and this fusion protein diffuses into the nucleus where mLexA binds 
to a LexA operon upstream of the firefly luciferase reporter gene and the VP16AD 
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drives transcription of luciferase.  In turn, the interaction of the proteins of interest can 
be quantified by measuring luciferase activity. 
 
Figure 3.1 Schematic of the principles of the intein-mediated luciferase reporter 
assay 
Schematic displaying how protein-protein interactions lead to intein splicing and luciferase transcription. 
Plum ball mLexA Blue ball VP16AD, Orange is Protein X and Red is Protein Y.  Luc. Represents the 
luciferase reporter. Adapted from Kanno et al, 2006. 
 
The pX8luc reporter gene, the pDcV and pmLDn constructs, and a pcmLV 
positive control that contains the mLexA and a VP16AD permanently fused together 
with a short linker between them were obtained from Kanno et al.  The backbone of 
these constructs is pcDNA3.1(+) with a two-amino-acid substitution to delete the 
nuclear localisation signal.  A renilla luciferase pGL4.74 reporter gene was used as a 
control for transfection efficiency of the constructs and in addition, the luciferase 
activity observed can be normalised to this renilla luciferase activity.  This luciferase 
assay also had the potential to be multiplexed with other assays such as those that 
measure cell viability.  For example, CellTiter-Blue reagent can be combined with 
luciferin reagents providing a fluorescence read-out of metabolic activity. 
3.2.2 Utilising the Intein Luciferase assay to monitor autophagy 
Conjugation of LC3 to PE occurs upon induction of autophagy and is the result 
of the interaction of LC3 with the E1-like enzyme Atg7 and with the E2-like enzyme 
Atg3 (See introduction, Figure 1.5).  If these protein-protein interactions increase as a 
result of autophagy induction then the induction could be measured using luciferase 
activity produced by the intein-mediate reporter gene assay.  In turn, I could measure 
the effect of siRNA-mediated gene knock-down on the induction of autophagy by 
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measuring luciferase activity.  To these ends, I cloned LC3, Atg7 and Atg3 into both 
pDcV and pmLDn (Figure 3.2). 
 
Figure 3.2 Intein construct cloning strategy 
Schematic of cloning strategy for the addition of genes-of-interest to pmLDn and pDcV constructs. 
 
I created the following constructs using pDcV (20 kDa) as a backbone: Atg3 
pDcV (58 kDa), Atg7 pDcV (98 kDa), and LC3 pDcV (36 kDa) and the following 
constructs using pmLDn (47 kDa) as a backbone: pmLDn Atg3 (82 kDa), pmLDn Atg7 
(120 kDa), pmLDn LC3 (62 kDa).  All constructs express at similar levels and at the 
sizes expected for the fusion proteins (Figure 3.3).  In addition to cloning the wild-type 
LC3 into each backbone, I cloned LC3 missing the C-terminal glycine (LC3ΔG), which 
is the amino-acid that is exposed by Atg4, where Atg7 and Atg3 bind during 
conjugation and onto which PE is added into pDcV and pmLDn.  The LC3 pDcV 
constructs allowed me to assess the extent to which LC3 exists in its primed or G-
exposed form.  When Atg4 cleaves the LC3 wild-type pDcV a smaller protein 
containing the DnaEc, VP16AD and myc remains but when the G is missing as in the 
LC3ΔG pDcV this cleavage does not occur and the full fusion protein is expressed 
(Figure 3.3).  It appears that all of the LC3 pDcV exists in its cleaved state suggesting 
that Atg4 constitutively primes LC3 in HEK cells. 
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Figure 3.3 Expression of Atg-Intein constructs 
Intein-containing fusion proteins are expressed in HeLa cells. Lysates are probed with anti-myc anti-
bodies to detect pDcV-containing proteins and with anti-LexA anti-bodies to detect pmLDn-containing 
proteins. 
 
I transfected Atg-containing intein pairs, the pX8luc reporter gene, and pGL4.74 
renilla luciferase control reporter gene into either HEK or HeLa cells plated in 96-well 
white plates, induced autophagy with Rapamycin and measured firefly luminescence 
and renilla luciferase activity using Promega’s Dual-Luciferase Reporter (DLR) Assay 
System.  I also transfected pcmLV as a positive control and the empty pDcV and 
pmLDn together as a negative control.  All values for luciferase luminescence were 
normalised to the corresponding renilla luminescence values for that given well.  Each 
test was done in triplicates at least, and often with many more replicates; these 
replicates were averaged.  The values for the positive control, pcmLV, in full medium 
were set equal to 1 and data for the test pairs was plotted accordingly (Figure 3.4).  
Corrected luciferase values for the pcmLV were consistently higher, usually at least 
five-fold higher than any transfected intein pair.  Similar activity is seen when the two 
empty intein constructs are transfected as to when two Atg-containing intein constructs 
are transfected.  I analysed the interaction of the Atg7 pDcV and Atg3 pmLDn intein 
constructs because I saw a trend that their activity increased with the addition of 
Rapamycin.  This was perhaps a good pair to analyse because they had been shown to 
co-immunoprecipitate (co-IP) in mammalian cells (Tanida et al., 2002) and Atg3 and 
Atg7 form an E1-E2 complex as in yeast that is required for autophagosome expansion.  
Although this complex was shown to occur in non-starvation conditions, after ten 
experiments I did see a small but consistent increase upon the addition of Rapamycin 
Chapter 3. Screen Optimisation 
 76 
with this pair but it was not statistically significant (Figure 3.4).  Discouragingly, I did 
not see a similar increase when Atg3 and Atg7 were cloned into the opposite intein 
constructs (pDcV and pmLDn accordingly). 
 
Figure 3.4 Intein luciferase assay analysing Atg7 and Atg3 interaction 
HEK or HeLa cells were transfected with reporter genes and shown intein pairs and incubated in full 
medium or full medium plus 11µM Rapamycin for 4 hours. Corrected luciferase values shown after 
normalisation to pcmLV+pcDNA3.1 (pcD). pcmLV + pcD (n=10); pDcV + pmLDn (n=8); Atg3 pDcV + 
pmLDn (n=2); Atg3 pDcV + pmLDn Atg7 (n=2); pDcV + pmLDn Atg3 (n=1); Atg7 pDcV + pmLDn 
(n=6); Atg7 pDcV + pmLDn Atg3 (n=10). Atg7 pDcV + pmLDn Atg3 p-value = 0.0857. 
 
In order to potentially increase the luciferase activity from intein pairs that 
included Atg7, I cloned an Atg7 mutant, Atg7CS  into the pDcV backbone (Figure 3.3).  
The Atg7CS mutation should improve the binding of Atg7 to LC3 as it changes the 
thiol-ester bond between Atg7 and LC3 to an irreversible covalent bond (Tanida et al., 
2006).  In turn, if this bond it non-reversible I might be able to increase the number of 
instances where Atg7 and LC3 are bound together, thereby increasing luciferase 
activity.  This, however, was not the case in my intein-mediated luciferase assay (Figure 
3.5).  Though there was a very small increase in activity in the Atg7CS-LC3 pairing 
compared to the Atg7 wild-type-LC3 pairing this increase was not significant.  As well, 
the Atg7CS pDcV construct did not improve the activity compared to Atg7 pDcV when 
binding to pmLDn Atg3 or pmLDn Atg7.  If anything, the luciferase activity decreases 
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after the addition of Rapamycin for these two pairings, though these decreases are not 
statistically significant (Figure 3.5). 
 
Figure 3.5 Intein luciferase assay with Atg7CS construct 
HEK or HeLa cells were transfected with reporter genes and shown intein pairs and incubated in full 
medium or full medium plus 11µM Rapamycin for 4 hours. Corrected luciferase values shown after 
normalisation to pcmLV+pcDNA3.1 (pcD). pcmLV+ pcD (n=4); pDcV + pmLDn (n=4); Atg7CS pDcV 
+ pmLDn (n=2); Atg7 pDcV + pmLDn Atg3 (n=4); Atg7CS pDcV + pmLDn Atg3 (n=2); Atg7 pDcV + 
pmLDn Atg7 (n=4); Atg7CS pDcV + pmLDn Atg7 (n=2); Atg7 pDcV + pmLDn LC3 (n=4); Atg7CS 
pDcV + pmLDn LC3 (n=4). 
 
Atg3 has been shown to co-IP with Atg7 and the intein-mediated luciferase 
assay results suggest that binding of Atg7 pDcV to pmLDn Atg3 possibly increases 
after induction of autophagy by Rapamycin, though not significantly.  I attempted to 
confirm this binding through co-IP experiments and overexpressed Atg7 pDcV and 
pmLDn Atg3 in HEK cells, incubated lysates with anti-myc antibody (for the pDcV 
constructs contain a myc-tag), and blotted for LexA, contained in the pmLDn construct.  
I could confirm pull-down of pmLDn Atg3 with Atg7 pDcV, although the amount of 
pmLDn Atg3 is not decreased in the unbound supernatant when compared to an equal 
amount of input lysate taken before co-IP (Figure 3.6, part a).  The amount of pmLDn 
Atg3 pulled down by the co-IP does not increase with the addition of Rapamycin to the 
cells.  Interestingly, Atg7 pDcV appears to be covalently bound to pmLDn Atg3 after 
co-IP for I observe a band corresponding to the size of Atg7 pDcV in the IP lane that, as 
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seen in the anti-myc blot, does appear to be reduced after co-IP incubation.  In addition, 
I appear to be co-immunoprecipitating a band of approximately 39 kilo Daltons that 
may correspond to the fusion protein containing mLexA, VP16AD, myc and linker that 
is created as a result of the intein-mediated protein splicing event.  I also tested the 
Atg7-containing intein constructs together as Atg7 is reported to homodimerise 
(Komatsu et al., 2001), though I do not see an increase in luciferase activity over 
controls for the Atg7 pDcV plus pmLDn Atg7 pairing (Figure 3.5).  When I overexpress 
Atg7 pDcV and pmLDn Atg7 and co-IP as above I see almost identical results as the 
Atg7 pDcV-pmLDn Atg3 binding.  Namely, pmLDn Atg7 is detected after anti-myc 
immunoprecipitation, a band corresponding to Atg7 pDcV is seen to be bound to this 
complex, and a band of 39 kDa is seen in the eluate as well (Figure 3.6, part b).  
Interestingly, a band of over 200 kDa is observed in the anti-myc blot, which may 
correspond to a pDcV Atg7-pmLDn Atg7 dimer. 
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Figure 3.6 Co-Immunoprecipitations of Atg7 and Atg3 intein-containing 
constructs and Atg7 and Atg7 intein-containing constructs 
a. Atg7 pDcV co-IPs pmLDn Atg3. Constructs are overexpressed in HEK cells, incubated with protein G 
beads and α-myc antibody, blotted for LexA, and stripped and blotted for myc. M is marker; Inp is 5% 
input or lysate; IP is beads, antibody and lysate; Unb is unbound supernatant after IP; NoL is beads and 
antibody with no lysate. Black arrow indicates pmLDn Atg3; blue arrow indicates Atg7 pDcV; red asterix 
indicates possible mLexA-VP16AD splicing product b. Atg7 pDcV co-IPs pmLDn Atg7. Constructs are 
overexpressed in HEK cells, incubated with protein G beads and α-myc antibody, blotted for LexA, and 
stripped and blotted for myc. Plum arrow indicates pmLDn Atg7; green asterix indicates possible Atg7 
pDcV-pmLDn Atg7 dimer. 
 
The intein-mediated luciferase assay at this point did not seem capable of 
reflecting an induction of autophagy upon Rapamycin treatment using Atg proteins 
known to bind to each-other as components.  In order to test the intein assay in my cell 
line and transfection conditions I attempted to use the Raf-1 and Ras intein constructs 
that served as proof-of-principle for Kanno et al.  I was unable to obtain the Raf-1 
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pDcV and pmLDn Ras DNA constructs so I cloned Raf-1 and RasV12 into pDcV and 
pmLDn accordingly using constructs containing Raf and RasV12 (J. Downward, LRI).  
I chose to use RasV12 because this constitutively active mutant of Ras interacts with 
Raf-1 without EGF stimulation (Sun et al., 2000).  I overexpressed Raf pDcV and 
pmLDn RasV12 in the luciferase reporter gene assay as above, measured luciferase 
activity and did not see an increase above the empty intein constructs alone (Figure 3.7).  
In fact, if anything, the signal was decrease with the Raf-RasV12 pair. 
 
Figure 3.7 Raf and RasV12 intein constructs do not bind as exhibited by the intein 
luciferase assay 
HEK or HeLa cells were transfected with reporter genes and shown intein pairs and incubated in full 
medium or full medium plus 11µM Rapamycin for 4 hours. Corrected luciferase values shown after 
normalisation to pcmLV+pcDNA3.1 (pcD). pcmLV+ pcD (n=3); pDcV + pmLDn (n=3); Raf pDcV + 
pmLDn (n=3); pDcV + pmLDn RasV12 (n=3); Raf pDcV + pmLDn RasV12 (n=3); Atg7 pDcV + 
pmLDn Atg3 (n=3). 
 
Raf-1 and RasV12 are expected to interact and this interaction has been 
demonstrated using the intein-mediated luciferase assay, though I could not replicate 
this data.  I attempted to confirm the interaction of Raf pDcV and pmLDn RasV12 by 
co-IP as before and do see binding of the two constructs (Figure 3.8). In contrast to the 
Atg7 pDcV co-IPs with pmLDn Atg3 and pmLDn Atg7, when I co-IP Raf and RasV12 
intein constructs I do not see bands of approximately 39 kDa potentially corresponding 
to the mLexA-VP16AD-myc intein-splicing product.  This may explain why the 
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luciferase levels I observe for Raf pDcV plus pmLDn RasV12 are so much lower than 
pDcV plus pmLDn alone (Figure 3.7); it appears that the presence of the Raf pDcV 
construct inhibits intein-mediated splicing.  I asked whether the addition of pDcV to Raf 
was preventing the Raf1-RasV12 interaction and attempted to co-IP myc-tagged Raf 
with pmLDn RasV12.  Opposite to this hypothesis, only a very weak band of pmLDn 
RasV12 is seen to co-IP with myc-tagged Raf (Figure 3.8). 
 
Figure 3.8 Raf pDcV and pmLDn RasV12 co-IP but Raf-myc does not co-IP 
pmLDn RasV12 
Constructs are overexpressed in HEK cells, incubated with protein G beads and α-myc antibody, blotted 
for LexA. Black arrow indicates pmLDn RasV12.  Red asterix indicates 39 kDa band seen after previous 
intein construct co-IPs. Blots were stripped and blotted for myc and Raf pDcV and Raf-myc were 
observed in the input and unbound supernatant lanes (data not shown). 
 
I asked whether induction of autophagy with a longer time frame (i.e. longer 
than two hours of starvation or Rapamycin treatment, as above) would be better suited 
to my reporter gene system.  It may take a significantly longer amount of time after the 
induction of autophagy for the proteins of the LC3-conjugation system to come 
together, intein splicing to occur, the mLexA-VP16AD fusion protein to diffuse into the 
nucleus, and luciferase transcription and translation to occur as compared to observing 
the formation of GFP-LC3 spots after autophagy induction, for example, which can be 
visualised after as little as ten minutes (Kochl et al., 2006).  I chose to induce autophagy 
with lithium chloride, whose induction of autophagy had been observed after 48 hours 
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treatment (Sarkar et al., 2005).  Treating the cells with lithium chloride, like 
Rapamycin, eliminates the handling and cell loss experienced with washing and 
starvation, but its long incubation time may allow for a higher efficiency of the intein-
mediated reporter assay.  I transfected HEK cells with luciferase reporter genes and 
intein-containing constructs as above and then incubated cells in low-dose Rapamycin 
or lithium chloride for 48 hours and measured luciferase activity.  I normalised for 
renilla as usual but due to a large increase in activity after lithium chloride treatment 
compared to full medium or Rapamycin, I set the full medium values equal to 1 and 
plotted the corrected values for Rapamycin and lithium chloride (Figure 3.9, part a).  As 
seen previously, Rapamycin does not induce luciferase activity above 1 but increased 
activity compared to the pcmLV plus pcDNA3.1 control for three intein pairs: Atg7 
pDcV plus pmLDn Atg3, Atg7 pDcV plus pmLDn LC3, and Atg3 pDcV plus pmLDn 
LC3. 
 
Figure 3.9 LiCl induces intein-mediated luciferase activity and LC3 lipidation 
a. HEK cells were transfected with reporter genes and shown intein pairs and dosed with 0.2µM 
rapamycin or 10mM lithium chloride (LiCl) for 48 hours. Corrected luciferase values were normalised to 
full medium values. b. Western blots against β-tubulin and LC3 after 2 hours incubation in full medium 
(FM) or Earle’s Buffered Saline Solution (ES) or 48 hours incubation in FM, 10mM lithium chloride (Li), 
or 0.2µM Rapamycin (Rap).  
 
In order to measure the extent of autophagy induction after 48 hours of 
Rapamycin or lithium chloride exposure, I observed LC3 lipidation by western blot.  
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After two hours of starvation, the LC3II form is in much higher abundance than the 
LC3I form in HEK cells (Figure 3.9, part b).  After 48 hours of LiCl treatment a large 
accumulation of LC3II is seen, an amount that is perhaps greater than that after two 
hours starvation.  This confirms that autophagy is induced after 48 hours of lithium 
chloride treatment.  Though these results reflect an ability to quantify autophagy 
induction with the intein-mediated reporter assay, induction of autophagy with lithium 
chloride is non-canonical in that it is suggested to be mTOR-independent (Sarkar et al., 
2005) and therefore not a good inducer for my genome-wide screen for autophagy. 
Another possible reason why the intein-mediated reporter assay was not 
reflecting autophagy induction is that I was overloading the cells with multiple 
constructs thereby inhibiting the reporter assay itself and over-taxing the cells.  In order 
to decrease the expression-load of the cells, I created a HeLa cell line stably expressing 
pX8luc, the reporter gene for the assay.  In addition to not having to overexpress 
pX8luc in the cells, I would also theoretically be able to leave out the renilla luciferase 
control reporter gene because the cell line would show homogenous pX8luc expression.  
When these cells are transfected with only intein-containing construct pairs, luciferase 
activity is observed (Figure 3.10).  As before, the greatest amount of activity is seen 
with the positive control pcmLV and similar activity is seem for the empty intein 
constructs as well as the Atg-containing intein pairs.  Also as before, a slight increase of 
activity is seen upon Rapamycin treatment with the Atg7 pDcV plus pmLDn Atg3 pair. 
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Figure 3.10 Intein-mediated luciferase assay is not improved by measuring 
interactions in a stable cell line 
HeLa cells stably expressing pX8luc were transfected with shown intein pairs and incubated in full 
medium or full medium plus 11µM Rapamycin for 4 hours. Luciferase values were normalised to pcmLV 
+ pcDNA3.1 (pcD) in full medium. 
 
Taken together, the results of the multiple attempts to use the intein-mediated 
luciferase reporter gene assay to quantify the interactions of the proteins involved in the 
LC3-PE conjugation reaction indicate that the assay is not sufficient to monitor 
autophagy induction.  The induction seen with the Atg7-Atg3 intein pair after 
Rapamycin treatment was not statistically significant, let alone strong enough on which 
to base a genome-wide screen.  In addition, I was unable to observe modulation of this 
read-out after knock-down of autophagy genes such as ULK1 (data not shown). 
3.2.3 Theories as to why the intein-mediated reporter gene assay cannot 
be used to monitor autophagy  
Overall, the intein-mediated reporter gene assay did not show significant-enough 
fold increase after autophagy induction.  One reason for this is that the background 
signal, that of pDcV and pmLDn alone was disturbingly high.  I used co-IP to determine 
whether these fusion proteins were interacting in the cell.  I overexpressed both fusion 
proteins in HEK cells, immunoprecipitated with anti-myc antibodies and blotted for 
LexA and could detect pmLDn bound to pDcV (Figure 3.11).  Interestingly, I also 
observed, as before, the 39 kDa band that possibly reflects the mLexA VP16AD protein 
that here results from a basal interaction between pDcV and pmLDn and this is reflected 
in the basal luciferase activity seen in the reporter assay.  Kanno et al refer to the 
dynamic range of the assay in their report claiming that the increase of activity caused 
by the Ras and Raf1 interaction is only four fold at most in that the background gives a 
signal of approximately 10 and maximum is signal of forty (Kanno et al., 2006). 
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Figure 3.11 Intein-containing backbone constructs pDcV and pmLDn co-IP 
pDcV and pmLDn are expressed in HEK cells, incubated with anti-myc antibody and blotted for LexA. 
Black arrow indicated pmLDn; blue arrow indicates pDcV; red asterix indicates possible mLexA-
VP16AD splicing product. 
 
Perhaps the fusion of the autophagy proteins LC3, Atg3, and Atg7 to inteins and 
either mLexA or VP16AD no longer allows these proteins to perform their normal 
function.  Specifically, Atg7, the largest of the three proteins, is perhaps no longer able 
to interact with LC3 or Atg3 in order to perform its E1-like enzymatic activity.  In 
addition, Atg7 has been reported to homodimerise yet the intein-mediated luciferase 
activity of the two Atg7-containing intein constructs is no higher that the empty intein 
controls.  Perhaps adding the bulky inteins and DNA binding proteins to Atg7 sterically 
hinders this known protein-protein interaction.  Similarly, Raf-1 is known to bind to 
RasV12 yet I do not see increased luciferase activity with their corresponding intein-
containing constructs.  As shown by co-IP, I do not see binding of myc-tagged Raf-1 
with RasV12 when it is expressed in the pmLDn.  Confusingly, Raf-1 expressed in the 
pDcV backbone even inhibits luciferase activity far below that seen with empty intein 
controls suggesting that the conformation of Raf pDcV is inhibiting the interaction of 
the intein constructs that is observed at a basal level in the reporter assay, as seen in 
Figure 3.11. 
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Overexpression of the three autophagy proteins might drive or even inhibit 
autophagy.  For example, it has been shown that Atg3, though ubiquitously expressed in 
all human tissue, when overexpressed facilitates the formation of the Atg12-Atg5 
conjugate perhaps above its basal levels (Tanida et al., 2002).  This might drive 
autophagy for it has been shown that the Atg12-Atg5 conjugate provides E3-like 
activity for LC3 conjugation (Hanada et al., 2007) and induction of autophagy with 
Rapamycin, for instance might not cause a detectable increase above this increased 
basal autophagy.  Conversely, overexpression of Atg7 and Atg3, which I have shown 
interact if overexpressed in intein-containing constructs and which are known to bind in 
normal growth conditions, could inhibit autophagy.  For these two overexpressed 
proteins may prefer to exist bound together, and may even bind endogenous Atg7 and 
Atg3 leaving less protein available to perform their E1- and E2-like activities. 
An inherent disadvantage to the intein-mediated reporter assay is that it requires 
the overexpression multiple proteins, thus multiple DNA transfections.  In order to 
perform the siRNA-based screen I will also have to knock down individual genes by 
transfecting said siRNA thereby increasing the load to the cells even further.  I 
attempted to reconcile this by creating a stable cell line containing the pX8luc reporter 
gene.  If the assay proved successful, however, I would have had to consider creating a 
cell line that not only overexpressed the reporter gene but also the chosen intein-
containing binding pairs as well. 
Another caveat is that the intein-mediated reporter assay may only work in the 
cell line in which is was first described, CHO cells.  Perhaps the assay needs to be 
optimised and modified for use in HEK or HeLa cells in that different cell types may 
have differential self-catabolising intein capabilities.  It was critical to me that I use 
human cells for my genome-wide screen, for I would be knocking out human genes 
with siRNA so an assay that only works in Chinese hamster ovary cells is of little use.  
Similarly, perhaps the assay only works well to monitor the Ras and Raf-1 interaction. 
Unfortunately I could not see an increase in activity with RasV12 and Raf-1-containing 
constructs that I cloned.  However, Kanno et al went on to utilise the intein-mediated 
reporter assay to monitor MAPK function by monitoring the Ras-Raf-1 interactions 
(Kanno et al., 2009).  No other publications to date describe successful use of the intein-
mediated reporter gene assay to detect other protein-protein interactions or assess 
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modulations of interactions.  Perhaps the assay only works for interactions close to the 
plasma membrane.  Initially Kanno et al state that the assay can be used to detect 
cytosolic protein-protein interactions but later clarify that the luminescence signals are 
“sufficient for evaluation of interactions close to cell membranes” or as they later called 
them “juxtamembrane protein-protein interactions”(Kanno et al., 2006).  The 
conjugation of LC3 occurs throughout the cytoplasm and is not reported to 
preferentially occur close to the plasma membrane, so perhaps the intein-mediated 
reporter assay is for this reason, not suited to monitor the protein-protein interactions 
required for LC3 lipidation. 
 
3.3 Optimisation of Imaged-based screen 
As the LRI did not have a suitable microscope and quantitative software to 
capture GFP-LC3-labelled autophagosomes on a large scale, I attempted, as described 
above, to create non-image-based but high-throughput assay for autophagy.  However, 
by 2007 the LRI had purchased a fluorescence microscope and accompanying image 
processing platform, the Thermo Scientific Cellomics ArrayScan VTI High Content 
Screening (HCS) reader.  In 2007, the High-Throughput Screening (HTS) lab was 
established within the LRI and I worked with members of the HTS lab to set up an 
image-based screen for autophagy. 
GFP-LC3 is incorporated specifically into the autophagosome membrane so that 
GFP-LC3 is a bona fide marker of autophagosomes and in stable cell lines over-
expressing the marker, each GFP-LC3 spot represents an autophagosome and can be 
quantified (Rubinsztein et al., 2009), (Klionsky et al., 2008).  The formation of GFP-
LC3-labelled autophagosomes, or ‘spots’ to which I hereafter refer, can be seen as 
quickly as ten minutes after induction of autophagy (Kochl et al., 2006).  A HEK293A 
cell line stably expressing eGFP fused to rat LC3, hereafter referred to as HEK-GFP-
LC3 cells had been established in the lab (Chan et al., 2007) and was successfully used 
as the basis of an siRNA-based kinome screen.  In this smaller-scale screen, Chan et al 
measured the lipidation of eGFP-LC3 after siRNA knock-down and discovered that 
ULK1, and not ULK2 was required for the formation of autophagosomes.  Furthermore, 
in 2007 a group published a screen based on a human glioblastoma H4 cell line stably 
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expressing LC3-GFP (Zhang et al., 2007b) and used the cell line to assay a library 
consisting of 480 known bioactive compounds and quantified spots using a Cellomics 
ArrayScan VTI in order to identify those compounds that increased spots, or inducers of 
autophagy.  I set out to utilise the Dharmacon siGenome library comprised of 21,127 
siRNA Smartpools, our documented GFP-LC3-HEK cell line, the Cellomics ArrayScan 
VTI and the HTS lab in order to find novel regulators of autophagy. 
3.3.1 Measuring the appearance of GFP-LC3 spots after induction of 
autophagy 
I first established I could both visualise the formation of GFP-LC3 spots but also 
quantify this induction of autophagy using the Cellomics ArrayScan fluorescence 
microscope and accompanying quantitative software that simultaneously converts these 
images into data.  GFP-LC3-HEK cells were plated onto clear-bottomed, black, 96-well 
tissue culture-treated plates, allowed to adhere to the plate and grown in normal nutrient 
conditions for 24 hours.  I induced autophagy either with the addition of Rapamycin as 
above or by starvation (Figure 3.12).  Starvation-induced autophagy was achieved by 
culturing cells in medium devoid of amino acids (Earle’s Buffered Salt Solution, EBSS) 
or EBSS plus leupeptin, a lysosomal protease inhibitor that partially prevents the 
degradation, allowing the assessment of the total number of autophagosomes formed 
during the incubation period.  After two hours of Rapamycin treatment or starvation, 
cells were fixed with Paraformaldehyde and their nuclei stained with Hoechst.  In full 
medium GFP-LC3 displays diffuse cytoplasmic staining and though LC3 is not a 
nuclear protein, GFP-LC3 that has diffused into the nucleus is also seen (Figure 3.12, 
panel a).  The diffuse cytoplasmic staining represents the unlipidated or GFP-LC3I form 
of the protein.  Upon induction of autophagy, GFP-LC3 is lipidated and this GFP-LC3II 
is incorporated into the autophagosome membrane, and these appear as spots. 
Images were collected using a 20X 0.45NA lens and analysed upon acquisition 
using the Cellomics SpotDetector V3 Bioapplication beginning in the middle of the 
plate, in both the DAPI/Hoechst and GFP channels (Channel 1 and Channel 2 
respectively).  Several parameters were recorded including the number of nuclei (object 
count; OC) from the Channel 1, and from Channel 2: the number of GFP-LC3 spots per 
cell (spot count per object; SCPO),  the total intensity of GFP-LC3 spots per cell (spot 
total intensity per object; STIPO), and the total area covered by GFP-LC3 spots per cell 
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(spot total area per object; STAPO).  Induction of autophagy with Rapamycin, EBSS or 
EBSS plus leupeptin increases SCPO, STIPO and STAPO compared to full medium 
(Figure 3.12, panel b) and incubation in EBSS plus leupeptin provoked the most robust 
increase in all three parameters.  This data was generated from at least 250 objects and 
since these were healthy, untransfected cells that were quite confluent this only required 
acquisition of images from two to three fields. 
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Figure 3.12 Induction of autophagy seen in Cellomics Images 
a. Cellomics ArrayScan images of GFP-LC3 spots captured on Channel 2 at 20X after 11µM Rapamycin 
treatment, EBSS or EBSS with 0.25mg/mL leupeptin for two hours. b. Quantification of SCPO (Spot 
count per object), STIPO (Spot total intensity per object), and STAPO (Spot total area per object). FM is 
full medium, Rapa is Rapamycin, and EBSS+L is EBSS plus leupeptin. Error bars represent standard 
deviation from 4 wells.  
 
As the GFP-LC3-HEK cells do not adhere to tissue-culture-treated plates as well 
as other adherent cells such as HeLa cells and tend to become detached from the plate 
when manipulated, I minimised cell loss by gently pipetting with a multi-channel 
pipette but also coated the plates with Poly-D-Lysine before plating the cells to help 
them adhere better.  We adjusted parameters in the Cellomics SpotDetector V3 
Bioapplication in order to accurately determine the number of nuclei which in turn 
establishes the number of validated objects, or object count (OC).  This object count is 
important for it is used to determine spot count, spot total intensity, and spot area per 
object.  GFP-LC3-HEK cells were plated on 96-well plates, fixed, and stained with 
Hoechst as above.  Images were collected at 20X on Channel l, the DAPI/Hoechst 
channel, and the SpotDetector program drew a mask, designated with a blue line, 
around the nuclear staining (Figure 3.13).  Staining that did not meet certain criteria set 
for parameters such as size or shape were not designated as objects and these can be 
seen as small yellow rings.  Some GFP-LC3-HEK cells are multinuclear and also 
depending on parameters set, these can be included or not.  Here, a large multinucleated 
cell or a clump of cells is called as an object (lower right-hand corner).  Objects that lie 
too close to the edge of the field are not considered in calculations for SCPO, STIPO, or 
STAPO because parts of their corresponding cytoplasm lie outside the field and spots in 
those areas will not be counted, thus skewing the data for SCPO, STIPO, and STAPO.  
These uncounted nuclei are also designated with yellow masks below. 
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Figure 3.13 Cellomics images depicting nuclear staining and determination of valid 
object count (OC) 
Images of GFP-LC3-HEK cells in Channel 1 (DAPI/Hoechst channel) shown without or with 
SpotDetector nuclei masks. Nuclei with blue masks contribute to the OC while those with yellow masks 
do not. 
 
The Cellomics SpotDetector V3 Bioapplication was best suited for counting 
spots and we confirmed that it was the most capable program to accurately assess 
changes in GFP-LC3 spots in our stable cell line.  GFP-LC3-HEK cells were plated on 
96-well plates, allowed to grow for 24 hours and then treated with Vinblastine in order 
to image the accumulation of autophagosomes (Arstila et al., 1974).  The cells were 
then fixed, stained with Hoechst, and images were captured at 20X in Channel 1 and 
Channel 2 (Figure 3.14) using the GFP channel (Channel 2) to set the focus with fixed 
illumination time.  In a similar way that a mask is drawn around nuclear staining as 
shown above, a mask is placed on GFP-LC3 spots in Channel 2 (the GFP channel) in 
order to designate them as countable spots.  First, a line is drawn around the nuclear 
staining determined by Channel 1 as described above (blue line).  Cells on the edge of 
the field are not counted and receive no blue ring.  Then a ring 22 microns from the 
edge of the nucleus is drawn (green line).  Last, GFP-LC3-labelled autophagosomes are 
defined by adjusting parameters including spot area, shape, and average intensity and 
marked with magenta spots if they meet said criteria.  After each optimisation 
experiment plates were scanned and adjustments to the SpotDetector parameters were 
made.  This was required because cell density as well as the strength of the induction of 
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autophagy differed between experiments.  We compared uninduced cells with a small 
number of basal GFP-LC3 autophagosomes per field to induced cells with multiple 
spots per cell and adjusted the parameters in an attempt to minimise the number of 
GFP-LC3 spots that were incorrectly not called and minimise the amount of cellular 
debris or other non-spots that were miscalled.  As described above, spots in cells close 
to the edge of the field are not marked with magenta and do not count towards 
quantification of SCPO or STIPO as shown (Figure 3.14, panel b).  Also we excluded 
any contribution from nuclear spots or areas of increased GFP intensity in the nucleus 
or cytoplasmic GFP-LC3 spots that lie above the nucleus thereby restricting the analysis 
to perinuclear and cytoplasmic GFP-LC3 spots. 
 
Figure 3.14 Counting GFP-LC3 spots with Cellomics SpotDetector 
a. Images of GFP-LC3-HEK cells in Channel 2 (GFP) after 50µM vinblastine treatment for two hours 
shown without or with SpotDetector nuclear, ring and spot masks. The blue ring designates the nucleus, 
the green designates the ring within which spots are counted and the magenta designates spots. 
 
In an attempt to determine whether using a different type of plate could lead to a 
more accurate quantification of GFP-LC3-labled autophagosomes as well as better 
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resolution in order that we might classify the GFP-LC3 spots in terms of different 
morphology (Zhang et al., 2007b), I plated GFP-LC3-HEK cells on plates with extra-
thin plastic bottoms (Imaging Plates, BD Falcon) and captured images at 20x 
magnification.  The data produced did not reflect the induction of autophagy better and 
in fact, were troublesome to the Cellomics ArrayScan.  The bottoms of the wells were 
quite fragile and easily damaged and thus, the ArrayScan had trouble focusing on the 
GFP-LC3 spots and data acquisition was not optimal.  Glass-bottomed plates were also 
tested and had similar problems as the Imaging Plates without significantly improved 
resolution or spot-calling.  We determined that we could capture images of GFP-LC3 
spots at 20x magnification (650nm/pixel) and quantification of these spots reflected 
induction of autophagy but we wanted to ask if the increased resolution resulting from 
capturing images at 40x would lead to more robust data.  The spots were slightly better 
resolved at higher magnification but the signal to noise ratio was not significantly 
resolved and the fold induction between uninduced and induced was not significantly 
greater.  In addition, the time needed to process plates from a genome-wide screen 
captured at 40x would at least double and in the interest of saving processing time, we 
determined it would not be feasible to capture imaging at 40x.  To conclude, I 
determined that induction could be quantified in terms of GFP-LC3 SCPO, STIPO, and 
STAPO using a Cellomics ArrayScan and that the best induction of autophagy was seen 
with EBSS plus leupeptin. 
3.3.2 Optimising siRNA transfection 
It had been shown that siRNA targeting Atg7 and ULK1 inhibited autophagy in 
the GFP-LC3-HEK cell line (Chan et al., 2007).  In fact, HEK cells are an established 
system for they are known to be relatively easy to transfect.  As a starting point to 
optimise of siRNA knock-down in GFP-LC3-HEK cells I copied the format of the 
kinome screen and used 96-well plates and 72 hours total incubation including a 24 
hour recovery, with induction of autophagy on day four.  Because of the experimental 
manipulations antibiotics (Penicillin and Streptomycin) were added throughout the 
screen.  It is established that antibiotics often hinder lipid-based transfections so I had to 
find a transfection method that was effective in the presence of antibiotics. 
The kinome screen was done using a conventional transfection protocol in which 
cells are plated onto the 96-well plates, left to adhere and grow for 24 hours, then 
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siRNA is incubated with Oligofectamine lipid transfection reagent (Invitrogen) for a 
short period of time (20 minutes), added to the cells, left for 48 hours, and the cells are 
finally put to recover in normal full growth medium for 24 hours.  Instead, I tested a 
‘reverse’ or ‘wet’ procedure where the siRNA and transfection reagent are incubated 
directly on the plate for 20 minutes and the cells are resuspended in 80% of the final 
volume and added to this mixture; this transfection method was suggested by 
Dharmacon to provide a more efficient siRNA knock-down (“Rapid Screening for 
Target Identification,” DHARMACON RNA Technologies).  For large scale siRNA 
screens there are several parameters that needed to be addressed.  First, on day one of 
the screen the siRNA will already have been aliquoted onto the plates because it can 
take up to a day for the robots to aliquot the siRNA library onto the plates due to the 
large size of the genome library.  Second, the number of times the siRNA of the 
siGenome library is frozen and thawed is limited.  I compared the conventional and 
reverse transfection using Oligofectamine and the cells knocked down by reverse 
transfection actually survived better (as measured by OC) and looked healthier than 
those knocked down by conventional transfection.  I believe that this is influenced by 
cell density during transfection: the cells need to be confluent enough to survive the 
toxicity of the lipid transfection reagent but sparse enough so that there are enough 
siRNA/lipid transfection reagent molecules for each cell.  In addition, the image-based 
quantification of GFP-LC3 adds another demand on density in that if the cells are too 
close together at the time of image acquisition and the cytoplasm is not spread out, 
GFP-LC3 spots appear to be bunched together and are not accurately called.  Also, if 
the cytoplasm is pushed up over the nuclei of the cells the cytoplasmic GFP-LC3 spots 
are excluded from the SpotDetector analysis, as described above.  Last, we have 
observed in the lab that if cells are too close in proximity to each other (too dense) then 
they do not starve as well by culturing them in EBSS.  
Therefore, I set up experiments to identify the best siRNA transfection reagent for 
a 72 hour reverse transfection in the presence of antibiotics at a optimal cell density for 
GFP-LC3-HEK cells.  I had observed that knock-down of ULK1 strongly inhibited 
GFP-LC3 spot formation and that the 72 hour transfection was extremely efficient for 
ULK1 siRNA.  Atg7 siRNA was used to find the best transfection reagent for my assay 
from a panel of 20 reagents acquired by the HTS lab because I observed that Atg7 
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knock-down was more variable and often its effect on spot parameters was more subtle.  
I tested the 20 reagents at three different final concentrations per well combined with or 
without Atg7 siRNA using reverse transfection.  The siRNA was mixed with the 
different amounts of reagent for 20 minutes, 4000 GFP-LC3-HEK cells in full medium 
supplemented with antibiotics were added per well, cells were incubated for 48 hours 
followed by a change to fresh full medium and a 24 hour incubation.  Finally, 
autophagy was induced by incubation in EBSS plus leupeptin for two hours, and the 
effect on GFP-LC3 spots was measured.  The 20 reagents, listed in Materials and 
Methods (2.3.2.1), had various effects on cell viability and the number of GFP-LC3 
spots per cell after Atg7 knock-down (Figure 3.15).  Six transfection reagents were 
toxic to the cells, reducing OC and often skewing SCPO; these reagents included 
numbers 2, 4, 9, 12, 14, 20.  Reagent number 8, Lipofectamine2000 (Invitrogen) was 
the best, achieving the strongest effect on SCPO at 0.33µL.  Although cell viability was 
not as good, Ambion’s siPORT Amine transfection reagent (2) had a dose-responsive 
effect on SCPO, though data is missing for the high dose of reagent without Atg7 
siRNA.  Oligofectamine (7, Invitrogen), the reagent used in the kinome screen, does not 
appear to be very effective in this assay. 
 
Figure 3.15 20 transfection reagents used to knock-down Atg7 have varying effects 
on GFP-LC3 spot formation 
SCPO after EBSS plus 0.25mg/mL leupeptin for 20 transfection reagents at three doses with or without 
Atg7 Smartpool siRNA as indicated. Controls (white bars) show effect with no transfection reagent, in 
full medium or EBSS plus 0.25mg/mL leupeptin, minus or plus Atg7 siRNA and were created from data 
from four wells. Data for all others come from single wells. 2 is Ambion siPORT Amine; 7 is Invitrogen 
Oligofectamine; 8 is Invitrogen Lipofectamine 2000. 
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I retested the best eight reagents in the same assay (Figure 3.16).  I adjusted the 
low, medium and high dose of reagent based on manufacturers’ recommendations. 
Lipofectamine2000 (8) again seems to be the best at decreasing SCPO compared to 
reagent with no siAtg7 at all three doses (0.3, 0.45, 0.6).  Reagent 1, siPORT NeoFX 
Transfection Agent (Ambion) is working at highest concentration 0.6µL per well, but 
not at lower concentrations.  Similarly, reagent 13, DreamfectGold (OZ Bioscience) is 
only working at the highest dose, 0.3µL.  Again, reagent 2, Ambion’s siPORT Amine 
Transfection Agent is somewhat toxic to the cells and in this experiment I obtained data 
for the reagent alone (black bar) and can see that SCPO is decreased even without 
siAtg7, most likely due to toxicity.  Reagents 3, 5, 6, and 15, when combined with Atg7 
siRNA do not lead to a decrease in GFP-LC3 spot number. 
 
Figure 3.16 Eight transfection reagents used to knock-down Atg7 have varying 
effects on GFP-LC3 spot formation and object count 
SCPO after EBSS plus 0.25mg/mL leupeptin for 8 transfection reagents at three different doses with or 
without Atg7 siRNA as indicated. Controls (white bars) show effect with no transfection reagent in full 
medium or EBSS plus 0.25mg/mL leupeptin, minus or plus Atg7 siRNA and were created from data from 
four wells. Data for all others come from duplicate wells. Ambion siPORT Amine is reagent number 2; 
Lipofectamine 2000 is reagent number 8. 
 
I next retested the most promising reagent, Lipofectamine2000, the reagent that 
is best at reducing SCPO when combined with Atg7 siRNA, Ambion’s siPORT Amine 
Transfection Agent, and the reagent used in the kinome screen, Oligofectamine.  I tested 
two doses, 0.3µL and 0.5µL, and measured SCPO and OC when treated with siControl 
siRNA pool versus siAtg7, in full medium or EBSS plus Leupeptin (Figure 3.17, part 
a).  siPORT reduces SCPO at the higher dose of 0.5µL when comparing siControl to 
siAtg7 addition but this high dose is compromising cell viability as seen by low OC 
numbers.  Knock-down of Atg7 with Lipofectamine2000 led to the greatest decrease of 
SCPO without compromising cell viability.  Again, we see that knocking down Atg7 
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with Oligofectamine is not effective at decreasing GFP-LC3 spot formation.  In order to 
assess the efficiency of protein depletion by the three transfection reagents I knocked 
down COPB1 in GFP-LC3-HEK cells and measured the amount of COPB1 protein 
remaining and can see the Lipofectamine2000 is best at decreasing proteins levels, 
siPORT does reduce protein levels, and Oligofectamine is not effective. 
 
Figure 3.17 Testing the efficacy of three transfection reagents 
a. SCPO after full medium or EBSS plus 0.25mg/mL leupeptin (EBSS+L) for 3 transfection reagents at 
two doses with 50nM siControl siRNA or 50nM Atg7 siRNA as indicated. Error bars represent standard 
deviation from four wells. b. Western blot showing COPB1 protein after treatment with 0.4uL reagent 
and 50nM siControl or 50nM siCOPB1 siRNA. PonseauS shows equal loading between samples. 
 
These experiments show that Lipofectamine2000 is the best transfection reagent 
for GFP-LC3-HEK cells under my screen assay conditions and did not threaten cell 
viability.  I confirmed that 4000 cells per well is the optimal density for efficiency of 
knock-down and final density of cells for optimal data acquisition in subsequent 
experiments.  Similarly I determined that 0.4µL, not 0.3µL or 0.35µL of 
Lipofectamine2000 achieved the most significant decrease of GFP-LC3 spot parameter 
with knock-down of ULK1 and Atg7. 
The next parameter to optimise was the concentration of siRNA for the screen.  
Using the optimal conditions of 0.4µL Lipofectamine2000 and plating 4000 cells per 
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well I tested siControl, siULK1, siAtg7 and siAtg13 at three siRNA concentrations, 
25nM, 37.5nM and 50nM.  I measured SCPO after treatment with EBSS plus leupeptin 
and saw that the concentration of siRNA did not have a drastic effect on GFP-LC3 spot 
parameters though 37.5nM and 50nM of siRNA against ULK1 and Atg7 seemed 
slightly better than 25nM at inhibiting SCPO (Figure 3.18).  Also, a slightly greater fold 
induction of autophagy was seen with the siControl siRNA at 37.5nM compared to 
50nM.  The siGenome library was aliquoted to be used at a concentration of 37.5nM 
and prepared to be further aliquoted for this final siRNA concentration on the screen 
plates. 
 
Figure 3.18 Testing to find the optimal siRNA concentration 
GFP-LC3-HEK cells were treated with three concentrations of siRNA and incubated in full medium or 
EBSS plus 0.25mg/mL leupeptin (EBSS+L). Spot Count Per Object (SCPO) was determined. Data 
represents averaged SCPO from two wells. 
 
Last, using the optimal conditions for reverse transfection I identified the best 
siRNA controls to use in the screen.  The siGenome library was to be aliquoted onto 80 
wells of 96-well plates leaving the first two columns of the plate for 16 positive and 
negative controls.  To find negative controls, I tested Dharmacon’s siControl non-
targeting pool 1 and siControl RISC-free siRNA and found RISCfree did not affect 
GFP-LC3 spot number, size and intensity as much as the siControl pool.  The RNA-
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induced silencing complex (RISC) is an effector nuclease that carries siRNA to the 
nucleus and without it, RNAi does not occur (Hannon, 2002).  The siControl pool 
contains four siRNA duplexes that are not predicted to target any known genes; in GFP-
LC3-HEK cells, however, it seems to stress the cells (perhaps by inadvertently target a 
gene that is required for normal cell maintenance) thereby slightly elevating levels of 
autophagy.  I showed that knock-down of ULK1, Atg7, and Atg13 decreases SCPO, 
STIPO, and STAPO, though siULK1 was the most efficient positive control for 
decreasers of spots.  The siRNA kinome screen identified an siRNA pool called 
siLOC340371 that increased GFP-LC3 lipidation (Chan et al., 2007).  This protein, now 
known as NRBP2 or nuclear receptor binding protein 2 is uncharacterised though it has 
been shown to be induced by differentiation of neural stem/progenitor cells (Larsson et 
al., 2008).  Interestingly, the Drosophila NRBP homologue, CG1098 was found in a 
RNAi screen to be involved in HRP secretion and Golgi organisation and was shown to 
localise to cytoplasm and Golgi membranes (Bard et al., 2006).  Mammalian NRBP1 
has been shown to interact with the small GTPase Rac3, and when overexpressed, 
perturbs early Golgi membranes in mammalian (De Langhe et al., 2002).  Also, NRBP1 
is recruited to Golgi membranes upon viral infection (Chua et al., 2004).  I found that 
knock-down of LOC340371 decreases the mRNA levels of NRBP2 and increases 
SCPO and STIPO above control and thus provides me with a positive control for 
increasers of GFP-LC3 spots (Figure 3.19, part a, b).  Thus I have established 
parameters that allow quantification of GFP-LC3 spots after autophagy induction when 
cells are treated with RISC-free siRNA (spots are represented by magenta dots in the 
Cellomics SpotDetector program and are quantified for count and total intensity (Figure 
3.19, part a, b).  The number and total intensity of these spots is decreased after ULK1 
knock-down and conversely increased after NRBP2 knock-down. 
Object calling was further optimised using the nuclear staining, eliminating 
small nuclei and clumped or multinucleated cells (see yellow ring, Figure 3.19, panel a).  
Similarly, we further optimised spot calling in Channel 2: cells plated at 4000/cells per 
well are evenly spread throughout the well at a proper density for autophagy induction 
and spot calling, examples of which are displayed here.  When cells are plated at this 
density, accurate information is gathered after imaging ten fields, leading to an object 
count in this experiment in the range of 152 to 537 with an average OC of 366.  In 
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parallel, I knocked down ULK1 using these conditions in GFP-LC3-HEK cells, lysed 
the cells and probed for ULK1 in order to determine protein levels remaining after 
ULK1 siRNA treatment (Figure 19, panel c).  ULK1 protein levels are significantly 
reduced by siULK1.  As expected, ULK1 protein levels are reduced by Atg13 knock-
down, as it has been shown that Atg13 is required for ULK1 stabilisation (Chan et al., 
2009), (Ganley et al., 2009). 
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Figure 3.19 Quantification by Cellomics of the effect of control siRNA Smartpools 
on GFP-LC3 spot formation 
a. Cellomics images with masks after indicated siRNA treatment and incubation with EBSS plus 
0.25mg/mL leupeptin. The blue line indicates a ring around nuclear staining, the red line is the ring 
within which spots are counted, and the magenta designates GFP-LC3 spots. b. SCPO, STIPO for 
indicated siRNA knock-down. RF is RISCfree. Full medium values are generated from averaging 
duplicates, error bars represent standard deviation of triplicates. c. Western blot after indicated knock-
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down in HEK-GFP-LC3 cells. The blot was probed for ULK1 and actin. RF is RISCfree, siN2 is 
siNRBP2, siU1 is siULK1, siA7 is siAtg7, and siA13 is siAtg13. 
 
An interesting phenomenon that I observed during experiments to optimise the 
image-based assay for autophagy was the reproducible increase in object count after 
ULK1 knock-down.  When compared to siControl, knock-down of ULK1 increased cell 
number, represented by the number of nuclei or objects in the Cellomics SpotDetector 
programme (Figure 3.20).  Autophagy inhibits cell growth so conversely it is 
conceivable that inhibition of proteins required for autophagy might increase cell 
growth.  This is perhaps the reason for the small increase in OC observed with siAtg7 
and siAtg13 but this increase is less than that seen with siULK1.  The increase of cell 
growth after ULK1 inhibition is contrary to some data from D. melanogaster where it 
has been shown that ULK1 can directly inhibit TOR leading to cell growth in an 
autophagy-independent way (Scott et al., 2007).  In should be noted that, as discussed in 
the introduction, Atg1 and TOR in D. melanogaster display some different 
characteristics to ULK1 and mTOR in mammalian cells (Chan and Tooze, 2009).  
Bearing this in mind, high levels of Atg1 overexpression in Drosophila triggered 
downstream pathways and stimulated autophagy, reducing cell size and leading to 
apoptotic cell death (Scott et al., 2007), so perhaps in the opposite way, ULK1 knock-
down could increase cell growth.  A different study in Drosophila demonstrated that 
Atg1 inhibits cell growth by positively regulating p70S6 kinase (Lee et al., 2007). In 
mammalian cells, it has also been shown that both ULK1 and ULK2 can provide 
feedback regulation upstream to the mTOR-p70S6 kinase pathway, and in this way, 
ULK1 knock-down could increase cell proliferation. 
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Figure 3.20 Knock-down of ULK1 increases cell number 
Valid object count (OC) after knock-down with three doses of indicated siRNA. 
3.3.3 Optimising the induction of autophagy 
I have previously observed that after a certain number of passages in tissue 
culture, GFP-LC3-HEK cells begin to loose their GFP-LC3 expression.  This can be 
observed in Figure 3.14 where seven cells, from a culture passaged 17 times, appear as 
objects based on nuclear staining (indicated by the blue ring) but display no nuclear or 
cytoplasmic GFP-LC3 (indicated by magenta spots).  These cells are counted as objects 
but do not contribute to spot counting in the GFP channel therefore decreasing the 
values for spot count, intensity and area per object.  I tested the effect of passage 
number on autophagy induction as measured by SCPO, STIPO and STAPO, comparing 
GFP-LC3-HEK cells at passage number eight to those at passage number 18.  I saw a 
24.8% reduction in SCPO when cells at P18 were induced with EBSS plus leupeptin 
(data not shown).  It follows that in order to achieve the best fold induction of GFP-LC3 
spots during the screen I must insure that the GFP-LC3-HEK cells are at a low passage 
number. 
I saw that values for SCPO, STIPO and STAPO are greater after induction of 
autophagy with EBSS plus leupeptin compared with EBSS alone, thus I determined the 
best concentration of leupeptin in order to obtain the best induction for the screen.  The 
use of leupeptin in the screen also had cost implications.  I tested three concentrations of 
leupeptin, 0.25mg/mL, 0.125mg/mL and 0.083mg/mL and confirmed previous findings 
that the best induction was seen with the highest dose, 0.25mg/mL of leupeptin.  We 
decided that the greatest possible fold induction of autophagy was needed in order to 
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capture modulations in the three spot parameters during the screen, despite the high cost 
of leupeptin. 
Last, the optimisation experiments were done using a multi-well pipette to add 
reagent, wash, induce autophagy, fix and stain.  It was important to be gentle while 
washing the plates and adding EBSS with leupeptin in order to avoid cell loss but 
equally important for the induction step that all full growth medium was washed away 
from the cells before the addition of EBSS with leupeptin.  It was not, however, 
possible to manually was the plates of a genome-wide screen in this way.  After testing 
multiple liquid-handling robots and manual washing techniques we determined that 
washing the plates by inverting them into large vats of PBS then adding the induction 
medium with a Thermo Scientific Matrix WellMate microplate dispenser at its slowest 
and gentlest speed was not only gentle enough to maintain cell numbers but efficient in 
inducing autophagy.  We also determined that adding 8 per cent formaldehyde at equal 
volume directly to the plates after induction using the WellMate would adequately fix 
the cells at 4 per cent final concentration again without significantly disturbing the cells. 
3.3.4 Summary of optimisation conditions 
After optimising the image-based assay to measure modulation of starvation-
induced autophagy by siRNA knock-down of GFP-LC3-HEK cells the following 
protocol was established: a reverse knock-down for 72 hours would be used with 0.4µL 
Lipofectamine2000, 37.5nM siRNA with 4000 cells per well.  Formation of GFP-LC3 
spots would be induced by incubation in EBSS plus 0.25mg/mL leupeptin for two hours 
and SCPO, STIPO and STAPO measured using the SpotDetector program that had been 
optimised for best object and spot calling.  I determined the range of the assay under 
these conditions by combining data from experiments that followed the protocol just 
described (Figure 3.21).  A greater-than-two-fold increase is seen for spot count, 
intensity and area when cells are treated with RISCfree control siRNA and induced with 
starvation medium.  This induction is significantly decreased by treatment with positive 
control siRNAs ULK1 and Atg7 and significantly increased by treatment with the 
positive control NRBP2 siRNA. 
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Figure 3.21 The effect of various siRNA treatments on SCPO, STIPO and STAPO 
SCPO, STIPO, STAPO after siRNA treatment in GFP-LC3-HEK cells. FM is full medium, E+L is EBSS 
plus 0.25mg/mL leupeptin. Error bars represent standard error of the mean. Each experiment consists of 
at least duplicate values. SCPO siULK1 p=0.0002; siAtg7 p=0.0078; siNRBP2 p=0.0088. STIPO siULK1 
p<0.0001; siAtg7 p=0.0060; siNRBP2 p=0.0041. STAPO siULK1 p<0.0001; siAtg7 p=0.0037; siNRBP2 
p=0.0028. RISCfree (n=5), siULK1 (n=5), siAtg7 (n=3), siNRBP2 (n=3). 
 
3.3.5 Pilot Screens 
Before screening the entire genome I had to prove that the assay I developed 
would provide an accurate read-out for siRNA-based modulations in autophagy, I 
undertook two small pilot screens.  First I assayed plate number ten of the kinome 
library used previously in the lab following the protocol above on duplicate plates 
containing negative and positive control siRNAs; this is also plate 10 of the siGenome 
library.  Plate number ten was chosen because it contained ULK1 and ULK2 siRNA 
and indeed I saw a strong inhibition of GFP-LC3 spot formation by siRNA against 
ULK1 but not against ULK2.  I saw a significant increase of SCPO with siRNA against 
my positive control NRBP2 and also siRNA against TLK2 (NM_006852). 
I also tested a plate that was generated to hold a small library of siRNA against 
genes that code for nuclear membrane receptor proteins.  Duplicate plates were 
processed and I obtained raw data for SCPO as before and then normalised the data as 
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might be done in the large-scale screen of the genome.  First, I divided the raw data by 
the individual plate median absolute deviation, creating a Z-score or value indicating 
standard deviations away from the median.  Then I determined the median of the 
duplicate Z-scores for each well.  These median Z-scores range between -2.88 (a strong 
decreaser of spots) and +4.62 (a strong increaser of spots) (Figure 3.22, part a, b).  The 
two wells that received siULK1 showed strong negative Z-scores and the two wells that 
received siNRBP2 showed strong positive Z-scores though one of the duplicates wells 
mistakenly received less transfection reagent and therefore showed a more subtle 
increase in GFP-LC3 spots.  Though the range of the assay is relatively small 
(approximately two-fold; Figure 3.21), the results are reproducible and the data 
generates significant Z-scores.  Thus, it was determined that the image-based assay was 
capable of producing robust data in a high-content screen for starvation-induced 
autophagy. 
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Figure 3.22 Pilot screen of Nuclear Membrane Receptor Protein Plate 
a. Heat map of the 96-well plate assayed depicting the strength of median Z-score from duplicate plates. 
Wells that received siULK1 and siNRBP2 are indicated. b. Scatter plot displaying plate position versus 
median Z-score for duplicate plates. Two wells with siNRBP2 knock-down and two wells with siULK1 
are shown. 
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Chapter 4. Primary, Repeat and Deconvolution 
Screens 
4.1 Overview of the screening strategy 
A genome-wide screen for starvation-induced autophagy in GFP-LC3-HEK cells 
was preformed on the 21,121 genes targeted by the Dharmacon siGenome library 
(Appendix Table 9.1, 9.2).  The 1000 genes whose knock-down led to the strongest 
increase or decrease of GFP-LC3 spot count, total area, and total intensity were taken 
forward and the primary screen assay was repeated (Appendix Table 9.3, 9.4).  Images 
from the secondary screen were visually inspected for 371 of the gene knock-downs and 
those that were mis-called or that caused cell death were eliminated from the hit list.  
200 genes were taken forward to the deconvolution screen during which individual 
siRNA duplexes that comprise the Dharmacon siGenome Smartpools were individually 
assayed (Appendix Table 9.5).  Of these, 51 genes had at least two out of four siRNA 
duplexes that repeated the primary and secondary screen spot phenotype.  20 of these 
had three of four siRNA duplexes that validated and are expected to be expressed in 
HEK cells.  These nine ‘decreasers’ and 11 ‘increasers’ were taken forward for further 
validation.  This process is summarised in Figure 4.1 and I will now describe the 
primary screen, secondary/repeat screen and deconvolution screen in greater detail. 
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Figure 4.1 Strategy for the genome-wide screen for starvation-induced autophagy 
Summary of the primary screen, secondary or repeat screen, deconvolution screen and their results. 
 
4.2 Primary Screen: The autophagy screen of 21,121 genes 
4.2.1 Preparing for the primary screen 
There were many reagents to purchase and prepare in a large scale before 
undertaking the primary screen.  As I determined that Lipofectamine2000 was the best 
transfection reagent for my assay, I performed a test screen on a batch and confirmed it 
gave a robust effect.  This batch was purchased and used for the primary, repeat and 
deconvolution screens as well as the further analysis of the 20 strongest hits, described 
in chapter 5.  As I had determined that a final concentration of 0.25mg/mL of leupeptin 
in starvation medium was required for the best induction, I similarly tested two lots of 
the chemical and determined that the effect of these were comparable to that seen 
during the screen optimisation and obtained the required 1.4 grams.  Finally, I ordered 
and tested all batches of reagents (siRNA controls, Poly-D-lysine, growth medium, 
EBSS etc.) in test screens before performing the large-scale screen. 
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The required 801 Falcon Microtest 96-well Optilux Assay Plates were coated 
with Poly-D-lysine and barcodes were added to the plates.  The Dharmacon Human 
siGENOME siRNA library (including the Protein Kinase and G Protein-Coupled 
Receptors libraries, and the Human Druggable Set and Human Genome Set) was then 
aliquoted in onto triplicate plates so that there was 375nM Smartpool siRNA in 10µL 
Hank’s Buffered Salt Solution (HBSS) in each well.  The plates were kept at -20°C until 
day one of the screen. 
The GFP-LC3-HEK cells were prepared so that they would be at their optimal 
health and responsiveness during the screen.  Cells were thawed from their lowest 
passage available (from their original freeze after stable GFP-LC3 expression was 
obtained) and tested for their ability to be induced for autophagy and affected by siRNA 
knock-down; the screen was performed with cells at passage number 11.  I estimated 
that I needed 50 175cm flasks and split the cells to a density that was below confluency 
and optimal for counting on day 1 of the screen. 
4.2.2 Performing the primary screen 
The primary screen was performed over a four day period.  The 801 plates, 267 
plates in triplicate, contained the 21,121 genes in the siGENOME library and 16 empty 
wells for controls per plate and were processed together.  We divided the plates into 
four batches of 200 plates for easier handing on the most labour-intensive of the 
screening days, day 1 and 4.  Using the recommended 20 minute incubation period for 
siRNA and Lipofectamine mixing we determined that four people were needed to 
process each of the 200-plate batches in two hours on day 1.  In turn, our experimental 
plan was mostly dictated by the speed at which the WellMate robots could add 
transfection reagent and cells to the plate (approximately 30 seconds a plate for each 
addition) (Figure 4.2).  I was responsible for preparing the positive and negative siRNA 
controls and preparing the cells by counting and resuspending them in medium.  A 
detailed protocol of the reverse transfection performed on the 801 plates is contained in 
the Materials and Methods section. 
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Figure 4.2 Time plan to process 200 plates on Day 1: transfection and plating cells 
It required four people to process 200 plates in two hours. Two WellMate liquid handling robots in two 
tissue culture hoods.  Following the reverse transfection protocol previously described, transfection 
reagent is added to the siRNA on the plate. See Materials and Methods for further details. 
 
The plates were kept at 37°C in three incubators and cells on several plates were 
checked on day 2 and appeared to be growing well and at an expected density.  On day 
3 the transfection medium was removed from the plates and fresh full grown medium 
was added.  On day 4 autophagy was induced for two hours in EBSS plus 0.25mg/mL 
leupeptin and the cells were then fixed with 4% formaldehyde and sealed.  On day 5, 
the plates were de-sealed, the fixation medium was replaced with 100µL PBS, re-sealed 
and stored at 4°C.  Plates were stained with 1µg/mL DAPI for 20 minutes immediately 
before data acquisition and images were obtained and data simultaneously generated on 
the Cellomics ArrayScan usually in batches of 20 overnight. As a control for basal 
GFP-LC3 spot number, a plate of cells that received transfection medium but no siRNA 
was incubated on day 4 in full medium, not starvation medium, for two hours and fixed.  
This plate as well as control wells on the screen plates were used to set the spot 
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thresholds in the Cellomics SpotDetector program and these parameters were used to 
analyse all plates.  The Cellomics machine captured at least 250 cells per well 
(determined to be valid objects based on nuclei of normal area, shape and intensity, as 
described above); on average it took approximately 50 minutes to read each plate.  In 
turn, it took approximately two months to image and collect data from the 801 plates. 
4.2.3 Normalisation and analysis of data from the primary screen 
Data was collected from all sets of triplicate plates except for plate 10 (the last 
plate of the series of the protein kinase sub-set of the siGenome library), which is the 
plate that contains the siRNA Smartpool against ULK1.  This set of triplicate plates had 
very few cells remaining after the screen and we determined that this loss was most 
likely due to these plates being left out of Poly-D-lysine coating or washing.  The assay 
was repeated in triplicate on this plate as in the primary screen at a later date and the 
data was normalised as below in the exact same way as the screen plates. 
Upon examining the 801 screen plates after fixation, I noticed that the density of 
the cells in each well was not optimal in that the cells were more sparse than previously 
seen.  In turn, this made finding 250 cells per well and reading each plate a longer 
process than expected.  Because the cells seemed to be growing normally and at an 
expected density up until day 4, I concluded that the cell loss must have occurred on 
day 4 during the induction of autophagy.  The plates were outside of the incubator for 
longer than when I was working with just one or two plates and therefore not at optimal 
temperature (37°C) and CO2 (10%).  In addition, because we were taking and putting 
plates out of and into the incubators often, the incubators themselves did not maintain 
the desired temperature and percentage CO2.  We believe that this increased the amount 
of cells lost during washing, incubation in starvation medium and fixation. 
It was observed across the entire set of plates that some wells had particularly 
low cell counts possibly due the siRNA being toxic or manipulation of those cells was 
especially harsh.  We did not want to incorporate results from the wells with low cell 
counts as these data were possibly skewed because there is a possibility that the 
remaining cells were not representative.  We set a cell number cut-off to 50 cells per 
well and applied this filter to the raw data such that any wells with a valid object count 
less than 50 were flagged and not used in any calculation and therefore did not 
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contribute to the analysis for that siRNA Smartpool.  Triplicate wells with more than 
one replicate flagged as below this 50-cell threshold were not considered in any 
evaluation and this siRNA Smartpool was not evaluated. 
All data was processed with the Cell HTS Normalisation programme (Boutros et 
al., 2006) by Rebecca Saunders of the HTS lab, LRI.  First, raw data for the three 
individual parameters, Spot Count per Object (SCPO), Spot Total Intensity per Object 
(STIPO), and Spot Total Area per Object (STAPO) were normalised using the B-score 
method to correct for plate row and column effects.  To determine a B-score, the plate 
median and estimated well and column effects are subtracted from each well’s raw 
value to account for differences within an individual plate.  This first round of 
normalisation is effective in minimising measurement bias due to so-called edge-effects 
(defined as the advantages or disadvantages in condition to which an individual well is 
subjected due to its position on the plate) (see Appendix 9.1.1 for further explanation on 
B-score normalisation). 
Next, this B-score is centred around zero by dividing each well value by the 
plate median absolute deviation (MAD), thus creating a Z-score (Malo et al., 2006) (see 
Appendix 9.1.2 for further explanation on Z-score normalisation).  The Z-score gives a 
value for the distance, or units of standard deviation, above or below the plate median 
and allows us to compare the data across the entire screen.  Then triplicate values were 
summarised by taking the median Z-score for each siRNA Smartpool.  These two 
rounds of normalisation (B-score then Z-score) were essential because we observed a 
‘bounciness’ of the raw data or differences between groups of plates (Figure 4.3, panel 
a).  Once the raw values for SCPO, STAPO, and STIPO were normalised twice as 
described the range of the median Z-score data across the 267 triplicate plates appears 
similar (Figure 4.3, panel b.).  The differences between plates may have been due to 
dividing the plating of the cells into four batches on day 1, differences in incubation 
conditions during the screen, differences in DAPI staining between different batches or 
even differences between when plates were scanned over the course of the two-month 
data acquisition period.   
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Figure 4.3 STIPO raw values and normalised Z-scores for the Primary screen. 
a. Median raw values for STIPO for the 267 triplicate screen plates. b. Z-scores or standard deviations 
above and below the mean for STIPO for the 267 screen plates. 
 
As mentioned, the SCPO, STAPO, and STIPO Z-score for each siRNA 
Smartpool was determined by taking the median Z-score for each triplicate.  The siRNA 
Smartpools were then ranked according to their Z-score for each of the three parameters 
and these were then combined to create a rank product (RP) and a new ranked list was 
created.  In order to assess the overlap between the three spot parameters, I compared 
the approximate 500 best increasers of SCPO, determined by their SCPO Z-score rank, 
to the approximate 500 best increasers of STIPO and also to the approximate 500 best 
increasers of STAPO (Figure 4.4).  The knock-down of 212 genes led to an increase of 
SCPO, STIPO and STAPO that ranked in the approximate top 500 for each parameter.  
90 siRNA Smartpools lead to an increase of GFP-LC3 spot number that ranked in the 
top 480 for SCPO only, 195 siRNA Smartpools lead to an increase of GFP-LC3 total 
intensity that ranked in the top 498 for STIPO only, and 127 siRNA Smartpools led to 
an increase in GFP-LC3 spot area that ranked in the top 488 for STAPO only.  The 
knock-down of different genes may affect the three spot parameters differently or the 
data generated from only one or two of the parameters may reflect the knock-down’s 
affect on autophagy less accurately.  It was therefore important to incorporate the data 
obtained from the analysis of all three spot parameters because the combined data was 
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more informative than data obtained from the analysis of just one of the spot 
parameters.   
 
Figure 4.4 Venn Diagram of the overlap of the best increasers of the three 
parameters 
833 total gene knock-downs leading to an increase of SCPO, STIPO or STAPO are shown. Overlap 
represents siRNA Smartpools whose effect caused them to rank in the top 500 increasers for more than 
one spot parameter.  
 
I analysed the SCPO Z-scores for all siRNA Smartpools including those from 
the control wells and plotted these ranked Z-scores (Figure 4.5).  The range of SCPO Z-
scores is +4.7 for the strongest increaser and -4.1 for the strongest decreaser.  Indicated 
in red are the 267 median SCPO Z-scores for well C01, which held the positive control 
siRNA Smartpool targeting ULK1.  These values are all negative indicating that these 
knock-downs lead to a decrease in GFP-LC3 spot count per object and most Z-score 
values are less than -2 indicating a strong effect or greater than 2 standard-deviations 
distance away from the screen mean. This scatter plot also displays the 1242 wells 
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whose siRNA treatment lead to fewer than 50 cells per well for at least two out of three 
of the replicates and therefore whose Z-scores were not generated. 
 
Figure 4.5 Scatter plot of median SCPO Z-scores against rank for all siRNA 
Smartpools 
All tested siRNA Smartpools were ranked in terms of SCPO Z-scores and plotted.  The red dots represent 
median values from well C01, which contained ULK1 siRNA.  The blue bar represents siRNA knock-
downs that led to less than 50 cells per well in at least two out of three replicates and so Z-scores for these 
Smartpools were not generated. 
 
All 21,121 siRNA Smartpools were ranked by rank product (RP) as increasers 
and conversely as decreasers and roughly the top and bottom 500 are shown (Appendix, 
Table 9.1 and 9.2).  These were chosen to be taken forward and the assay was repeated 
with these 1000 siRNA Smartpools (see section 4.3).  Values for SCPO, STAPO and 
STIPO for the three replicates, corresponding ranks, rank product (RP) and object count 
(OC) for the three replicates were recorded.  When object counts were less than 50 cells, 
corresponding data was not determined for that replicate designated by a ‘ND.’  Data 
for siRNA Smartpools contained on plate 10 are shown at the bottom of each list and 
genes of interest discussed below are also highlighted. 
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4.2.4 Results of the primary screen 
A number of autophagy-related (Atg) genes previously shown to be required for 
starvation-induced autophagy were identified as being required for autophagy in the 
primary screen (Figure 4.6), (Appendix, Table 9.2).  siRNA Smartpools targeting two 
members of the ULK1 kinase complex showed a significant effect: knock-down of 
ULK1 in the primary screen significantly decreased GFP-LC3 spots confirming 
previous findings that it is required for autophagy (Chan et al., 2007) and supporting our 
use of the siRNA again ULK1 as a positive control in the screen.  The mammalian 
orthologue of Atg17 FIP200, when knocked down, also led to a decrease of SCPO, 
STIPO, and STAPO and ranked 731st among decreasers when ranked by rank product 
of the three parameters (seen also in Figure 4.7). 
Multiple proteins that are included in the four Vps34/PI3-kinase complexes 
scored significantly in the screen and are discussed below.  Atg14, also known as 
BARKOR, interacts with Beclin1 and positively regulates autophagy (Zhong et al., 
2009), (Matsunaga et al., 2009); knock-down of the gene showed strong inhibition of 
GFP-LC3 spots.  siRNA against ATG14 has been shown to inhibit long-lived protein 
degradation and LC3 lipidation after starvation. These results highlight the importance 
of Atg14 in autophagosome formation and regulation of autophagy by the PI3-kinase 
complex 1.  
Multiple components of the Atg5-12 conjugation reaction and the LC3 lipidation 
complexes were also highlighted in the primary screen.  Knock-down of ATG4C had 
the strongest effect on GFP-LC3 spot formation of all the proteins involved in the two 
conjugation reaction complexes; it ranked 46th out of all genes when listed by rank 
product (RP) which was 64.5.  ATG4C is one of three human ATG4 genes that cleave 
LC3, priming it for PE conjugation.  Interestingly, ATG4C is the only form that has 
been shown to be required for starvation-induced autophagy, not basal autophagy 
(Marino et al., 2007): Atg4C knock-out mice are normal and are capable of inducing 
autophagy during development but show decreased autophagy during starvation.  This 
has not been reported for Atg4A or Atg4B, and interestingly, knock-down of ATG4A 
and ATG4B did not robustly affect GFP-LC3 spots (Figure 4.6).  Atg7 is required for 
both conjugation reactions and had an average Z-score across the three parameters of -
1.0 in the primary screen but did not make the 500 decreaser cut-off.  Atg10, the E2-like 
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enzyme required for Atg5-Atg12 conjugation reaction was seen in the primary screen to 
increase GFP-LC3 spots when knocked down ranking 19482nd as a decreaser of spots 
(conversely 639th as an increaser of spots).  This result is the opposite of what one 
would expect as Atg5-Atg12 conjugation is an important requirement for 
autophagosome membrane elongation.  Interestingly, it was recently shown that knock-
down of ATG16L2, another essential component of the Atg5-Atg12 complex, increased 
basal autophagy flux in neuroblastoma H4 cells (Lipinski et al., 2010) and ATG16 
knock-down in the primary screen also slightly elevated GFP-LC3 spot parameters. 
Last, knock-down of ATG9A with Dharmacon’s siRNA Smartpool significantly 
inhibited GFP-LC3 spots (Figure 4.6, Figure 4.7).  It ranked close to FIP200 and ATG7 
as Atg9, like these two critical autophagy proteins, has been shown to be required for 
autophagy (Saitoh et al., 2009). 
 
Figure 4.6 Identification of known Atg genes in Primary Screen 
20 Autophagy-related genes identified in the primary screen are listed by increasing Rank Products (RP) 
expressed as decreasers. Accession number, Gene ID, current Gene Symbol, Dharmacon name (when the 
siGenome library was purchased); Dharmacon siGenome Smartpool catalogue number, median SCPO, 
rank determined by SCPO, median STIPO, rank determined by STIPO, median STAPO, rank determined 
by STAPO and Rank Product of SCPO, STIPO and STAPO ranks are shown. 
 
Other genes whose knock-down was previously shown to affect starvation-
induced autophagy but are not classified as Atg proteins were uncovered during the 
primary screen and some of their Z-scores for SCPO are shown in Figure 4.7.  Several 
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of these proteins are components of the four PI3-kinase complexes (Figure 1.3).  
Ambra1, named FLJ20294 in the screen, has been shown to be required for starvation-
induced autophagy (Fimia et al., 2007) and its knock-down in the primary screen 
significantly inhibits GFP-LC3 spots, ranking 27th as a decreaser (Appendix Table 9.2).  
Ambra1 was originally characterised as a Beclin 1 interacting partner and knockdown 
AMBRA1 with siRNA resulted in less LC3-punctated cells and less LC3 lipidation.  
Conversely, RUBICON/KIAA0226, a component of the PI3-kinase RUBICON 
complex has been shown to be a negative regulator of autophagy (Zhong et al., 2009) 
and consequently it was found among the genes whose knock-down increased GFP-
LC3, ranked 1049th.  RUBICON is expected to be an increaser when knocked down 
because it inhibits autophagosome maturation through its inhibition of Vps34 kinase 
activity.  Last, Bif-1 or SH3GLB1 ranked 139th of increasers in the original screen 
(Appendix Table 9.1).  Initially described as a BAX interactor, it is an SH3-domain-
containing protein that has recently characterised as a member of the PI3-kinase 
UVRAG sub-complex that contains p150, VPS34, Beclin1, and UVRAG (Figure 1.3).  
Bif-1 was shown to regulate not autophagy initiation but degradative endocytic traffic 
and in turn, autophagosome maturation (Thoresen et al., 2010).  Thus knock-down of 
Bif-1 may inhibit autophagosome maturation and lead to the accumulation of GFP-LC3 
spots. 
Another gene that is involved in endosome maturation that led to an increase in 
GFP-LC3 spots is VPS16 (Appendix Table 9.1).  Vps16 is a core component of all four 
of the class C Vps complexes (the three other core components are Vps11, Vps18, and 
Vps33) (Liang et al., 2008).  The class C Vps complexes exist in two main 
configurations and are responsible for different functions; the CORVET complex 
(including also Vps3 and Vps8) acts as a vacuole/endosome tethering factor and 
functions at the endosome.  It was shown by Liang et al that UVRAG binds the 
CORVET complex through direct interaction with Vps16 and together they assist in the 
fusion of the autophagosome to the lysosome in the maturation of endosomes and 
autophagosomes.  Very recently it was shown that a new Drosophila endosomal 
membrane protein called ema is required for endosomal maturation and binds to the 
class C Vps complex also through direct binding with Vps16 (Kim et al., 2010). Of 
note, the human homologue of ema, Clec16A, ranked 2030th as an increaser in the 
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primary screen.  The importance of endosome/lysosome maturation for efficient 
autophagic flux is highlighted by these results.  
Knock-down of ROBLD3 increased GFP-LC3 spots in the primary screen and 
ranked 709th as an increaser (Figure 4.7).  ROBLD3, or p14, is a component of the 
‘Ragulator,’ a necessary regulator of TORC1 activation by amino acids (Sancak et al., 
2010).  My screen recapitulated the finding that the size and number of GFP-LC3 spots 
were increased in p14 null cells as expected from the release of suppression of 
mTORC1 after p14 knock-down. 
 
Figure 4.7 Scatter plot of median SCPO Z-scores against rank for siRNA 
Smartpools assayed in the Primary Screen; some Atg genes and other known 
autophagy regulators are shown 
siRNA Smartpools in the siGenome library were ranked in terms of SCPO Z-scores and plotted. The 
green dots represent median values for some genes shown to be involved in autophagy. The dashed lines 
represent the approximate SCPO cut-off corresponding to the 500 cut-off determined by RP. The siRNA 
Smartpools that lead to less than 50 cells per well in at least two out of three replicates are left out of this 
plot. 
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4.3 Secondary Screen: Repeat the autophagy screen with the 
1000 best hits 
4.3.1 Preparing for the repeat screen 
It was decided that a numerical cut-off would be made based on strength of 
phenotype and the number of siRNA Smartpools I wanted to handle in the second 
screen.  The assay was repeated with the Smartpools that led to the best 500 decreases 
and best 500 increases of GFP-LC3 spots in the primary screen as determined by the 
rank product of the three spot parameters.  The median Z-score cut-off point for SCPO, 
STAPO and STIPO was approximately +1.7 for the increasers (those above +1.7 were 
taken forward) and -1.6 for the decreasers (those below -1.6 were taken forward).  This 
secondary or repeat screen was done in order to improve our confidence in and test the 
reproducibility of the hits and so that I could make further cut-offs with assurance.  We 
were able to use the siGENOME Smartpool siRNA that was left over after the 
aliquoting of the library to re-test these 1000 best hits.  I ‘cherry-picked’ the 1000 
siRNA Smartpools from the 267 plates containing the left-over reagent placing it into 
13 intermediate holder plates.  Plates for the repeat screen were coated with Poly-D-
lysine, washed and tested as above and the picked siRNA was dispensed from the 
holder plates in triplicate onto 39 plates (3x13 plates). 
A low passage aliquot of GFP-LC3-HEK cells was tested to ensure that the cells 
responded to the induction of autophagy and that knock-downs of siRNA controls that 
affected the number of GFP-LC3 spots after induction were working as before.  The 
same lots of control siRNA, Lipofectamine2000 and leupeptin were used as in the 
primary screen. 
4.3.2 Performing the repeat screen 
The repeat screen was preformed exactly as the primary screen: on day 1, the 
reverse knock-down was performed once with one batch of cells.  On day 3 the 
transfection medium was exchanged for fresh, full medium and on day 4 the plates were 
washed and starvation medium was added as before.  Images of 14 fields per well were 
captured for each well of the 39 plates.  At a later point, images of 14 different fields 
were also captured for each well by beginning image acquisition in a different area of 
the well.  The Cellomics SpotDetector programme was run simultaneously to acquire 
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images as before and spots were called based on similar settings to the primary screen 
but optimised for the repeat screen plates as new thresholds were set by maximizing 
fold induction determined by visual analysis of images from control siRNA treatments 
(Figure 4.8).  The images and data generated from the repeat screen were stored with 
the primary screen images and data on the High-Throughput Screening Lab’s server 
and, of note, occupied approximately 0.5 terabytes (500 GB) of space. 
 
Figure 4.8 Cellomics images of controls from repeat screen 
Cellomics images (at 20x) of one field of cells after indicated siRNA treatment and incubation conditions 
(EBSS+L represents EBSS plus 0.25mg/ml Leupeptin). Masks designate nuclei (objects), rings within 
which spots are counted and spots. After induction cells are treated with RISCfree control siRNA exhibit 
multiple many GFP-LC3 spots (shown in red). These spots are diminished after treatment with siRNA 
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against ULK1 and increased after treatment with siRNA against NRBP2 (see Chapter 3.3.2 and Figure 
3.19 for an explanation of the controls chosen for the screen). 
 
4.3.3 Analysis of the repeat screen 
4.3.3.1 Normalisation and analysis of data from the repeat screen 
Normalisation of the data from the repeat screen was performed as in the 
primary screen.  A threshold of 50 cells per well was required for the replicate to be 
considered in calculations.  As above, raw data for SCPO, STAPO and STIPO were 
normalised first to adjust for the well’s position on the plate by creating a B-score.  
Then the data was normalised to the plate median, creating a Z-score.  The Z-scores for 
each of the three replicate plates show a linear distribution with a slope close to one, 
indicating that the Z-scores for the replicates show high correlation and therefore 
reproducibility (Figure 4.9).  The Z-scores for the three control wells that received 
siRNA against ULK1 are negative and cluster together in the lower left-hand corner of 
the plot.  The median Z-score for the three replicates was determined and the siRNA 
Smartpools were ranked based on the rank product of the three spot parameters 
(Appendix Table 9.3 and 9.4).  This process was repeated for the second set of images 
acquired (referred to as “new images”).  Finally, the rank product of the primary screen 
was combined with the rank product generated of the data from the first set of images of 
the repeat screen to create a combined rank product for the two screens.  The 500 
increaser and 500 decreaser hits were listed according to this combined rank product 
and those Smartpools with the best combined rank products (as well as some interesting 
genes) are listed in Appendix Table 9.3 and 9.4. 
 
Figure 4.9 Scatter plots comparing replicate plates 
Z-scores for three replicate plates are compared for the 1000 siRNA Smartpools plus negative and 
positive controls tested in the repeat screen. Values for three siULK1 controls wells are shown in red. 
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As the scale of the repeat screen was much smaller than the primary screen (39 
versus 801), the cell density and overall cell heath at the time of fixation was much 
better than that of the primary screen.  The 39 plates were processed much more quickly 
on day 1 and day 4 and spent less time outside of the incubators, especially during the 
induction process on day 4, than during the primary screen.  On day 4, after addition of 
the induction medium, plates were transferred to an unoccupied incubator that 
maintained the desired temperature and CO2 concentration for the two hour incubation.  
The result of this more-attentive handling was that the cells, once fixed, were at a more-
desired density for imaging (Figure 4.8).  In turn, we generated a large number of 
images (two sets of 14 fields for each replicate) and thus had more confidence in the 
repeat screen data as the data set (number of valid objects) was much greater. 
4.3.3.2 Visual inspection of the repeat screen images 
The repeat screen provided me with a large number of images for each siRNA 
knock-down that I visually inspected.  This resource allowed me to eliminate the siRNA 
Smartpools that had a toxic effect on the GFP-LC3-HEK cells.  siRNA that was toxic 
often caused cells to shrink and round up, leaving little cytoplasm.  These were often 
mis-called as decreaser hits because GFP-LC3 spots were no longer visible or counted 
in this small cytoplasm.  By visually inspecting the wells, I was also able to eliminate 
the false-positives that may have been classed as decreasers because the Cellomics 
microscope was out-of-focus when the image was acquired.  If multiple fields were 
captured out-of-focus, spots were under-called skewing the data towards a negative Z-
score for all three spot parameters.  
I visually examined images from 198 decreaser hits and 173 increaser hits in 
order to create a new hit list comprising of 100 increasers and 100 decreasers that would 
be taken forward to the next stage, deconvolution (Appendix Table 9.3, 9.4).  I noted for 
each well GFP-LC3 spottiness or lack of spottiness (namely, if it was a true increaser or 
decreaser, respectively) and toxicity when observed.  Overall, more increaser hits 
seemed to repeat compared to decreaser hits for two reasons, 1) any toxicity that caused 
cells to round up leading to reduced cytoplasmic area or unfocused images would both 
lead to gene knock-downs being incorrectly designated as decreasers of spots and 2) 
siRNA Smartpools that increase spots because loss of the target genes could increase 
autophagy through several mechanisms.  Loss of these genes could provoke a stress 
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response that activates autophagy, could lead to an inhibition of the degradation of 
autophagosomes or if the gene is a negative regulator, its loss could initiate autophagy.  
Of note, all of these scenarios are of interest for this screen for novel mammalian 
autophagy regulators.  Decreaser hits, however, are most likely only those genes that are 
required for autophagy and is presumably a smaller set of genes.   
As a result of the visual inspection, I came across some interesting GFP-LC3 
spot phenotypes in both the spot increaser and decreaser hits that differed from the spot 
phenotype of cells treated with RISCfree control, ULK1 or NRBP2 siRNA (see Figure 
4.8 for typical images of cells after treatment with these controls).  For example, after 
treatment with siRNA for CNOT1 a significant increase in SCPO, STAPO and STIPO 
was recorded.  I visually observed a large number of GFP-LC3 spots but these spots 
were smaller than normal (Figure 4.10).  Also the cells appeared somewhat swollen and 
the nuclear staining of GFP was not as strong as normally seen.  Conversely, knock-
down of RPL22 lead to the accumulation of larger-than-normal GFP-LC3 spots that 
seemed to cluster in a juxta-nuclear region.  ZFX also ranked high as an increaser in the 
primary screen but not in the repeat screen.  Upon inspection of the images, I noticed 
that the GFP-LC3 in the cells was very bright but there did not seem to be many spots 
perhaps because knock-down of this gene increases the production or turnover of GFP-
LC3 protein but does not affect autophagy and in light of the abnormal phenotype, this 
siRNA Smartpool was not taken forward as a hit.  RAB28 was taken forward as a 
decreaser hit despite the odd spot phenotype that resulted from its siRNA, as the small 
GTPase proteins are important regulators of membrane trafficking processes and it is 
thus conceivable that Rab28 plays a potential role in autophagy.  A decrease of SCPO, 
STIPO, and STAPO resulted from RAB28 knock-down (Appendix Table 9.4) but I 
observed large aggregates of GFP-LC3 in some of the cells and the area of these spots 
was perhaps above the threshold set and were not recorded as spots.  It is conceivable 
that knock-down of RAB28 causes a type of maturation phenotype where the GFP-
LC3-tagged autophagosomes are not degraded by the lysosomes and aggregate in the 
cytoplasm, and this is of potential interest as we seek to identify proteins involved in 
autophagosome maturation. 
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Figure 4.10 Cellomics Images of unusual spot phenotypes 
Cellomics images (20x) of GFP-LC3 signal after indicated gene knock-down and induction of autophagy. 
 
 
4.3.4 Results of the repeat screen 
In general, an siRNA Smartpool for a given gene had a similar effect in the 
primary screen and the repeat screen.  The range of Z-scores for SCPO was -2.3 to +3.0.  
Of the 500 best decreasers from the primary screen 81% had a SCPO Z-score less than 
0 in the repeat screen.  59% had a Z-score less than -0.5 and 42% had a Z-score less 
than -0.75.  Of the 500 best increasers from the primary screen 85% had a SCPO Z-
Chapter 4. Screens 
 128 
score greater than 0.  58% had a Z-score greater than +0.5 and 48% had a Z-score 
greater than +0.75. 
Of the known autophagy proteins and regulators (discussed above) that made the 
500 increaser or decreaser cut-off, ATG4C, AMBRA1, and VPS16 repeated their 
primary screen phenotype (Appendix Table 9.3 and 9.4).  ULK1 was not repeated 
because it was on plate 10, which was lost in the primary screen and assayed for the 
first time in the repeat screen.  The siRNA against Bif-1 (SH3GLB1), however, did not 
recapitulate the primary screen results of increasing GFP-LC3 spots, as the Smartpool 
had no effect in the repeat screen (Appendix Table 9.3).  Differences between the 
primary and repeat screen could be due to a diminished quality of siRNA in the repeat 
screen as a result of being subjected to at least one but most likely at least two more 
freeze/thaw cycles compared to the siRNA from the primary screen.  Also, the 
difference in density between the two screens (the cells from primary screen were more 
sparse at the time of imaging than the cells from repeat screen) could account for 
differences in results.  The density of the cells from both screens appeared to be 
relatively comparable on day 4 but the cells of the repeat screen survived the washing, 
induction and fixation to a much greater extent and data from more cells was gathered 
as a result; it is a possibility that the data from the primary screen was skewed due to a 
smaller number of cells from which it was generated.  Also, the cells of the repeat 
screen were slightly more dense during the two day incubation with siRNA, which may 
have altered the effectiveness of a given siRNA Smartpool.  There were also instances 
when the results from the two screens were highly discordant for GFP-LC3 spot 
parameter data and sometimes even object count.  This could perhaps be due to an error 
made during the picking of the siRNA from the left-over siRNA plate.  Perhaps the 
mostly likely explanation for differences between the primary and secondary screen is 
the biological variation that occurs when siRNA is used in two separate experiments (to 
be discussed in greater detail in section 4.5). 
As a result of the repeat screen, I gained confidence in the Smartpools that 
repeated the original screen phenotype.  If a given knock-down lead to a robust effect 
(as measured by a large positive or negative Z-score) in two independent experiments 
with slightly different densities and conditions then I could be more sure that that 
Smartpool modulates GFP-LC3 spot formation than if I had only performed the primary 
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screen.  The visual inspection of the images generated from the repeat screen also 
allowed me to eliminate mis-called hits and the siRNA Smartpools that caused toxicity.  
Eliminating toxic siRNA Smartpools was not only important because severe toxicity 
can lead to cells rounding up, making cytoplasmic spots difficult to count but also 
siRNA that is somewhat toxic may stress the cell triggering autophagy thus an increaser 
may be mis-designated as a hit not because of a direct effect on autophagy but because 
it evokes a stress response. 
4.3.5  Choosing 190 genes to take forward 
Of the siRNA Smartpools that repeated, some were eliminated because it is 
likely that their knock-downs affected processes unrelated to autophagy.  For instance, 
knock-down of two genes that are subunits of the polymerase (RNA) II complex, 
POLR2B and POLR2C, lead to a decrease in GFP-LC3 spots presumably because the 
expression of GFP-LC3 was inhibited.  Knock-down of PSMD8, a component of the 
26S proteasome caused a large quantity of diffuse cytoplasmic GFP-LC3 perhaps 
because it could not be degraded by the proteasome causing this gene to be mis-called 
as an increaser hit.  ATG4C and AMBRA1 were taken off the hit list because it was 
known that they are required for autophagy.  Finally, there were 13 genes whose 
Smartpools caused an increase or decrease but whose deconvoluted sets of siRNA 
duplexes were not available for purchase from Dharmacon usually because they are 
designated as pseudogenes or their record has been discontinued or withdrawn as a gene 
(indicated in Appendix Table 9.3 and 9.4).  There is, however, evidence that 
pseudogenes have a function and the PTEN pseudogene, PTENP1 has recently been 
shown to be biologically active and contribute to the tumour suppressor functions of 
PTEN (Poliseno et al., 2010).  This study suggests that pseudogenes can not only 
regulate coding gene expression but also affect non-coding messenger RNA and 
perhaps the pseudogene Smartpools that had a robust affect on GFP-LC3 spots could be 
revisited in the future when more is known about the non-coding regions of the human 
genome. 
The ultimate goal of the repeat screen and consequent visual inspection of the 
images was to create a list of approximately 100 increasers and 100 decreasers to take 
forward to the next step of validation, deconvolution of the siRNA Smartpools or 
analysis of the individual siRNA duplexes for each hit.  It was determined that we had 
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only enough funds to buy 190 sets of siRNA for the deconvolution screen.  Last, 
deconvolution of 190 sets of siRNA duplexes when done in triplicate would yield a 
screen of 30 plates, which was determined by the repeat screen to be a manageable size.  
Going forward, I felt confident that the chosen 190 Smartpools had a strong and 
reproducible effect of GFP-LC3 spot phenotype and their targeted genes were potential 
novel regulators of starvation-induced autophagy.  The list of 190 sets of individual 
siRNA duplexes is contained in Appendix Table 9.5. 
4.4 Deconvolution Screen: Increased confidence in 51 hits 
In order to determine that the effect of the 190 Smartpools is due to the siRNA-
mediated effect on its suggested target gene, I performed a deconvolution screen.  It is 
generally agreed that if two or more individual siRNA duplexes of a so-called 
deconvoluted set of siRNA duplexes for a given gene induce the same phenotype as 
their pool then there is increased likelihood that it is knock-down of that specific gene 
that causes the phenotype (Mike Howell (LRI, HTS lab), personal communication; 
(Krausz, 2007)).  In turn, that hit proceeds closer to becoming validated.  Another way 
to increase confidence that a candidate Smartpool is targeting a gene involved in 
autophagy is to test an siRNA pool generated by a different vendor that uses alternate 
algorithms to generate siRNA sequences.  Since the GFP-LC3-HEK cell knock-down 
protocol with Lipofectamine2000 was optimised for Dharmacon siRNA controls, I 
worried that switching siRNA source would require further optimisation.  Thus, I chose 
to perform a deconvolution screen, testing the four individual siRNA duplexes for each 
Dharmacon Smartpool using the same image-based assay for starvation-induced 
autophagy in GFP-LC3-HEK cells. 
4.4.1 Performing the screen and normalisation and analysis of the data 
Sets of four siGENOME duplexes targeting the chosen 190 hits were ordered 
from Dharmacon.  These siRNA reagents were resuspended and aliquoted onto 
triplicate plates for the deconvolution screen, again leaving two columns free for control 
siRNA.  The plates, cells and induction conditions were tested to assure that all the 
materials for the screen were behaving as normal.  The deconvolution screen was 
preformed on 30 plates following the same protocol as the primary and repeat screens 
described above.  Images for 16 fields per well were collected and values for SCPO, 
Chapter 4. Screens 
 131 
STIPO and STAPO were analysed.  The results for each parameter were expressed as 
the median percent of control with respect to RISCfree control (Appendix Table 9.5).  
Individual siRNA duplexes were designated a hit if they caused more than a 20% 
increase or decrease in spot parameters and scored as positive or negative respectively 
for each parameter. 
To increase our confidence in the data and the correct selection of hits to carry 
forward we repeated the deconvolution screen with sixty sets of four individual siRNA 
duplexes using several criteria.  First, if they had three out of four siRNA duplexes that 
copied the original screen phenotype, they were potential validated-by-deconvolution 
hits.  Second, I chose to re-test those for which two out of four of the siRNA duplexes 
showed the desired effect on spots and through two iterations of protein-protein 
interactions analysis (using the program Cytoscape to analyse network data), it was 
noted that these proteins interact with the potential three-out-of-four hits through one or 
two binding partners.  These genes are GAB1, MRPS7, CDH18, FOXO4, KIF5B, and 
TRAM2.  The data generated by this repeat deconvolution screen was similar to that of 
the first deconvolution screen; most importantly, the siRNA duplexes of the potential 
three-out-of-four hits had the same effects in the repeat deconvolution screen.  I 
therefore based my decisions about each gene’s deconvolution success on the first 
deconvolution screen data only. 
In order to classify the genes as having two out of four repeating duplexes or three 
out of four decreasing duplexes I devised a set of rules.  If three out of four of the 
individual siRNA duplexes repeated the original screen phenotype of increaser or 
decreaser for any of the three spot phenotypes that gene was designated as a three-out-
of-four hit.  The designation of two-out-of-four hits was more complex because often at 
least one of the duplexes did not repeat the primary screen phenotype, having the 
opposite effect on spots.  We did not consider a gene a hit that had two siRNA duplexes 
that scored as positive and two siRNA duplexes that scored as negative.  Two examples 
of this are SLC27A1 and GAB1.  Their siRNA Smartpools decreased GFP-LC3 spots in 
the primary and repeat screen, but after deconvolution two siRNA duplexes gave 
positive scores for all three parameters and two siRNA duplexes gave negative scores 
for all three parameters in the deconvolution screen.  However, when two siRNA 
duplexes for a given gene repeated the primary screen phenotype but one siRNA had 
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the opposite effect the gene was classed as a two-out-of-four hit.  Some examples of this 
are MLLT7/FOXO4 and SEL1L.  Whether a gene was decided to be a two-out-of-four 
hit or a three-out-of-four hit based on these criteria are indicated in Appendix Table 9.5. 
Nine genes had three siRNA duplexes that decreased GFP-LC3 spot parameters 
and 15 genes had three siRNA duplexes that increased GFP-LC3 spot parameters; these 
are listed in Table 4.1.  27 genes were two-out-of-four hits for their original screen 
phenotype.  In total, the effects on autophagy for 51 genes were confirmed by 
deconvolution of siRNA Smartpools. 
 
Table 4.1 51 gene knock-downs whose effects on autophagy in GFP-LC3-HEK cells 
were confirmed by deconvolution of siRNA Smartpools 
Current gene symbols for genes whose knock-down decrease and increaser GFP-LC3 spots are shown. 
(3/4) indicates if three out of four siRNA duplexes repeated the spot phenotype. (*) indicates genes that 
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are three-out-of-fours if alternate normalisation is used. (§) indicates genes that have a tissue-specific 
distribution (to be discussed later in section 4.4.3). 
4.4.2  Annotation of the validated-by-deconvolution hits 
Deconvolution of 51 genes was deemed successful in that at least two out of 
four of the individual siRNA duplex validated the effect on GFP-LC3 spots in the 
primary and repeat screen.  I manually annotated this list of genes using data available 
in the public domain using several different resources.  Using NCBI/PubMed and the 
Human Protein Reference Database (HPRD), I discovered that these 51 genes are 
mostly uncharacterised and they do not map to known signalling networks such as the 
mTOR pathway.  Of note, the genes on the list of 190 hits created after the repeat screen 
were also not enriched for any known signalling pathways.  The 51 hits were analysed 
using Panther annotation for protein class and the hits were classified in terms of 
molecular function and biological processes.  Again, the hits did not form large 
networks or group together based on these classifications.  The 51 hits were then 
analysed for using GENE ONTOLOGY (GO) tools available in order to discover more 
about their biological process, molecular function and cellular component.  I probed this 
database to find generic GO slim terms based on their proposed biological process and 
molecular function and then used the Generic GO Term Mapper to group the 51 genes 
into broad categories based on these GO slim terms (see Materials and Methods for an 
HTML table of results).  Again, these 51 genes did not group together based on their 
slim terms. 
Last, I determined the cellular localisations of the proteins on the list of 51 
validated-by-deconvolution hits, using a GO tool and found that their distribution 
differs from the proteins of the human genome (Figure 4.11).  The proteins on my hit-
list are slightly enriched in the Golgi apparatus, endoplasmic reticulum, cytosol, and 
cytoplasm.  This distribution is expected of genes involved in autophagy, a process that 
takes place in cytoplasm and because proteins of the Golgi apparatus and the ER have 
been shown to contribute to the formation of autophagosomes (van der Vaart and 
Reggiori, 2010), (Hayashi-Nishino et al., 2009).  Perhaps the most striking difference is 
seen in the plasma membrane: significantly less plasma membrane proteins are 
contained in the hit list compared to the genome frequency.  Until recent work by the 
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Rubinsztein lab, few if any plasma membrane-bound proteins had been shown to be 
involved in autophagy (Ravikumar et al., 2010). 
 
Figure 4.11 Differential frequency of distribution of the list of 51 and the genome 
Frequency of cellular localisation of genes in the human genome (red bars) compared to the genes on the 
list of 51 validated-by-deconvolution hits (blue bars). 
 
Of interest, the following validated-by-deconvolution decreasers are contained 
in the ‘Druggable’ gene set of the Dharmacon siGenome library: CDH19, CSTB, 
FABP4, HERC4, SEL1L, and SUPT5H.  Of the validated increasers HOXB3, KIF25, 
KLRG1, MFAP5, MYBPC3, STAT2, and WDR6 are contained on the ‘Druggable’ 
plates.  TLK2, the only kinase in the list of 51, could be a potential drug target because 
of its enzymatic properties.  Though I did not confirm that these genes are recorded as 
drug targets in the literature, it is promising that drugs that target the six decreasers 
could be more-specific inhibitors of starvation-induced autophagy than the inhibitors 
currently available, such as 3-MA. 
4.4.3 Selection of hits for further validation 
Due to a limited amount of time available for me to further validate that these 51 
genes are true regulators of autophagy and wanting to have high confidence in the hits, I 
took the opportunity to be very stringent when determining the cut-off after 
deconvolution.  I decided that I would take forward only those hits that had three out of 
four individual siRNA duplexes that repeated the primary and repeat screen phenotypes.  
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Three genes, PAFAH1B2, FBXL14, and RBM12 are designated as having two duplexes 
that validated by deconvolution (Appendix Table 9.5, Table 4.1) but were taken forward 
because using an alternate normalisation (values were divided by the screen RISCfree 
mean instead of the median because plate 13 contained mostly non-knocked-down 
wells) they achieved a three out of four rank.  I did not take forward four genes that had 
three validated siRNA duplexes but whose expression patterns are limited to a certain 
cell or tissue type.  C10orf116 is expressed in adipose tissue, KLRG1 is expressed in 
NK cells, MYBPC3 is reported to be expressed only in heart muscle, and TCL1B only 
in lymph tissue.  Of note, knock-down of all four of these genes caused an increase in 
GFP-LC3 spots and perhaps these siRNA duplexes target different (off-target) genes 
expressed in HEK cells eliciting a stress response that increases autophagy.  Making the 
decision to exclude these genes I was, however, relying on experimental data in the 
public domain, the quality of which I could not determine.  It is possible that these 
genes are indeed expressed in GFP-LC3-HEK cells and other tissues and their knock-
down may increase autophagy.  In turn, their expression levels in tissues could be re-
tested the role of these genes in autophagy could be explored. 
Thus, nine genes for which three individual siRNA duplexes decreased GFP-LC3 
spot parameters were taken forward: C1orf198, CDH19, GHSR, LARP1, NAA25, 
PAFAH1B2, SCOC, SUPT5H and WAC.  Eleven genes for which three individual 
siRNA duplexes increased GFP-LC3 spot parameters were taken forward: ADHFE1, 
CNOT1, FBXL14, KIF25, RASGRF2, RASIP1, RBM12, SNX20, STAT2, TLK2, and 
WDR6. 
4.5 Discussion of image-based screens and results 
4.5.1 Considerations for the image-based siRNA screens 
The image-based high-content screens allowed me to determine the effect of 
21,121 siRNA Smartpools on GFP-LC3 spot count, area and intensity after induction of 
autophagy with starvation.  In addition to analysing these multiple parameters, I was 
able to visually inspect the images and draw conclusions about the effect of the siRNA 
Smartpools on cell heath and even GFP-LC3 levels in the stable cells.  One of the 
benefits of the Cellomics system is that the stored images can be reanalysed using 
different thresholds or different programs and thus, the primary data can be analysed to 
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generate additional information.  One possible extension of this could be to classify the 
GFP-LC3 spot increasers in terms of the distribution or phenotype of GFP-LC3 spots 
they induce.  For instance, these Smartpools could lead to more spots spread throughout 
the cell or conversely clustered in regions within the cell.  Also, the data itself could be 
revisited and cut-offs could be altered to allow for the analysis of more candidates.  
After the primary screen, 500 increasers and 500 decreasers were taken forward but 
there were multiple autophagy genes (ATG9, FIP200, ATG14) whose knock-downs 
lead to a significant inhibition of GFP-LC3 spots but did not meet the cut-off of 500 
(Figure 4.7).  If I expanded the cut-off to 1000 increasers and 1000 decreasers these 
three genes and thus many other potential regulators of autophagy would be included.  
Also, the data could be normalised differently producing a different data set. 
By analysing multiple parameters of GFP-LC3 spots and also cell viability using 
minimum valid object counts and visually inspecting the cells in addition to eliminating 
data that was mis-called by the Cellomics HCS reader due to focusing and other issues, 
I attempted to limit false-positive and false-negative results.  Doing the primary, repeat 
and deconvolution screens in triplicate also improved the results.  However, it is 
thought that image-based cellular assays have more intrinsic variability compared to 
biochemical assays or reporter gene-based assays, mainly due to the relatively small 
number of cells analysed (Krausz, 2007).  In addition, the screens relied on the even 
distribution of cells across the area of analysis, which was critical for the microscope to 
sample enough cells during the automated image acquisition.  These are reasons why 
the repeat screen was so important; because the cells were at optimal density at the time 
of imaging, a large amount of cells were analysed (usually approaching 1000 cells per 
replicate, Appendix table 9.3, 9.4).  In contrast, the imaged cells of the primary screen 
were at a less-optimal density due to the problems generated when handling a large 
number of plates.  Improvements for the future could be made by using more incubators 
or improved incubators that maintain a more constant temperature and CO2 
concentration despite unusual amounts of opening.  Because of the density of the cells 
and the amount of data captured, the repeat screen generated more trust-worthy results. 
I found there were differences in the results between the primary screen and the 
repeat screen that I attribute to biological variability due to slight technical variations 
(i.e. density during transfection) and the differential ability of siRNA to knock-down a 
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given gene on a given plate on a given day.  The data for the screen is widely 
distributed, with a majority of the negative controls clustering in the middle and the 
positive controls clustering at the ends.  But there is variation even when examining one 
control well, as seen with the ULK1 siRNA in well C01 in the primary screen (Figure 
4.5).  Though every SCPO median Z-score is negative, there is a range of Z-scores and 
some of these wells are not in the best 500 decreasers and therefore would not make the 
strict cut-off that was set.  In this way, a gene that scored significantly in the primary 
screen, achieving the 500 marked cut-off but might not have achieved a strong enough 
effect when assayed again to make the repeat screen’s cut-off.  In addition, I introduced 
the variable of human error when creating the siRNA library for the repeat screen 
because I manually cherry-picked the siRNA Smartpools from plates holding the 
siGenome library.  
Perhaps instead of repeating the image-based GFP-LC3 spot counting screen I 
could have used a different assay to improve my confidence in the hits.  Using a 
different assay could have provided a different read-out for starvation-induced 
autophagy.  Assays such as LC3-lipidation with and without lysosomal protease 
inhibitors monitored by western blot and long-lived protein degradation could have 
provided me with additional information about how the gene knock-downs were 
affecting the autophagy pathway (Klionsky et al., 2008).  These assays, however, are 
difficult and too time-consuming to do in a large scale, which is why I originally tried 
the intein-based luciferase assay.  Alternatives could have been a flow cytometry-based 
assay that uses the amount of total GFP-LC3 remaining after autophagy induction to 
measure modulation in the pathway (Shvets et al., 2008a) or a luciferase-based assay 
that measures the kinetics of autophagic flux (Farkas et al., 2009).  I however, chose to 
delay the use of alternate assays until I had a small set of candidate hits for which I had 
high confidence. 
The caveats of RNA interference screens are that a given siRNA may not work 
in a specific assay because of time frame, or the siRNA duplexes themselves may fail.  
It is thought that the transient and specific silencing of a particular gene using siRNA 
typically reaches its peak after 24 hours and then declines but then recovers by about 96 
hours after transfection and so the window of time between 48 hours to 96 hours is 
generally optimal (Hannon, 2002).  But this depends on the targeted gene and proteins 
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with a longer half-life may fail to give a phenotype within that time frame.  Thus, there 
were genes that were not optimally targeted by the 72-hour-long transfection period of 
my screens.  In addition, the siRNA duplexes contained within the Dharmacon 
Smartpools are not guaranteed to target only their intended gene.  Though algorithms 
are constantly improved and non-targeted siRNAs substituted for new ones, the 
siGenome library is not perfect. 
In turn, there is a risk of false positives due to off-target effects; the duplexes 
contained within a Smartpool may knock-down unknown genes that are themselves 
causing the autophagy-related phenotype.  I tackled this problem by testing the four 
siRNA duplexes that make up the Dharmacon siGenome Smartpools individually for 
their effects on autophagy.  It is generally thought that if two out of four duplexes 
phenocopy the Smartpool then one can have confidence in the result.  As mentioned 
above, I could have alternatively used siRNA from a different company that employs 
different algorithms.  The only way to assure that a siRNA is affecting its target is to 
test the ability of that siRNA to reduce the gene’s mRNA levels or protein expression.  
However, like using an alternate assay for autophagy, measuring knock-down efficiency 
was only possible to do in a small scale. 
4.5.2 Other genome-wide screens for autophagy 
Recently, a genome-wide screen for non-induced, basal autophagy was 
described (Lipinski et al., 2010).  Lipinski et al also used the Dharmacon siGenome 
library and the Cellomics HCS platform to quantify GFP-LC3 spot formation in a 
neuroblastoma cell line.  Overall, there is very little overlap between my hits and their 
hits suggesting the regulation and mechanisms of basal autophagy are highly different 
to those of starvation-induced autophagy.  In the case of one gene, GHSR, their results 
are opposite to mine.  They show that knock-down of GHSR increased basal GFP-LC3 
spots but I found that three out of four siRNA duplexes for GHSR in fact inhibited spot 
parameters (GHSR is further analysed in Chapter section 5.4.1).  One Smartpool that we 
both identified to decrease spot formation was GAB1.  In my deconvolution screen, two 
siRNA duplexes for GAB1 decreased GFP-LC3 spot parameters and two increased and 
for this reason, we chose not to carry GAB1 forward though it is an interesting gene 
with many known interacting partners and is involved in insulin receptor signalling, 
which has been linked to autophagy (Yamamoto et al., 2006). 
Chapter 4. Screens 
 139 
Another screen was also done to identify regulators of basal autophagy; it 
utilised proteomics to identify protein interaction subnetworks built upon known 
autophagy genes (Behrends et al., 2010).  There was no overlap between their high-
confidence hits (meeting strength, reproducibility and peptide number cut-offs) and my 
hits but there was some overlap between my hits and their full data set (Table 4.2).  In 
fact, nine of the validated-by-deconvolution hits were found to bind to autophagy 
interacting proteins, placing them within the autophagy interaction network (AIN). 
 
Chapter 4. Screens 
 140 
Table 4.2 Validated-by-deconvolution hits found in the autophagy interaction 
network (AIN) 
Nine of the 51 hits were found to interact with autophagy proteins or autophagy protein-interacting 
proteins in a proteomic screen (Behrends et al., 2010).  Shown are the gene symbols, baits with which 
they were pulled down, the p_value, WD_score, and Z-score from the screen.  **Denotes hits that passed 
further validation steps in my screen (described in Chapter 5). 
 
4.5.3  Other interesting hits not taken forward 
There were multiple other interesting genes linked in the literature to autophagy 
in the top 1000 of the screen whose knock-down either decreased GFP-LC3 spots or 
increased.  Due to issues described above, these results were not reproduced in the 
repeat screen but I think it is of interest to discuss PINK1, RAB7, RILP and PRKAR1A 
below (these are highlighted in blue in Appendix Table 9.1 and 9.2).  In the primary 
screen, PTEN induced putative kinase 1 or PINK1, ranked 289th as a decreaser required 
for autophagy.  Mutations in the kinase domain of this gene have been shown to cause 
early-onset Parkinson’s disease through increased susceptibility to cellular stress 
(Valente et al., 2004).  More recently, PINK1 has been shown to be recruited to 
damaged mitochondria and associate with LC3, triggering autophagy (Narendra et al., 
2010).  It is suggested that the degradation of damaged mitochondria by autophagy 
(mitophagy) is triggered by PINK1 and Parkin together coordinating the accumulation 
of damaged mitochondria in a perinuclear aggregates (Kawajiri et al., 2010). 
As discussed above, an increase in GFP-LC3 spots could result from a loss of 
negative regulation of the initiation of autophagy or inhibition of the maturation of 
autophagosomes.  Rab7 is a GTPase that is known to control late endocytic trafficking, 
a process that is also required for autophagosome maturation (Gutierrez et al., 2004), 
(Jager et al., 2004).  In turn, one would expect that when Rab7 is knocked known in 
GFP-LC3-HEK cells an accumulation spots would be seen, but in fact RAB7A knock-
down in the primary screen led to a somewhat significant decrease in GFP-LC3 spots 
(ranking 1362nd of decreasers; RP was 1457) suggesting Rab7 is potentially involved in 
the initiation of autophagy.  Conversely, knock-down of Rab interacting lysosomal 
protein, RILP increased GFP-LC3 spot formation or led to a significant accumulation of 
GFP-LC3 spots (ranked 451st of increasers; RP was 517).  This is perhaps expected as 
RILP is a downstream effector of Rab7 and has been shown to coordinate with Rab7 to 
control endosomal maturation and fusion of autophagosomes with lysosomes (Liang et 
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al., 2008).  Most recently, however, it was also shown that the Rab7/RILP interaction 
can be stimulated by IGF-1 in neurons and that their interaction increased autophagy 
(Bains et al., 2010); this interaction could perhaps provide a mechanism for the positive 
regulation of autophagy by Rab7.  In my primary screen, PRKAR1A, the regulatory 
subunit of protein kinase A, increased GFP-LC3 spot formation (ranked 96th of 
increasers; RP was 127).  The protein has been shown to interact with mTOR kinase 
and affect its activity during starvation thus acting upstream of mTOR as a regulator of 
autophagy (Mavrakis et al., 2007).  Seemingly opposite to my results, Mavrakis et al 
showed that PRKAR1A knock-down activates mTOR, decreasing autophagy efficiency 
and PRKAR1A knock-down also decreased GFP-LC3 lipidation in the kinome screen 
performed in our lab (Chan et al., 2007).  Perhaps knock-down of PRKAR1A inhibits 
both autophagosome formation, through mTOR but also autophagosome maturation.  
Interestingly PRKAR1A has been shown to colocalise with Rab7- and LC3-positive 
vesicles (Bains et al., 2010) perhaps linking the mTOR complex to autophagosome 
maturation.  Conversely, linking Rab7 to mTOR through Rab7’s interaction with 
PRKAR1A may explain how knock-down of RAB7A inhibited autophagosome 
formation in the primary screen. 
An interesting gene for which only one out of four of the siRNA duplexes 
reproduced the primary and repeat screen phenotype has also been previously linked to 
autophagy: SAV1 (salvador homologue 1) knock-down inhibited GFP-LC3 spot 
parameters.  This scaffold protein critical for the Warts (Wts) tumour suppressor 
pathway (also known as the Hippo pathway) has also been shown, along with other 
members of the pathway, to be required for autophagy in Drosophila (Dutta and 
Baehrecke, 2008).  The Hippo pathway is regulated by the class I PI3-kinase pathway 
and is a negative regulator of cell growth (Tapon et al., 2002).  Though only one duplex 
met the threshold of 20% inhibition and thus scored as negative in the deconvolution 
screen, two other duplexes decreased STIPO and the remaining duplex did not have a 
significant effect on the spot parameters (Appendix Table 9.5).  I have confirmed that 
this one duplex inhibits LC3 lipidation and if I could rescue the knock-down with 
expression of an siRNA resistant clone and show that this duplex was also the most 
effective in reducing SAV1 mRNA or protein levels then salvador homologue 1 could 
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be a positive regulator of autophagy and potentially link the Hippo and class I PI3-
kinase pathways to autophagy. 
In conclusion, in order to identify novel autophagy regulators by a genome-wide 
siRNA screen I relied on a cell model system that provided a robust read-out for 
autophagy in the form of the quantifiable starvation-dependent formation of GFP-LC3-
labelled autophagosomes.  The hit-selection strategy to identify both negative and 
positive regulators of starvation-induced autophagy was based on multiple rounds of 
screening (primary, secondary, and deconvolution) coupled with the elimination of 
candidates that did not satisfy strict criteria.  Using this approach, I have identified 20 
potential negative and positive regulators of starvation-induced autophagy, the further 
investigation of which is described below.  It is likely that relaxation of some of the 
thresholds in the deconvolution screen or further study of the hits with two out of four 
or even one out of four deconvoluted siRNA duplexes will reveal more candidate genes 
in the data set. 
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Chapter 5. Further Validation of the ‘Three-out-of-
Four’ Hits 
Nine genes, when knocked down by three individual siRNA duplexes, cause a 
decrease in GFP-LC3 spot number, area and/or intensity and were selected to take 
forward for further confirmation and investigation of their role in autophagy.  These 
‘decreasers’ are: C1orf198, CDH19, GHSR, LARP1, NAA25, PAFAH1B2, SCOC, 
SUPT5H, and WAC.  Conversely, eleven gene knock-downs lead to an increase of 
GFP-LC3 spots.  These ‘increasers’ are: ADHFE1, CNOT1, FBXL14, KIF25, 
RASGRF2, RASIP1, RBM12, SNX20, STAT2, TLK2, and WDR6.  From the data 
produced in deconvolution screen, I determined which were the two most potent siRNA 
duplexes in terms of their effects on spots from for each of the genes and also were not 
toxic to the cells.  I used these siRNA duplexes to further validate the involvement of 
their target genes in autophagy, testing their effects on autophagy after induction in 
alternate conditions, measuring their ability to knock-down the mRNA levels of their 
intended target, and measuring their effect with an alternate autophagy assay, a process 
that I called ‘supervalidation.’ 
5.1 Induction Screen of the 20 validated hits 
As a result of the primary, repeat and deconvolution screens I demonstrated that 
twenty genes were potential modulators of starvation-induced autophagy.  I next asked 
whether these genes were similarly required for GFP-LC3 spots using different inducers 
of autophagy.  Perhaps the most important question I asked was whether the 
involvement of these hits in autophagy was mTOR-dependent or mTOR-independent.  
Because the signalling between amino acid sensing and mTOR inactivation that leads to 
autophagy has not been fully elucidated it is conceivable that a lack of nutrients can 
directly activate the autophagic machinery, bypassing mTOR.  Thus, I asked whether 
knock-down of my hits would have the same effects with initiation of spot formation 
with drugs that are reported to induce autophagy in an mTOR-dependent, mTOR-
independent, and also Beclin-independent manner.  In turn, if the decrease or increase 
of GFP-LC3 spots after knock-down is repeated in conditions of autophagy activation 
through the direct inhibition of mTOR but also though mTOR-independent pathways 
then I can tentatively conclude that my hit is functioning downstream of these signalling 
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pathways perhaps modulating autophagosome formation or maturation.  Conversely, if 
differential effects were seen as a result of the various induction methods then I could 
perhaps group the hits into different autophagy induction signalling pathways based on 
the proposed mechanism of action of the inducers.  I also asked whether knock-down of 
the hits affected autophagic flux during a two-hour period by culturing the cells in 
starvation medium alone without leupeptin.  Of great interest was to discover whether 
the 20 hits increased or decreased basal autophagy, or autophagy that occurs in full 
growth medium.  The kinome screen of GFP-LC3-HEK cells (Chan et al., 2007) 
uncovered a that loss of subunits of the COP1 coat complex leads to increased 
autophagy in full medium conditions because they are required for the fusion of 
autophagosomes with early endosomes; their loss increases autophagosome 
accumulation without increasing autophagic flux (Razi et al., 2009). 
To determine whether my hits were influencing GFP-LC3 spot parameters 
through the activity of the negative regulator mTOR, I induced autophagy by treating 
cells with an inhibitor of mTOR.  Tor was originally discovered as the main regulator of 
autophagy in yeast and it was shown that rapamycin, an inhibitor of TOR, induced 
autophagosome formation (Noda and Ohsumi, 1998) and rapamycin has been shown to 
similarly induce autophagy in mammalian cells.  Recently Torin, a potent inhibitor of 
mTOR kinase activity has been shown to be a stronger activator of autophagy compared 
to rapamycin perhaps by inhibiting mTOR’s rapamycin-resistant phosphorylation of the 
translation initiating factor binding protein 4E-BP1 (Thoreen et al., 2009). 
To assess the effect on autophagy that is induced by mechanisms reported to act 
independently of mTOR, I treated cells with lithium chloride.  I have previously shown 
that treatment with lithium chloride for 48 hours induced LC3 lipidation in HEK cells 
(Figure 3.9).  It is proposed that lithium induces autophagy by inhibiting inositol 
monophosphatase (IMPase) levels, which decreases free inositol and decreases myo-
inositol-1,4,5 triphosphate (IP3) levels, eventually altering membrane availability 
(Sarkar et al., 2005).  Sarkar et al suggest that this process is mTOR independent 
because rapamycin does not affect IP3 levels and alternately IP3 itself does not affect 
rapamycin efficacy.  In addition, lithium and rapamycin work synergistically to clear 
aggregate-prone mutant proteins (Sarkar et al., 2008). 
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Resveratrol has been shown to induce autophagy in DLD1 cancer cells and 
MCF7 breast cancer cells (Trincheri et al., 2008), (Scarlatti et al., 2008).  Scarlatti et al 
have shown that this induction in MCF7 cells is insensitive to PI3K inhibitors and have 
therefore classed resveratrol as a non-canonical, beclin 1/vps34-independent activator of 
autophagy.  Of note, they show that the response is TOR dependent.  Another target of 
resveratrol is the NAD+-dependent deacetylase Sirtuin-1.  It has recently been shown 
that activation of sirtuin-1 induces autophagy and that sirtuin-1 is required for the 
starvation-induced autophagy response (Morselli et al., 2010).  Contrary to Scarlatti et 
al who show that the response to resveratrol is TOR dependent, Morselli et al suggest 
that this sirtuin-1-mediated autophagy response does not involve the inhibition of 
mTOR or the negative regulator p53.  Instead, they suggest that resveratrol activates 
sirtuins, which in turn deacetylate the autophagy proteins involved in the Atg5/Atg12 
complex thereby directly activating autophagy. 
I performed the induction screen following the procedure used for the primary 
and deconvolution screens in 21 96-well plates.  On each plate, the two siRNA duplexes 
for each of the twenty hits and both negative and positive control siRNA duplexes were 
added.  Triplicate plates were incubated in the following treatments: full medium plus 
leupeptin or lithium chloride for 24 hours, full medium plus leupeptin for 2 hours, 
EBSS or EBSS plus leupeptin for 2 hours, Torin plus leupeptin for 2 hours, and 
resveratrol plus leupeptin for two hours.  The GFP-LC3 spots were analysed using the 
Cellomics SpotDetector program and triplicate values for each siRNA treatment were 
averaged (Figure 5.1).  Values for control knock-down with RISCfree or siControl show 
that there is an increase in GFP-LC3 spots after starvation medium incubations or 
treatment with Torin or resveratrol.  More spots were seen in EBSS supplemented with 
leupeptin compared to EBSS alone, as seen before.  Lithium chloride only leads to a 
subtle increase of STIPO and STAPO; this treatment caused a morphological change in 
the cells, suggesting a toxic effect of the drug, and the GFP-LC3 spots were larger and 
aggregated which presumably led to spot under-calling.  The effects of positive control 
siRNA knock-downs on STAPO and STIPO are more pronounced than on SCPO but 
are consistent.  Knock-down of ULK1 and ATG4C inhibited GFP-LC3 spot parameters 
for all conditions including basal autophagy.  Knock-down of NRBP2 led to an increase 
after EBSS, EBSS plus leupeptin, Torin and resveratrol but not after lithium chloride or 
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incubation in full medium suggesting that NRBP2’s effects on autophagy are dependent 
on the activation of mTOR. 
 
Figure 5.1 GFP-LC3 spot parameters are altered by positive control siRNA in the 
induction screen 
Values for SCPO, STAPO and STIPO after indicated siRNA knock-down and medium conditions in 
GFP-LC3-HEK cells. 24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 
10mM lithium chloride, EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 
128µM resveratrol. Bars represent averaged triplicate values from three plates that were then pooled and 
averaged again based on the number of wells occupied by that siRNA (n). Error bars represent standard 
deviation from averaged pooled triplicate values (RF n=5, siAtg4C n=2, siNRBP2 n=4, siControl n=2, 
siULK1 n=3). 
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The results of the induction screen for nine of the hits will be discussed below.  
To summarise the results from the eleven not discussed below: both siRNA duplexes 
for C1orf198, CDH19, and NAA25 decreased GFP-LC3 spots in all basal and induced 
autophagy conditions in the induction screen.  Knock-down with duplexes against 
GHSR lead to a decrease in basal and starvation-induced autophagy but not after 
induction with Torin or resveratrol.  Of the increasers, ADHFE1 and CNOT1 duplexes 
increased GFP-LC3 spots in all conditions and the ADHFE1 knock-downs greatly 
increased basal GFP-LC3 spots.  The two duplexes against FBXL14, RBM12 and 
SNX20 had differential effects in the induction screen in that one duplex led to an 
increase and the other resembled the response with negative control siRNA.  Knock-
down of STAT2 increased SCPO and STAPO but not STIPO.  Knock-down of 
RASGRF2 increased spots after all inductions but lead to a greater increased after 
resveratrol treatment.  Overall, knock-down of most of the hits caused similar effects on 
GFP-LC3 parameters in all induction conditions to those seen in the primary and 
deconvolution screen with EBSS plus leupeptin. 
5.2 High-resolution imaging of GFP-LC3-HEK cells and 
measurement of the efficiency of siRNA knock-down for 
the 20 validated hits 
5.2.1 Analysis and quantification of GFP-LC3 spots by confocal 
microscopy 
In order to obtain high-quality, high-resolution and higher magnification images 
of GFP-LC3-HEK cells after knock-down with the 20 validated-by-deconvolution hits I 
plated the cells on glass coverslips and captured images of the cells using confocal 
microscopy.  The use of coverslips required that the experiment be done in a larger-
sized well and I scaled-up the screen reverse transfection protocol from a 96-well 
format to a 24-well format.  Two siRNA duplexes for each of the 20 hits were used to 
knock down cells on coverslips, autophagy was induced by incubation in EBSS plus 
leupeptin, and the cells were fixed and nuclei were stained with Hoechst dye.  The cells 
were analysed by indirect immunofluorescence microscopy and images were generated 
from the Hoechst labelling and GFP-LC3 fluorescence at 63X magnification and 
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identical laser settings.  Images of cells treated with negative control RISCfree siRNA 
and siRNA against ULK1 and NRBP2 were also generated (Figure 5.2, part a). The 
confocal images mimic the images generated from the epifluorescence Cellomics 
ArrayScan microscope.  GFP-LC3-containing autophagosomes are seen after induction 
of autophagy, and the number of GFP-LC3 spots is reduced after ULK1 knock-down 
and increase after NRBP2 knock-down confirming that a scaled-up reverse knock-down 
in a 24-well format mimics that in a 96-well format. 
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Figure 5.2 Confocal immuno-fluorescence microscopy images of GFP-LC3-HEK 
cells mimic Cellomics images 
a. Confocal images at 63X of GFP-LC3-HEK cells after knock-down with indicated siRNA and 
incubation in EBSS plus 0.25mg/mL leupeptin.  Hoechst labelling (blue) and GFP-LC3 (green) are 
shown. b. Relative ULK1 mRNA levels after treatment with RISCfree or ULK1 siRNA determined by 
qRTPCR. c. Relative NRBP2 mRNA levels after treatment with RISCfree or NRBP2 siRNA determined 
by qRTPCR from 24-well samples done in parallel with IF. 
 
I quantified the number of GFP-LC3 spots after knock-down with the individual 
duplexes for the 20 hits.  I captured Hoechst and GFP-LC3 confocal images from 
approximately ten fields (with representative density but chosen randomly) for each 
siRNA duplex knock-down and converted these images to black and white.  Then these 
images were imported into the Cellomics ArrayScan and analysed using the 
SpotDetector program as before.  Values for object count (OC) were generated from the 
images of Hoechst labelling and values for SCPO, STAPO and STIPO were generated 
based on the GFP-LC3 signal.  Knock-down with each siRNA duplex for all nine 
decreaser hits reduced GFP-LC3 spot number, total area and total intensity (Figure 5.3, 
panel a).  The reduction of SCPO for most siRNA duplexes was similar to that seen 
with ULK1 knock-down though individual duplexes against CDH19, NAA25 and WAC 
reduced SCPO to a greater extent than the ULK1 siRNA duplex.  Quantification of the 
increase in SCPO, STAPO and STIPO for the confocal images of the increasers of spots 
was not as successful (Figure 5.3, panel b).  Though most siRNA duplexes lead to an 
increase of STIPO above that of RISCfree control, the STIPO for some was comparable 
to the negative control, which contrasts with the deconvolution screen data.  Visual 
inspection of the confocal images indicated that the increaser duplexes did in fact 
increase the number, area and intensity of the GFP-LC3 spots.  Perhaps the GFP-LC3 
signal was too saturated for the Cellomics machine or the spot-parameters that we set 
within the Cellomics SpotDetector were not accurate to capture bigger, brighter spots 
seen with the confocal images at the higher magnification (63x as opposed to 20x). 
Thus, I concluded that quantifying GFP-LC3 spot parameters using the Cellomics 
SpotDetector program and confocal images is sufficient to measure a decrease in GFP-
LC3 spots but was not fully capable of accurately reflecting increases in GFP-LC3 
spots.  Overall, as a result of performing reverse knock-down on coverslips and 
analysing the cells with confocal microscopy, I generated high quality images for the 
two best duplexes for each hit. 
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Figure 5.3 Quantification of GFP-LC3 confocal images using Cellomics image 
processing software 
a. SCPO quantified from black-and-white versions of confocal images of GFP-LC3-HEK cells after 
knock-down with indicated siRNA duplex and incubation in full growth medium (FM) or EBSS with 
0.25mg/mL leupeptin (EBSS+L).  Sets of approximate 10 images from each coverslip were analysed. 
Error bars represent standard deviation from the following: 4 RISCfree (RF) coverslips in FM, 2 RF 
coverslips in EBSS+L, and 3 siULK1 coverslips in EBSS+L were quantified. b. STIPO quantified from 
black-and-white versions of confocal images of GFP-LC3-HEK cells after knock-down with indicated 
siRNA duplex and incubation in full growth medium (FM) or EBSS with 0.25mg/mL leupeptin 
(EBSS+L). Error bars represent standard deviation from the following: 4 RISCfree (RF) coverslips in 
FM, 3 RF coverslips in EBSS+L, and 2 siNRBP2 coverslips in EBSS+L were quantified. The grey line 
indicates average STIPO for RISCfree control in EBSS+L. 
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5.2.2 Quantification of the siRNA knock-down efficiency by qRTPCR 
I have shown that the treatment of GFP-LC3-HEK cells with siRNA duplexes 
against the 9 decreaser hits decreased GFP-LC3 spots in a 24-well format as they did in 
a 96-well format (Figure 5.3, part a).  Similarly, I observed that knock-down with 
siRNA duplexes for the 11 increaser hits increased GFP-LC3 spot formation in a 24-
well format (Figure 5.3, part b).  I next asked if the individual siRNA duplexes target 
the gene and decreased the corresponding mRNA levels (shown for siULK1 and 
siNRBP2 in Figure 5.2).  Using Qiagen QuantiTect primers targeting each of the 20 
genes and quantitative reverse transcriptase PCR (qRTPCR), I measured relative 
mRNA levels of the target gene after knock-down with the individual siRNA duplexes 
compared to levels after RISCfree knock-down . 
For 16 of the 20 hits, at least one of the siRNA duplexes significantly decreased 
relative mRNA levels (nine of these are shown in Figure 5.8 to 5.16).  Neither of the 
two siRNA duplexes against decreaser hits CDH19 and GHSR and against increaser 
hits ADHFE1 and SNX20 significantly reduced mRNA levels of their target genes 
(Figure 5.4). 
 
Figure 5.4 siRNA duplexes against four validated-by-deconvolution hits do not 
reduce corresponding mRNA levels 
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Abilities of two duplexes against CDH19, GHSR, ADHFE1 and SNX20 to reduce mRNA levels are 
quantified by qRTPCR. Error bars represent the standard deviation derived from triplicate wells. 
 
5.3 Endogenous LC3 lipidation in HeLa cells 
In order to further validate the effects of the siRNA duplexes on autophagy I 
assayed the extent of endogenous LC3 lipidation after incubation in starvation medium 
plus leupeptin.  In addition, I assayed LC3 lipidation in full growth medium and 
starvation medium alone.  These additional incubation conditions allowed me to 
distinguish the effects on autophagy initiation versus autophagosomal maturation, 
which can be affected by perturbation of endocytic pathways.  In addition to measuring 
modulations of autophagy using this better read-out, I used an alternate human cell line, 
HeLa, to assess endogenous LC3 lipidation.  As expected, RISCfree negative control 
siRNA and ULK1 and NRBP2 positive control siRNA behave identically in HeLa cells 
as they do in GFP-LC3-HEK cells in which ULK1 and NRBP2 were found to decrease 
and increase GFP-LC3 lipidation respectively (Chan et al., 2007).  When HeLa cells are 
exposed to RISCfree negative control siRNA, and incubated in full medium, both the 
unlipidated LC3I form and lipidated LC3II form are observed (Figure 5.5, panel a,e).  
When autophagy is induced, LC3I is converted to LC3II and a loss of LC3I, an increase 
in LC3II, and an increase of the ratio of LC3II/LC3I is seen (Figure 5.5, panel a,b,e,f).  
Decrease in ULK1 protein levels using a single siRNA duplex for ULK1 leads to an 
inhibition of LC3 lipidation in full medium, starvation medium and starvation medium 
supplemented with leupeptin in HeLa cells (Figure 5.5 panel a,b).  Conversely, knock-
down of NRBP2 leads to an increase of endogenous LC3 lipidation in full medium 
starvation medium and starvation medium with leupeptin (Figure 5.5 panel e,f). 
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Figure 5.5 Knock-down of ULK1 decreases endogenous LC3 lipidation and knock-
down of NRBP2 increases endogenous LC3 lipidation in HeLa cells 
a. Anti-ULK1, -Actin, and -LC3 blots after indicated siRNA treatment in HeLa cells and incubation in 
full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). b.,f. Quantification of 
LC3II/LC3I after indicated siRNA and incubation conditions. c.,g. Quantification of LC3II/actin after 
indicated siRNA and incubation conditions. d.,h. Quantification of LC3II/(LC3I+LC3II) after indicated 
siRNA and incubation conditions. e. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa 
cells and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). 
 
The greatest fold induction of autophagy in HeLa cells after RISCfree control 
siRNA knock-down is seen when the ratio of LC3II/LC3I is quantified.  Induction of 
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autophagy in HeLa cells appears less dramatic when LC3II levels over actin or LC3II 
over total LC3 levels are quantified.  In addition, the effect of ULK1 or NRBP2 knock-
down is most remarkable when the LC3II to LC3I ratios are compared.  A higher 
amount of LC3II is usually observed in HeLa cells in full medium compared to HEK 
cells possibly reflecting a higher amount of basal autophagy.  However, the levels of 
LC3I and LC3II in full medium in HeLa cells can be dramatically dissimilar in different 
experiments (Figure 5.5, panel a,e).  As a result, I chose to use the ratio of LC3II levels 
to LC3I levels when assessing the effect of knock-down by the siRNA duplexes of the 
20 validated-by-deconvolution hits. 
Knock-down with two siRNA duplexes each for C1orf198 and NAA25 caused a 
decrease in GFP-LC3 spot number (Figure 5.3, panel a) and were effective in reducing 
the mRNA levels in GFP-LC3-HEK cells but the siRNA for these two hits did not 
decrease LC3 lipidation in HeLa cells.  One possible reason for this is that C1orf198 
and NAA25 are required for the transcription or translation of GFP-LC3 and knock-
down of these genes leads to a decrease in GFP-LC3 protein levels and in turn, 
decreases in GFP-LC3 SCPO, STAPO, and STIPO.  C1orf198 is an uncharacterised 
gene but NAA25, also known as MDM20, is a component of the NatB N-
acetyltransferase complex and is reported to co-sediment with ribosomal components 
and is involved in protein translation (Starheim et al., 2008). 
I have shown above that knock-down of ADHFE1 or alcohol dehydrogenase, 
iron containing 1, in GFP-LC3-HEK cells causes a partial reduction of mRNA levels 
(about 25-35%) (Figure 5.4).  These two duplexes caused a significant increase of 
SCPO, STIPO and STAPO in the deconvolution screen (Appendix Table 9.5) and as 
previously mentioned, increased GFP-LC3 spots in the induction screen after all 
induction conditions and notably in basal conditions.  Of note, these results were not 
recapitulated when confocal images of ADHFE1 knock-down cells were quantified for 
GFP-LC3 STIPO using Cellomics (Figure 5.3, panel b).  These two duplexes also led to 
an increase of LC3 lipidation in basal and starvation conditions in HeLa cells (data not 
shown).  Perhaps only a small decrease of ADHFE1 mRNA is enough to cause a 
significant decrease of ADHFe1 protein levels and in turn, an increase of autophagy.  
Or perhaps the ADHFE1 knock-down in GFP-LC3-HEK cells in a 96-well screen 
Chapter 5. Further Validation 
 155 
format and in HeLa cells is more effective than in GFP-LC3-HEK cells in a 24-well 
format.  Nonetheless, ADHFE1 was not taken forward as a validated hit from this point. 
siRNA duplexes against RASGRF2 and STAT2 decreased their target gene 
mRNA levels and increased GFP-LC3 spot total intensity (Figure 5.3, panel b) but these 
siRNA duplexes did not increase LC3 lipidation in HeLa cells.  In the induction screen 
RASGRF2 knock-down increased GFP-LC3 spots in starvation, Torin-treated and 
Resveratrol-treated conditions and STAT2 knock-down led to the accumulation of very 
large, bright spots after starvation with leupeptin, as observed by confocal microscopy.  
However, knock-down of RASGRF2 and STAT2 did not increase GFP-LC3 spots in 
basal conditions in the induction screen and thus, I do not predict that these genes are 
required for the fusion of autophagosomes to endosomes or the lysosome or required for 
the degradative activity of the lysosome.  One explanation for these results could be that 
knock-down of these genes could lead to an increase in the overexpression of GFP-LC3 
in GFP-LC3-HEK cells; it would be interesting to test whether knock-down of 
RASGRF2 or STAT2 increased autophagosome numbers measured with endogenous 
LC3 in non-overexpressed conditions.  The increasers RASGRF2 and STAT2 did not 
validate as autophagy regulators after testing their effect on endogenous LC3 lipidation 
in HeLa cells. 
Knock-down of FBXL14 with siRNA duplex-01 decreased its target mRNA 
pool and increased GFP-LC3 spot intensity as measured by confocal microscopy 
(Figure 5.6, panel c), (Figure 5.3, panel b) and significantly increased GFP-LC3 spot 
parameters in all basal and induced conditions in the induction screen (Figure 5.6, panel 
a) (note, FBXL14 duplex-04 does not decrease FBXL14 mRNA levels).  When 
attempting to measure the effect of FBXL14 knock-down on endogenous LC3 
lipidation, I came across an unusual phenomenon: knock-down of FBXL14 led to the 
almost complete reduction of the levels of both LC3I and LC3II (Figure 5.6, panel b).  
Though the actin levels are slightly reduced after FBXL14 knock-down, this does not 
account for the great loss of total LC3.  One explanation could be that knockdown of 
FBXL14 increases the rate of autophagy so much that all the LC3 in the cells is used to 
make autophagosomes and is thus depleted, although if this was the case then the LC3 
levels should be rescued in the presence of leupeptin. 
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Figure 5.6 Knock-down of FBXL14 increases GFP-LC3 spots but decreases total 
LC3 levels 
a. Quantification of STIPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Anti-Actin and -LC3 
blot after indicated siRNA treatment in HeLa cells and incubation in full medium (FM), EBSS (ES) or 
EBSS plus 0.25mg/mL leupeptin (EL). This experiment was done once. c. Quantification of FBXL14 
mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard 
deviation derived from triplicate wells. 
 
Knock-down of RBM12, or RNA binding motif protein 12, with both of its 
duplexes increased GFP-LC3 spots (Figure 5.3, panel b, Appendix Table 8.5) and 
caused a large (approximately 75%) reduction of RBM12 mRNA levels.  However, 
after knock-down in HeLa cells, an increase of LC3II/LC3I was not observed 
suggesting that RBM12 does not act as negative regulator of autophagy or induce a 
stress response that triggers autophagy (Figure 5.7).  Instead, knock-down of RBM12 
appeared to block maturation of autophagosomes, as the amount of LC3 lipidation in 
starvation medium without leupeptin was the same compared to starvation medium with 
leupeptin.  In conclusion, FBXL14 knock-down causes a non-canonical effect on 
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autophagy, increasing GFP-LC3 spot formation and decreasing LC3II levels and 
RBM12 is perhaps a regulator of autophagosome maturation. 
 
Figure 5.7 RBM12 knock-down possibly inhibits autophagosome maturation 
a. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in full medium 
(FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). b. Quantification of LC3II/LC3I after 
indicated siRNA and incubation conditions. Values for siRBM12-03 and siRBM12-04 are the averages of 
duplicates; the experiment was done once. 
 
5.4 The nine that passed further validation 
5.4.1 Five ‘decreasers’ 
Using two of the best siRNA duplexes from the deconvolution screen, I could 
confirm that knock-down of five genes caused a decrease in GFP-LC3 spots, a 
reduction of mRNA levels with at least one duplex after knock-down in GFP-LC3-HEK 
cells, and a decrease in endogenous LC3 lipidation in HeLa cells.  These further 
validated knock-down mediated decreasers of autophagy are LARP1, PAFAH1B2, 
SCOC, SUPT5H and WAC.  These results indicate that these genes are required for 
autophagy and are thus bone fide positive regulators. 
LARP1 or La ribonucleoprotein domain family, member 1, like RBM12, is an 
RNA-binding protein.  The LARP family of proteins is characterised by a common N-
terminal RNA-binding La domain.  This family of proteins is able to traffic into the 
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nucleus due to a nuclear localisation signal.  In Drosophila, larp mutant embryos display 
impaired mitotic phenotypes and defects in cytokinesis suggesting that larp1 is involved 
in spermatogenesis, embryogenesis and cell-cycle progression (Blagden et al., 2009).  
Another member of the La domain-containing family, LARP5 (KIAA0217) was 
identified as decreaser by the primary and secondary screens but did not pass the 
deconvolution screen (Appendix Tables 8.5). 
Two of the best siRNA duplexes against LARP1, duplex-01 and -04, led to a 
decrease in of STIPO in GFP-LC3-HEK cells in all basal autophagy and induced 
conditions similar to ULK1 knock-down (Figure 5.8, panel a).  LARP1 mRNA levels 
were reduced by these two duplexes in GFP-LC3-HEK cells (Figure 5.8, panel b) and 
the confocal images of these cells after induction of autophagy in EBSS plus leupeptin 
convey the decrease in GFP-LC3 spots (Figure 5.8, panel c).  LARP1 siRNA duplex-01 
also inhibits endogenous LC3 lipidation in HeLa cells (Figure 5.8, panel d,e).  
Confusingly, duplex-04 leads to an increase of LC3 lipidation though this may be 
caused by a toxicity stress response as the actin and LC3 levels are drastically reduced 
by this duplex (Figure 5.8, panel d).  This quantification, however, may be inaccurate 
due to low protein levels and different results may be obtained if equal amounts of 
lysate were loaded. 
More recently, LARP1 in human cells has been found at the leading edge of 
migrating cells and has also been shown to exist in a complex with poly A binding 
protein and eukaryotic translation initiation factor 4E (EIF4E) and separately with 
ribosomal subunits consequentially controlling global protein synthesis rates (Burrows 
et al., 2010).  Burrows et al show that siRNA-mediated decrease of LARP1 inhibits 
protein synthesis and perhaps here, knock-down of LARP1 leads to an decrease of 
autophagy protein expression thereby inhibiting the autophagy machinery. 
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Figure 5.8 Knock-down of LARP1 inhibits autophagy 
a. Quantification of STIPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
LARP1 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63X after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. Taken with the exact same magnification and settings as images in Figure 5.2 and can be 
compared to RISCfree control. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells 
and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. 
Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
siLARP1-01 and siLARP1-04 are the averages of duplicates; the experiment was done once. 
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PAFAH1B2 or platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 
(30kDa) is ubiquitously expressed and is involved in lipid metabolism; it is part of a 
complex that hydrolyses platelet-activating factor which is a phospholipid reported to 
play a role in multiple biological processes including spermatogenesis and brain 
development (Zhang et al., 2007a).  siRNA duplex-03 and -04 were the best decreasers 
of spots in the deconvolution screen and both decreased STIPO in the induction screen, 
though to a lesser extent than siULK1 control (Figure 5.9, panel a).  The siRNA 
duplexes robustly reduce PAFAH1B2 mRNA level (Figure 5.9, panel b).  Some GFP-
LC3 spots remain after knock-down (Figure 5.9, panel c) and again the PAFAH1B2 
knock-down does not seem as efficient as ULK1 knock-down at reducing spots (Figure 
5.9, panel a).  Though knock-down with duplex-03 is not sufficient to decrease 
endogenous LC3 lipidation in HeLa cells, knock-down with duplex-04 does decrease 
LC3II/LC3I compared to RISCfree controls in starvation conditions.  Duplex-04 may 
have a stronger effect on LC3 lipidation due to its greater ability to decrease 
PAFAH1B2 mRNA levels. 
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Figure 5.9 Knock-down of PAFAH1B2 inhibits autophagy 
a. Quantification of STIPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
PAFAH1B2 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63X after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. Taken with the exact same magnification and settings as images in Figure 5.2 and can be 
compared to RISCfree control. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells 
and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. 
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Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
siPAFAH1B2-03 and siPAFAH1B2-04 are the averages of duplicates; the experiment was done once. 
 
The gene SCOC encodes a Golgi-resident protein called short coiled-coil protein 
(Van Valkenburgh et al., 2001).  Knock-down of SCOC with the two strongest 
decreaser duplexes from the deconvolution screen causes a decrease of STAPO after 
autophagy induction in all conditions in the induction screen and after starvation plus 
leupeptin in GFP-LC3-HEK cells to a similar extent as ULK1 knock-down (Figure 
5.10, panel a,c).  Duplex-03 sufficiently reduced SCOC mRNA levels but duplex-02 
does not appear to target SCOC (Figure 5.10, panel b).  However, knock-down with 
both duplexes leads to a reduction of LC3 lipidation in HeLa cells (Figure 5.10, panel 
d,e).  Duplex-02 could be decreasing the levels of a different gene that is required for 
autophagy, having a so-called ‘off-target’ effect.  I further characterised the role of 
SCOC in autophagy and this is discussed in Chapter 6. 
SUPT5H or suppressor of Ty 5 homolog (S. cerevisiae) is a transcription 
elongation factor that binds enzymes and has been shown to be both a positive and 
negative regulator of transcription and involved in chromosome activity (Yamada et al., 
2006).  Also known as SPT5, it has many interactors including cyclin dependent kinases 
and HIV proteins.  It is suggested that SUPT5H suppresses senescence and apoptosis 
and is phosphorylated during mitosis (Komori et al., 2009).  It is related to the zebrafish 
protein foggy, which is a regulator of transcription elongation and controls neuronal 
development (Guo et al., 2000).  Remarkably, all four siRNA duplexes for SUPT5H 
decreased GFP-LC3 STIPO to below 80% of control in the deconvolution screen.  In 
the induction screen, both chosen SUPT5H duplexes decreased GFP-LC3 spot intensity 
in all conditions though duplex-01 was better than duplex-04 (Figure 5.11, panel a).  
These siRNA duplexes reduced SUPT5H mRNA levels, GFP-LC3 spots as seen by 
confocal microscopy, and endogenous LC3 lipidation after starvation in HeLa cells 
(Figure 5.11, panel b,c,d,e).  Both duplexes also seem to slightly decrease LC3 
lipidation in full medium conditions, though the statistical significance of this has not 
been determined.  Of note, knock-down with duplex-01 increased the levels of both the 
unlipidated and lipidated forms of LC3 (Figure 5.11, panel d). 
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Figure 5.10 Knock-down of SCOC inhibits autophagy 
a. Quantification of STAPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
SCOC mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63X after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. Taken with the exact same magnification and settings as images in Figure 5.2 and can be 
compared to RISCfree control. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells 
and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. 
Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
siSCOC-02 and siSCOC-03 are the averages of duplicates. The experiment was done four times; 
representative blots are shown. 
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Figure 5.11 Knock-down of SUPT5H inhibits autophagy 
a. Quantification of STIPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
SUPT5H mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63X after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. Taken with the exact same magnification and settings as images in Figure 5.2 and can be 
compared to RISCfree control. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells 
and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. 
Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
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siSUPT5H-01 and siSUPT5H-04 are the averages of duplicates. The experiment was done twice; a 
representative blot is shown. 
 
Knock-down of WW domain containing adaptor with coiled-coil (WAC) 
decreases autophagy.  An extensive inhibition of GFP-LC3 spots was observed after 
knock-down of WAC with duplexes -03 and -04 (Figure 5.12, panel c) and reduction of 
STIPO was to the same or even greater extent as ULK1 knock-down in all induction 
conditions (Figure 5.12, panel a).  Both duplexes were effective in reducing WAC 
mRNA levels to less than 15% of levels in control-treated cells (Figure 5.12, panel b).  
In addition to the reduction of GFP-LC3 spot count, an overall reduction of GFP-LC3 
levels is seen (Figure 5.12, panel c).  When used to knock-down WAC in HeLa cells, 
both duplexes decreased endogenous LC3 lipidation.  Like SCOC, I wanted to further 
characterise WAC and its involvement in autophagy, the results of which are contained 
later in this thesis in Chapter 7. 
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Figure 5.12 Knock-down of WAC inhibits autophagy 
a. Quantification of STAPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
WAC mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard 
deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63X after knock-down with 
indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. 
Taken with the exact same magnification and settings as images in Figure 5.2 and can be compared to 
RISCfree control. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and 
incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. Quantification 
of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for siWAC-03 and 
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siWAC-04 are the averages of duplicates. The experiment was done four times; a representative blot is 
shown. 
5.4.2 Four ‘increasers’ 
By measuring the ability of siRNA duplexes to decrease their intended 
transcription levels and corresponding increase in GFP-LC3 spot formation, and their 
ability to increase LC3 lipidation in HeLa cells, I confirmed that four hits are validated 
‘increasers’ of autophagy.  These potential negative regulators of autophagy are KIF25, 
RASIP1, TLK2 and WDR6. 
Kinesin family member 25 (KIF25), also named kinesin-like 3 (KNSL3) has 
kinesin motor catalytic domain that is shared among the kinesin family and is 
responsible for their ATP-binding and microtubule-dependent molecular motor function 
(Verhey and Hammond, 2009).  Kinesins transport organelles throughout the cell and 
aid cell division by moving chromosomes on microtubules.  KIF25 is an 
uncharacterised member of the kinesin family and its function is not determined.  It was 
cloned using RTPCR and was found to be ubiquitously expressed (Okamoto et al., 
1998).  Two translated isoforms (called isoform 1 and isoform 2) with differential tissue 
expression patterns were noted and KNSL3 shares 31% sequence identity with KIF5B, 
though its C-terminal appeared to be unique among other kinesins.  KIF25 is contained 
in Dharmacon’s Druggable library. 
Knock-down of KIF25 caused an increase of GFP-LC3 spot parameters after all 
conditions though only duplex-03 increased GFP-LC3 STAPO in basal conditions (full 
medium plus leupeptin for 24 hours) (Figure 5.13, panel a).  Both siRNA duplexes 
reduce KIF25 mRNA levels (Figure 5.13, panel b).  Both duplexes appear to greatly 
increase GFP-LC3 spot number and intensity compared to RISCfree control (Figure 
5.13, panel c) and when these images were quantified using the Cellomics quantitative 
software, duplex-03 exhibited the largest increase of all the siRNA duplexes, causing an 
almost four-fold increase in STIPO over the RISCfree control (Figure 5.3, panel b).  I 
observed an interesting phenotype in the cells that received KIF25 siRNA duplex-03 in 
that the GFP-LC3 appeared to accumulate in long strings stretched within the cell.  
Endogenous LC3 lipidation was increased after KIF25 knock-down and duplex-03 
increased basal LC3 lipidation.  Overall, duplex-03 led to a greater increase of GFP-
LC3 spots and LC3 lipidation. 
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Figure 5.13 Knock-down of KIF25 increases autophagy 
a. Quantification of STAPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
KIF25 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63x after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in 
full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. Quantification of LC3II/LC3I 
after indicated siRNA and incubation conditions. LC3II/LC3I values for siKIF25-01 and siKIF25-03 are 
the averages of duplicates. The experiment was done three times; a representative blot is shown. 
 
Ras interacting protein 1 (RASIP1) was discovered in a yeast-two-hybrid assay 
searching for hRAS interactors (Mitin et al., 2004).  RAIN, as they called it, contains a 
Ras association (RA) domain and was shown to interact with Ras in a GTP-dependent 
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manner in that it had a higher affinity for Ras-GTP than Ras-GDP.  This interaction 
required an intact Ras core effector-binding domain and thus they conclude that 
RASIP1 is a Ras effector.  Ras, a small GTPase, is a hub for many cellular functions 
including growth and differentiation and acts by receiving extracellular signals and then 
interacting with multiple effectors that then activate multiple signalling cascades.  Mitin 
et al discovered that RASIP1 is not a plasma membrane Ras effector but a Golgi Ras 
effector as it is recruited by activated Ras to the Golgi and localises to perinuclear juxta-
Golgi vesicles.  RASIP1 has more recently been shown to be required for vessel 
formation and is strongly expressed in vascular endothelial cells during development in 
mice and frogs (Xu et al., 2009).  Xu et al also show that siRNA knock-down of 
RASIP1 in human endothelial cells impairs angiogenesis (as measured by endothelial 
tube formation) and cell motility (as shown by ‘wound-healing’ assays) though it is 
unclear whether RASIP1 links Ras to vascular development or exerts these effects by 
impacting other signalling pathways. 
When RASIP1 is knocked down by two siRNA duplexes, GFP-LC3 STIPO is 
increased in all conditions including full medium and lithium treatment (Figure 5.14, 
panel a).  RASIP1 is knocked down by duplex-03 well but not fully by duplex-04. 
Knock-down with duplex-03 leads to the increased formation of large, bright GFP-LC3 
spots scattered throughout the cell with duplex-03 (Figure 5.14, panel b,c).  The effect 
of duplex-04 appears to be different, causing an overall increase of GFP-LC3 and spots 
but also leading to some cell toxicity.  Both duplexes increase endogenous LC3 
lipidation in HeLa cells in basal and starvation conditions mimicking the increase in 
basal GFP-LC3 spots and duplex-03 causes a very large increase in basal lipidation 
(Figure 5.14, panel d,e).  Duplex-04 seems to have a different effect on autophagy, 
displaying more of a maturation phenotype as the addition of leupeptin to EBSS does 
not increase LC3 lipidation compared to EBSS alone.  Perhaps duplex-04 is targeting a 
different gene that is involved in autophagosome maturation.  Nonetheless, the effects 
of siRNA duplex-03 show that knock-down of RASIP1 increases basal and nutrient 
dependent autophagy. 
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Figure 5.14 Knock-down of RASIP1 increases autophagy 
a. Quantification of STIPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
RASIP1 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63x after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in 
full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. Quantification of LC3II/LC3I 
after indicated siRNA and incubation conditions. LC3II/LC3I values for siRASIP1-03 and siRASIP1-04 
are the averages of duplicates. The experiment was done twice; a representative blot is shown. 
 
TLK2 or tousled-like kinase 2 is a serine/threonine kinase that was first cloned 
together with TLK1 by Yamakawa et al who called them PKU-α and PKU-β 
respectively.  Both genes contain a kinase domain and a nuclear localisation signal and 
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overexpressed TLK2 is shown to localise in the nucleus of cells (Yamakawa et al., 
1997).  TLK2 shares 86% sequence homology to TLK1 and 94% in their catalytic 
regions.  TLK2 has three coiled-coil domains and has been shown to interact with 
TLK1 by a yeast-two-hybrid assay and interestingly, knock-down of TLK1 was seen to 
also increase GFP-LC3 spots in the primary screen though it did not pass the 
deconvolution screen in that only one individual duplex increased GFP-LC3 spots 
(Appendix Table 9.5).  It was reported that both TLK1 and TLK2 are involved in the 
cell cycle and that their highest kinase activity is displayed in S phase and their function 
is linked to periods of DNA replication; both also regulate chromatin assembly (Sillje et 
al., 1999).  More recently, TLK1 and TLK2 were shown to be targets of the DNA 
damage checkpoint and were rapidly inactivated (dephosphorylated) by ionizing 
radiation (Groth et al., 2003). 
I first identified TLK2 as a potential negative regulator of autophagy during the 
pilot screen of plate 10 of the kinase; knock-down of TLK2 with its siRNA Smartpool 
increased GFP-LC3 spots.  In the deconvolution screen, duplexes -03 and -04 increased 
SCPO and STAPO but duplex-04 confusingly decreased STIPO.  Both duplexes reduce 
TLK2 mRNA levels but at least one third of the message remains after knock-down 
(Figure 5.15, panel b).  Duplex-03 was not tested in the induction screen but TLK2 
knock-down with duplex-04 in fact decreased GFP-LC3 STIPO like in the 
deconvolution screen but also decreased SCPO and STAPO in all conditions (Figure 
5.15, panel a).  The two duplexes have varying effects on GFP-LC3 spots as analysed 
by confocal microscopy.  Knock-down with duplex-03 appears to lead to a slight 
increase in both GFP-LC3 intensity and spots as compared to RISCfree and though 
duplex-04 causes a decrease in GFP-LC3 intensity, the accumulation of large 
aggregates of GFP-LC3 is observed (Figure 5.15, panel c).  The duplexes again have a 
differential effect on endogenous LC3 levels in that duplex-04 causes a strong reduction 
of LC3 protein levels (Figure 5.15, panel d).  Duplex-03 does not increase LC3 
lipidation but knock-down with duplex-04 causes a large increase in LC3 lipidation in 
full medium and EBSS with and without leupeptin.  These differential abilities to 
induce LC3 lipidation are perhaps due to the ability of duplex-04 to better reduce TLK2 
mRNA levels but this difference in efficiency is only slight and does not explain the 
varied GFP-LC3 spot phenotypes and LC3 protein levels. 
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Figure 5.15 Knock-down of TLK2 increases autophagy 
a. Quantification of STAPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
TLK2 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard 
deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63x after knock-down with 
indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. d. 
Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in full medium 
(FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. Quantification of LC3II/LC3I after 
indicated siRNA and incubation conditions. LC3II/LC3I values for siTLK2-03 and siTLK2-04 are the 
averages of duplicates. The experiment was done twice; a representative blot is shown. 
 
WD repeat domain 6, WDR6, contains eleven WD protein binding domains and 
a predicted transmembrane domain.  As a result of its ability to complex with other 
proteins it has many interacting partners.  WDR6 was found to interact with 
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serine/threonine kinase 11 (aka LKB1) by a yeast-two-hybrid assay and confirmed by 
co-immunoprecipitation and they were shown to localise together in the cytoplasm 
though both experiments were done with tagged, overexpressed WDR6 (Xie et al., 
2007).  LKB1 is a tumour suppressor and its inhibition of cell proliferation is thought to 
occur mostly through its modulation of p21/Cip1, which controls cell cycle arrest.  
WDR6 activity was shown to synergise with that of LKB1 as co-over-expression of 
both proteins caused an increased inhibition of HeLa cell proliferation (Xie et al., 2007).  
Xie et al suggest that WDR6 may also acts as a tumour suppressor by regulating the 
cyclin dependent kinase inhibitor p27/Kip1.  In a different study, WDR6 was found to 
be among genes that are enriched in the rat brain hypothalamus, the functional site for 
coordination of metabolism, feeding behaviours and stress response and thus controller 
of energy balance (Chiba et al., 2009).  The authors show that WDR6 gene expression 
was reduced by caloric restriction that has been shown to increase life span.  They also 
show that WDR6 interacts in vivo with IRS-4, an important insulin receptor substrate in 
the brain, by co-immunoprecipitation of rat brain slices and WDR6 gene expression was 
increased by insulin signalling.  WDR6 is also a potential drug target as it is contained 
in Dharmacon’s ‘Druggable library.’ 
The two best GFP-LC3 spot-increasing siRNA duplexes for WDR6, duplex-02 
and duplex-03 increased GFP-LC3 STAPO after induction of autophagy with lithium 
chloride, Torin, resveratrol and incubation in starvation medium (Figure 5.15, panel a).  
Both duplexes greatly reduce WDR6 mRNA levels and lead to the formation of more 
GFP-LC3 spots (Figure 5.16, panel b,c).  Both duplexes increase LC3 lipidation in 
HeLa cells and knock-down with duplex-03 causes an increase in LC3 protein levels 
(Figure 5.16, panel d,e).  Of note, knock-down with duplex-02 greatly increased LC3 
lipidation in full medium in HeLa cells. 
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Figure 5.16 Knock-down of WDR6 increases autophagy 
a. Quantification of STAPO after indicated siRNA knock-down and inductions in GFP-LC3-HEK cells. 
24H is 24 hours treatment, 2H is 2 hours treatment, FM is full medium, LiCl is 10mM lithium chloride, 
EBSS+L is EBSS plus 0.25mg/mL leupeptin, Torin is 250nM Torin, and RV is 128µM resveratrol. Error 
bars represent the standard deviation of triplicate well values (from three plates). b. Quantification of 
WDR6 mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the 
standard deviation derived from triplicate wells. c. GFP-LC3 confocal images at 63x after knock-down 
with indicated siRNA duplex and induction of autophagy by incubation in EBSS plus 0.25mg/mL 
leupeptin. d. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in 
full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). e. Quantification of LC3II/LC3I 
after indicated siRNA and incubation conditions. LC3II/LC3I values for siWDR6-02 and siWDR6-03 are 
the averages of duplicates. The experiment was done three times; a representative blot is shown. 
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5.5 Discussion 
5.5.1 Considerations for the further validation measuring mRNA levels 
and LC3 lipidation  
The group of nine further-validated hits contain multiple proteins with protein 
binding domains (SCOC (CC), WAC (WW and CC), RASIP1 (RA), TLK2 (CC), 
WDR6 (WD40)).  They are a diverse group of genes but their proteins seem to share 
some common functions.  Two hits, PAFAH1B2 and WDR6 have been linked to 
metabolic pathways.  Two bind nucleic acid (LARP1 and SUPT5H) and a large fraction 
of the nine are reported to be involved in cell-cycle control: LARP1, SUPT5H, TLK2, 
and WDR6.  Last, SCOC, SUPT5H and RASIP1 have been implicated in development, 
a process that has been shown to require autophagy.  Two proteins have been shown to 
reside in the Golgi: SCOC and RASIP1.  Four are potential therapeutic targets: 
decreaser SUPT5H, and increasers KIF25, WDR6, and the kinase TLK2. 
The five genes whose siRNA-mediated reduction leads to a decrease in autophagy 
are presumably positive regulators autophagy.  More specifically, results from the 
induction screen suggest that they are involved in the initiation or formation of the 
autophagosome because they all appear to act down-stream of mTOR inactivation.  The 
four hits whose gene knock-downs cause an increase of autophagy may be negative 
regulators of autophagy and when their inhibitory actions are reduced, autophagy 
proceeds at a higher rate.  But also, inhibition of these genes may cause a stress 
response that the cells respond to by increasing the rate of autophagy.  These genes 
could alternatively be required for the trafficking of endosomes required for proper 
maturation or transport of the autophagosomes themselves to the lysosome or even the 
degradative conditions of the lysosome itself.  Perturbation of any of these processes 
may lead to the accumulation of undegraded autophagosomes and further upregulation 
of autophagy to compensate because the system is not working properly to recycle 
cytoplasmic contents in times of nutrient deprivation.  Because I perceived it to be more 
straight-forward to work on hits that are required for autophagy, I chose to further 
characterise two ‘supervalidated’ positive regulators, SCOC and WAC.  These two 
proteins were also of interest because of their protein-protein interacting domains and 
reported interacting partners (discussed in Chapter 6 and 7). 
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The endogenous LC3 lipidation data could be improved for seven of the nine hits; 
only the SCOC and WAC knock-downs have been done enough times to generated 
statistically significant data.  In addition, though I chose the two best duplexes from the 
deconvolution screen, there are instances where one of these duplexes does not decrease 
mRNA levels (SCOC and RASIP1).  In these cases, the third GFP-LC3 spot-affecting 
duplex could be ordered and tested (this was done with SCOC, see Chapter 6).  Also, 
the knock-down of TLK2 is not complete which perhaps limits the autophagic response.  
It should also be noted that the mRNA levels were measured in GFP-LC3-HEK cells 
and corresponded to the coverslips that were examined by confocal microscopy.  
mRNA levels of the 20 genes were not tested in HeLa cells, in which I performed the 
LC3 lipidation assays. 
Perhaps HeLa cells were not the best system to use for the endogenous lipidation 
assay.  Although other labs do use HeLa cells in autophagy assays, in my hands, the 
levels of LC3I and II are not constant across experiments and the cells appear to have a 
higher amount of basal autophagy compared to HEK cells.  HeLa cells are a commonly-
used immortal epithelial cell line derived from cervical cancer cells and it has been 
shown that the tumour suppressor LKB1 is missing in HeLa cells (Shaw et al., 2004).  
Shaw et al show that in low ATP conditions, LKB1 is required for the repression of 
TOR thereby inhibiting cell growth.  In turn, TOR signalling may be altered in HeLa 
cells lacking LKB1 and the loss of mTOR inhibition may lead to higher levels of 
autophagy.  In contrast, it has been shown that LKB1 is a positive regulator of 
autophagy (Liang et al., 2007).  LKB1 may be a toggle between cell growth and 
autophagy and may sense nutrient levels in order to switch between the two and 
regulate homeostasis; this system may be altered in HeLa cells. 
5.5.2 LARP1 
Knock-down of LARP1 decreases autophagy (Figure 5.8) and as LARP1 is a 
positive regulator of protein synthesis, it is conceivable that its effect on autophagy is 
due to a decreased expression of autophagy genes.  There are a large number of reported 
phosphorylation sites on LARP1 and recently it was included in a screen of 375 
phosphopeptides that include AKT, PDK1 or mitogen-activated protein kinase substrate 
recognition motifs (Andersen et al., 2010).  The authors of the screen profiled the 
phosphorylation of LARP1, and suggest that LARP1 may be used as a phospho-specific 
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biomarker in order to personalise patients’ oncology therapies with P13K pathway 
inhibitors.  Interestingly, Merck, the director of the phospho-profiling screen also claims 
to have phospho-specific antibodies of LARP1 and it could be tested to see if the 
phosphorylation state of LARP1 is altered when autophagy is activated.  Also, Merck 
possesses an inhibitor against LARP1 and this could potentially be a specific inhibitor 
of autophagy. 
5.5.3 PAFAH1B2 
Knock-down of PAFAH1B2 caused reduced autophagy (Figure 5.9).  This 
protein was shown to be involved in brain development through its interactions with 
reelin (RELN) (Zhang et al., 2007a).  Reelin shapes brain organisation during 
development by activating two receptors VLDLR and ApoER2 and phosphorylating 
Dab1 thereby controlling cell-cell interactions critical for cell positioning and neuronal 
migration.  Zhang et al show that PAFAH1B2 binds to phosphorylated Dab1 
downstream of reelin and also to VLDLR and through its interaction with VLDR, 
controls forebrain development. 
PAFAH1B2 was shown in a large-scale two hybrid experiment to interact with 
parkin (Stelzl et al., 2005) the E3 ubiquitin ligase, mutations of which are known to 
cause Parkinson’s disease.  As discussed previously, parkin has been shown to interact 
with PINK1, and together they congregate mitochondria in a perinuclear region so that 
they can be eliminated by autophagy (Kawajiri et al., 2010).  Also, parkin was found to 
recognise these damaged mitochondria (Narendra et al., 2010) though it is not known 
how and it would be interesting to find out whether PAFAH1B2 plays a role in this 
process. 
5.5.4 SUPT5H 
Knock-down of SUPT5H with both siRNA duplexes decreased the target 
mRNA levels and LC3 lipidation (Figure 5.11).  During the deconvolution screen all 
four of its siGenome duplexes reduced STIPO below 80% or control.  The siRNA 
Smartpool for SUPT5H resides in Dharmacon’s ‘Druggable Library’ suggesting that 
SUPT5H is a known drug target and in turn, this drug could be a specific inhibitor of 
starvation-induced autophagy.  It is suggested that this protein suppresses senescence 
and apoptosis (Komori et al., 2009) and it may suppress these pathways in order to 
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favour autophagy.  Overexpression of ULK3 has been shown to induce autophagy and 
oncogene-induced senescence (Young et al., 2009) and it would be interesting to ask 
whether SUPT5H and ULK3 coordinate to function in the cell. 
5.5.5 KIF25 
Loss of the microtubule motor protein KIF25 was shown to increase autophagy 
(Figure 5.13).  It has been shown that microtubules play a critical role in autophagy as 
disruption of their network inhibits autophagosome formation and fusion with the 
lysosome (Kochl et al., 2006).  In addition, it is thought that specific cargo such as 
aggregated huntingtin is recruited to the autophagy pathway via microtubule transport 
(Iwata et al., 2005).  KIF25 is an uncharacterised member of the kinesin molecular 
motor protein family and very little is known about this protein compared to the 
proteins in the kinesin 1 complex.  KIF5B transcribes the kinesin heavy chain for the 
kinesin 1 complex and KIF5B knock-out mice are embryonic lethal and as a result of 
loss of KIF5B, lysosomes do not disperse and mitochondria cluster around the nucleus 
(Tanaka et al., 1998).  KIF5B knock-down increased GFP-LC3 spot parameters in the 
primary and repeat screen but it did not pass deconvolution (Appendix Table 9.5).  
KIF25 differs from KIF5B and other KIFs in the C-terminal part of the protein, a region 
though to confer specificity of cargo (Verhey and Hammond, 2009).  Perhaps KIF25 is 
a kinesin motor protein whose specific role is to transport needed components for the 
autophagy pathway.  Or KIF25 may transport autophagosomes themselves to the 
lysosome in a similar way to dynein (Kimura et al., 2008) and its knock-down may 
impair autophagosome degradation leading to the vesicles’ accumulation.  Interestingly, 
the C. elegans homologue of ULK1, UNC-51 interacts with the kinesin heavy chain 
adaptor UNC-76 and these two proteins coordinate to control axon development (Toda 
et al., 2008); it would be interesting to ask whether KIF25 interacts with ULK1 or the 
human homologue of UNC-76, FEZ1.  In addition, KIF25 is in Dharmacon’s 
‘druggable’ library. 
5.5.6 RASIP1 
RASIP1 is one of two Ras-interacting proteins found to increase GFP-LC3 
spots.  RASGRF2 was discussed above and I found that though knock-down of 
RASGRF2 was targeted to that gene and led to an increase in GFP-LC3 spots, LC3 
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lipidation was not increased.  Perhaps RASGRF2 is required for the maturation of 
autophagosomes.  RASIP1 knock-down, however, did increase GFP-LC3 spots and 
endogenous LC3 lipidation (Figure 5.14).  RASIP1 has been found to be required for 
apoptosis and proper cell motility (Xu et al., 2009) and RASIP1 has been shown to 
localise on juxta-nuclear Golgi vesicles (Mitin et al., 2004).  It would be interesting to 
find out if these vesicles are positive for autophagy markers.  RASIP1 and RASGRF2 
provide a link between autophagy and the important signalling molecule Ras, which 
itself has been implicated in autophagy induction on the ER (Wu and Terada, 2010) and 
has even been shown to down-regulate Beclin 1 (Yoo et al., 2010). 
5.5.7 TLK2 
TLK2 is a relatively uncharacterised kinase that is thought to act in the nucleus 
(Sillje et al., 1999).  As mentioned above, both TLK1 and TLK2 were increasers in the 
primary screen but TLK1 did not pass deconvolution.  TLK2 was a three-out-of-four hit 
for GFP-LC3 spots and knock-down also increased LC3 lipidation (Figure 5.15).  I 
asked whether TLK2 could be regulating autophagy from the nucleus by affecting the 
transcription of autophagy genes.  TLK2 was knocked down in HEK cells using 
Dharmacon siRNA duplex-03 and -04 and I found that the mRNA levels of ULK1, 
GABARAP, and LC3 were increased compared to treatment with RISCfree control 
(data not shown).  This perhaps suggests that TLK2 is a negative regulator of autophagy 
by suppressing autophagy gene transcription.  As a kinase, TLK2 is an especially 
interesting hit because drugs can be found to inhibit TLK2 kinase activity.  
Interestingly, a polymorphism in the TLK2 gene has been linked to breast cancer 
(Kelemen et al., 2009) and it would be important to ask whether this mutation alters 
TLK2’s regulation of autophagy. 
5.5.8 WDR6 
WDR6 is also an interesting increaser that has potential links to cancer as it has 
been shown to interact with the tumour suppressor LKB1 (Xie et al., 2007).  In Figure 
5.16, I show that knock-down of WDR6 increases autophagy.  WDR6 contains WD40 
repeats that provide platforms for protein interactions and WDR6 may regulate 
autophagy by binding to autophagy proteins.  WDR6 has also been shown to interact 
with insulin receptor substrate 4 and through this interaction, may sense growth factors 
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and negatively regulate autophagy (Sano et al., 2002).  Like KIF25, WDR6 is also a 
potentially druggable increaser and these drugs may in the future be used to stimulate 
autophagy and provide therapy for neurodegenerative diseases by clearing protein 
aggregates in the cells via autophagy. 
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Chapter 6. SCOC 
6.1 Introduction to SCOC 
I chose to further characterise short coiled-coil protein (SCOC) as a positive 
regulator of autophagy for several reasons.  First, it had been shown to localise to the 
Golgi apparatus, where Atg9, an essential autophagy protein resides.  The Golgi, as 
discussed above, is also a proposed source of membrane for the autophagosome.  
Second, SCOC contains a coiled-coil domain presumably through which it interacts 
with other proteins, two of which, ADP-ribosylation factor-like 1 (ARL1) and 
fasciculation and elongation protein zeta 1 (zygin1) (FEZ1) have been previously 
studied and are involved in post-Golgi transport and axonal trafficking respectively.  
Last, SCOC homologues have been shown to play a role in important processes such as 
development and axonal transport. 
6.1.1 SCOC is an ARL1 interactor 
SCOC was first characterised as an interacting partner of ARL1, an ARF-like 
protein that at the time was not thought to share the ADP-ribosylation factor activities 
of ARFs but has since been shown to have GTP-ase activity and regulate endosomal 
trafficking in distinct ways from ARFs (Burd et al., 2004).  ARL1 has more recently 
been shown to regulate the retrograde transport of Shiga toxin to the TGN through its 
interaction with SNARE proteins (Nishimoto-Morita et al., 2009).  In an attempt to 
characterise the relatively unknown protein family of human ARLs, Van Valkenburgh 
et al performed a yeast two-hybrid screen with dominant active mutants of ARL1, 
ARL2 and ARL3 and discovered a set of proteins that interacted with one specific ARL 
or two or all three of the family members (Van Valkenburgh et al., 2001).  SCOC, 
which they refer to as SCOCO, was found to only bind to ARL1 and more specifically, 
binds only to the dominant active form of ARL1, not the wild-type form.  SCOC is 
widely expressed in human tissues including heart, brain, and skeletal muscle.  SCOC 
was tested and found not to contain ARL1 GAP activity though after overexpression of 
ARL1, the two proteins were shown to colocalise with β-COP in the Golgi of NRK 
cells.  The binding of SCOC to ARL1 was shown to be sensitive to the ARF GEF 
inhibitor brefeldin A suggesting that the SCOC-ARL1 interaction depends on the 
activity of one or more ARF GEFs and the activation state of ARL1 itself. 
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6.1.2 SCOC interacts with FEZ1 in C. elegans and mammals 
6.1.2.1 SCOC is UNC-69 in C. elegans and interacts with the FEZ1 
homologue UNC-76 
The C. elegans’ homologue of SCOC, UNC-69, has been shown to be required 
for normal development of neurons through its ability to complex with the FEZ1 
homologue UNC-76 in order to properly regulate vesicle trafficking to the growing 
axons and dendrites of the cell (Su et al., 2006).  UNC-69 and UNC-76 colocalise in 
puncta in the C. elegans nervous system and together promote axonal growth by 
directing these vesicles to sites of growth, extending the growth-cone and helping the 
synapse to form in the developing neurons.  Interestingly and unlike in mammalian 
cells, these neuronal functions of SCOC do not depend on its interaction with the C. 
elegans ARL-1 as these two proteins do not interact.  Instead, normal synaptic 
development requires the direct interaction of UNC-69 and UNC-76 on cytoplasmic 
vesicular structures for which they regulate the size and position.  The authors note the 
conservation of both UNC-69 and UNC-76 and suggest that their mammalian 
homologues SCOC and FEZ1 may function in a similar way and be required for normal 
presynaptic organisation in those organisms. 
In Drosophila, UNC-76 is a proposed kinesin heavy chain adaptor and is also 
required for functional axonal transport but not through its interaction with SCOC but 
through its interaction with the ULK1 homologue UNC-51 (Toda et al., 2008).  Here, 
UNC-51 is shown to interact with phosphorylated UNC-76, which, when activated 
binds to synaptic vesicles through Synaptotagmin-1 and in turn, directs vesicles from 
the soma to the synapse.  Though Toda et al suggest that the role of UNC-51/ATG1 in 
axonal transport in normal growth conditions is distinct from its role as the autophagy 
kinase, whose autophagy-specific activity is initiated by starvation, it is conceivable that 
the homologues of SCOC, FEZ1, and ULK1 cooperate to regulate both axonal 
outgrowth and autophagy in higher organisms. 
6.1.2.2 Mammalian SCOC and FEZ1 interact 
SCOC has in fact been shown to bind FEZ1 in human cells by yeast two-hybrid; 
SCOC was pulled out of a screen of a human foetal brain cDNA library using FEZ1 as 
bait (Assmann et al., 2006).  The authors attempted to express soluble SCOC protein 
but did not succeed in doing so and did not confirm the SCOC-FEZ1 binding.  
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Nonetheless, the yeast two-hybrid interaction was repeated and the binding of SCOC 
was shown to not occur with a FEZ1 mutant missing its coiled-coil region (Figure 6.1).  
Also, SCOC was shown to interact with FEZ2, whose conserved coiled-coil region is 
highly similar to that of FEZ1. 
 
Figure 6.1 Human SCOC, FEZ1 and FEZ2 domain structures 
Human SCOC, FEZ1 and FEZ2 are shown. Numbers represent amino acid residues. CC is coiled-coil 
domain. Worm 281 to 299 is the reported region in C. elegans FEZ homologue UNC-76 that is critical for 
SCOC binding (Su et al., 2006). 
6.1.3 The yeast homologue of SCOC is most likely Slo1 
A BLAST search of the S. cerevisiae genome against the human SCOC protein 
unveiled a novel protein that Panic et al named SCOCO-like ORF (SLO1) (Panic et al., 
2003).  These authors showed that SLO1 does not interact with the yeast ARL1 
homologue Arl1p but in fact interacts in vitro with the ARF-like protein Arl3p.  They 
identified a conserved tyrosine residue towards the C-terminal of SLO1 that is critical 
for this binding and suggest that the surrounding region is similar to that of a Golgi-
targeting GRIP domain (golgin-97, RanBP2alpha, Imh1p and p230/golgin-245 domain).  
Yeast Arl3p is a Golgi-associated GTP-binding ARF and acts as a vesicle-tethering 
factor for endosomes at the Golgi. 
Indeed, SLO1 is the best hit using a BLAST search of the S. cerevisiae genome 
against the mammalian SCOC protein, having the highest conservation, but performing 
my own BLAST search, I found two other yeast proteins that also show some similarity 
with SCOC.  A 33% sequence identity similarity is seen between the human SCOC 
protein and Vps30, the yeast Beclin 1 homologue.  Vps30, also known as Atg6, is a 
critical component of the yeast PI3-kinase complex and is required for autophagy.  It 
contains a coiled-coil domain and it is in this domain that the similarity between the 
proteins is seen.  Another protein that shows partial identity (27%) to SCOC around its 
coiled-coil is the golgin GOLGA2, also known as GM130.  It should be noted that 
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coiled-coil domains are infamous for sharing homology and these findings may be 
nonspecific to SCOC. 
6.1.4 BERT is the chicken homologue of SCOC and is required for early 
development 
The SCOC Gallus gallus homologue, known as BERT, is critical for normal 
chick embryo development (Papanayotou et al., 2008).  The chicken and human 
proteins have an identical sequence in the conserved C-terminal region containing the 
coiled-coil.  In the chicken, the expression of BERT is low throughout the life span but 
is sharply upregulated in an early embryonic stage 4-4+ when the neural plate will 
emerge.  Discovered by yeast two-hybrid as an ERNI-binding protein, BERT 
coordinates with ERNI to regulate the onset of expression of Sox2, a critical factor of 
neural plate development.  BERT is an antagonist of ERNI and both bind to each other 
and the cell cycle control protein Geminin through their coiled-coil domains.  The 
authors propose that BERT disrupts the inhibitory Geminin-ERNI interaction thereby 
removing a transcriptional repressor, inducing Sox2 expression and the onset of neural 
plate development.  Also, RNAi-mediated knock-down of BERT results in guidance 
and fasciculation defects in the epaxial nerves (Su et al., 2006) further supporting the 
idea that SCOC promotes development in higher organisms. 
6.2 Characterisation of SCOC as a positive regulator of 
autophagy 
6.2.1 Multiple isoforms of SCOC 
SCOC is a small protein whose tertiary structure is mostly comprised of a 
coiled-coil domain (Figure 6.1).  There are four suggested isoforms arising from 
multiple transcript variants that are the result of alternative splicing; the C-terminal 
region containing the coiled-coil is highly similar between the isoforms (Figure 6.2).  
The Entrez Gene ID for SCOC is 60592 and the accession number listed for 
Dharmacon’s SCOC Smartpool is NM_032547; this encodes a protein of with a 
molecular weight of approximately 14 kDa.  When first characterising the human 
protein SCOC, the group of Richard Kahn cloned an EST of SCOC into pCDNA3.1 
Myc-His (Van Valkenburgh et al., 2001) and we obtained this construct, from now on 
referred to as SCOC-myc, from this group.  The clone used to do so has the Nucleotide 
Accession of AF330205 and corresponding Protein Accession AAK01707.  This is a 
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shorter version of the protein whose translation begins at a conserved methionine within 
the coiled-coil and the predicted molecular weight of this protein is 9.4 kDa. 
 
 
Figure 6.2 SCOC isoforms and siRNA targeting regions 
Schematic depicting different isoforms of SCOC (Uniprot ID Q9UIL1). The amino acid sequence and 
predicted molecular weights of the protein is shown. Yellow box is the coiled-coil domain. Green boxes 
show Dharmacon siGenome duplex targeting areas; blue boxes show Ambion siRNA targeting areas. 
Rainbow box shows the region that is suggested to contain the Qiagen QuantiTect SCOC primer. (A 
larger version of this schematic can be found in the Appendix, Figure 9.1). 
 
I asked which isoform or isoforms exist in HEK cells using an affinity purified 
rabbit antibody also received from Rick Kahn that was generated against recombinant 
SCOC-myc protein (Van Valkenburgh et al., 2001).  I used this antibody to probe HEK 
cell lysates and like Van Valkenburgh et al, was not able to detect endogenous SCOC 
protein in these lysates.  In order to enrich for the SCOC protein, I performed an 
immunoprecipitation, binding the SCOC antibody to Protein A beads, incubating with 
HEK cell lysate and probing the bead eluate with the SCOC antibody (Figure 6.3).  
After a very long exposure, a band of approximately 8 kDa is visible in the IP and not 
the control lane.  This band is smaller than three of the Uniprot isoforms (Q9UIL1-1-3) 
and appears to be bigger than isoform 4 (Q9UIL1-4), which lacks just less than half of 
the conserved coiled-coil domain.  It is likely is that this band corresponds to the 
AAK01707 isoform whose corresponding open reading frame was used to generate the 
SCOC-myc construct.  Perhaps this form, which is not annotated as a Uniprot isoform, 
is the main isoform in HEK cells. 
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Figure 6.3 One isoform of SCOC is detected in HEK cells 
Anti-SCOC blot of HEK lysates (input, unbnd) and supernatant eluted from beads after 
immunoprecipitation with SCOC antibody (IP).  Unbnd is unbound HEK lysate after 
immunoprecipitation. IP is eluate after incubation of beads, lysate and SCOC antibody. Arrowhead 
indicates immunoprecipitated band. 
 
6.2.2 Differential effects of SCOC siRNA duplexes on GFP-LC3 spots, 
SCOC mRNA levels and LC3 lipidation 
I have previously shown that treating cells with SCOC Dharmacon siRNA 
duplexes-02 and -03 inhibits GFP-LC3 spot formation and endogenous LC3 lipidation 
in HeLa cells but while duplex-03 decreases SCOC mRNA levels, duplex-02 does not 
(Figure 5.10).  I obtained the third duplex that decreased SCPO, STIPO and STAPO in 
the deconvolution screen, SCOC siRNA duplex-01, and tested that duplex in the same 
assays alongside duplex-02 and -03 (Figure 6.4, panel a).  Observing the effect of 
duplex-01 on GFP-LC3 spots in GFP-LC3-HEK cells, one sees a reduction of spot 
number and intensity compared to RISCfree-treated cells, recapitulating the 
deconvolution screen data.  Duplex-01 also reduced SCOC mRNA levels and does so to 
a greater extent than duplex-03 (Figure 6.4, panel b).  However, while duplex-02 and -
03 again decrease LC3 lipidation, knock-down with duplex-01 leads to an increase in 
LC3 lipidation (Figure 6.4, panel c,d).  I postulate that duplex-02 is having an off-target 
effect in that I suspect it is knocking down an unknown gene that is required for 
autophagy.  I cannot however explain at this point why knock-down of SCOC with 
duplex-01 decreases GFP-LC3 spots but increases endogenous LC3 lipidation in HeLa 
cells. 
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Figure 6.4 Dharmacon siRNA duplexes against SCOC decrease GFP-LC3 spots 
but have differential effects on SCOC mRNA levels and LC3 lipidation 
a. GFP-LC3 confocal images at 63X after knock-down with indicated siRNA duplex and induction of 
autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. b. Quantification of SCOC mRNA levels in 
GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard deviation derived from 
triplicate wells. c. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation 
in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). d. Quantification of 
LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for siSCOC-01, 
siSCOC-02 and siSCOC-03 are the averages of duplicates. The experiment was done twice with duplex -
01 and four times with duplexes -02 and -03; representative blots are shown. 
 
In order to further characterise the effects of SCOC knock-down with the three 
Dharmacon siRNA duplexes, I employed an alternate autophagy assay, p62 
degradation.  p62/SQSTM1 is an LC3- and ubiquitin-binding protein that is selectively 
degraded by autophagosomes (Pankiv et al., 2007) and p62 protein levels are used as a 
read-out for autophagy.  As expected, after starvation of GFP-LC3-HEK cells treated 
with RISCfree control siRNA, a marked reduction in p62 levels is seen (Figure 6.5).  
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Knock-down of ULK1 inhibits the autophagic degradation of p62 and the protein 
accumulates; similarly and as expected, knock-down with SCOC duplexes-02 and -03 
leads to an accumulation of p62 to similar levels as those seen after ULK1 knock-down.  
Surprisingly, knock-down with duplex-01 leads to a greater accumulation of p62 than 
that seen after ULK1 knock-down.  One possible explanation is that duplex-01 induces 
cell death, as the protein levels are lower after treatment with that duplex, possibly 
skewing the quantification of p62 normalised to actin.  Cell stress-induced autophagy 
could also explain the increase in LC3 lipidation in HeLa cells treated with duplex-01 
but does not explain the inhibition of GFP-LC3 spots seen (Figure 6.4). 
 
Figure 6.5 Knock-down of SCOC with Dharmacon siRNA duplexes against SCOC 
leads to an accumulation of p62 
a. Anti-p62 and -actin blot after indicated siRNA treatment in GFP-LC3-HEK cells and incubation in full 
medium (FM) or EBSS (ES) for 4 hours. siS represents siSCOC. b. Quantification of p62/actin after 
indicated siRNA and incubation conditions. The experiment was done twice; representative blots are 
shown. c. Corresponding quantification of SCOC mRNA levels in GFP-LC3-HEK cells as determined by 
qRTPCR. 
 
In order to assess the effect of different individual siRNA duplexes against 
SCOC, I ordered three duplexes from Ambion, siSCOC-41, -42, and -43.  I tested their 
effects on GFP-LC3 spots and endogenous LC3 lipidation as well as their ability to 
knock-down SCOC (Figure 6.6).  All three duplexes reduced GFP-LC3 spots in 
starvation conditions compared to an Ambion siRNA control pool, though duplex -43 
was least effective in doing so.  Duplex-43 was also least able to reduce SCOC mRNA 
levels and also least inhibitory to LC3 lipidation in HeLa cells suggesting that enough 
SCOC protein remains in these cells for autophagy to function almost normally.  
Duplex-43, like duplex-02, targets the N-terminal region of SCOC and does not target 
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isoforms Q9UIL1-1 and Q9UIL1-4 (Figure 4.2) reinforcing the theory that the main 
isoform in HEK cells is one of the shorter forms (Q9UIL1-4 or that corresponding to 
the est AAK01707) (Figure 4.3) and suggests that one or both of these isoforms is 
required for the function of SCOC as a positive regulator of autophagy. 
 
Figure 6.6 Ambion siRNA duplexes against SCOC decrease GFP-LC3 spots, 
SCOC mRNA levels and LC3 lipidation to various extents 
a. GFP-LC3 confocal images at 63x after knock-down with indicated siRNA duplex and induction of 
autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. b. Quantification of SCOC mRNA levels in 
GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard deviation derived from 
triplicate wells. c. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation 
in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). d. Quantification of 
LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for siSCOC-41, 
siSCOC-42 and siSCOC-43 are the averages of duplicates. The experiment was done twice; 
representative blots are shown. 
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Of the six individual SCOC siRNA duplexes that decrease GFP-LC3 spot 
parameters only three duplexes, -03,-41, and -42 reduce its mRNA levels and inhibit 
LC3 lipidation in HeLa cells.  I confirmed that Dharmacon duplex-02, which also leads 
to a reduction of LC3 lipidation, is unable to target SCOC by testing the ability of 
duplex-02 to reduce the levels of overexpressed SCOC protein.  However, the DNA 
sequence that is targeted by duplex-02 lies outside of the region expressed in the SCOC-
myc construct (Figure 6.2), so I cloned the open reading frame of SCOC isoform 
Q9UIL1-3 into the GFP-containing vector pEGFP N1, placing SCOC on the N-terminal 
of eGFP, creating the construct hereafter referred to as SCOC-GFP.  The SCOC 
sequence in the SCOC-GFP construct has an extended N-terminus compared to the 
SCOC-myc construct and siRNA duplex -02, if effective, should decrease SCOC-GFP 
expression levels.  After knock-down with siSCOC-02 followed by overexpression of 
SCOC-GFP, a large amount of SCOC-GFP fusion protein is seen suggesting that 
duplex-02 is not targeting SCOC, corroborating the qRTPCR data for duplex-02 (Figure 
6.7). 
Using the same technique I confirmed that all five remaining SCOC siRNA 
duplexes reduce the levels of overexpressed SCOC-GFP protein (Figure 6.7).  Duplex -
01 is better than duplex-03 at reducing SCOC-GFP, corresponding to the mRNA data 
generated by qRTPCR.  Duplex-43 was shown by qRTPCR to only reduce SCOC 
mRNA levels to 60% but in this overexpression system, it completely inhibits the 
overexpression of SCOC-GFP and does so to the same extent as duplex -41 and -42. 
 
 
Figure 6.7 SCOC siRNA duplexes target SCOC expression vectors to various 
extents 
Anti-Actin, -GFP, and -myc blots of HEK cells after knock-down with indicated SCOC siRNA duplexes 
and overexpression of indicated constructs. 
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SCOC 
siRNA 
Isoforms 
that it 
targets 
(Uniprot 
Q9UIL1 or 
AAK01707)  
Effect on 
SCOC 
mRNA in 
GFP-LC3-
HEK cells 
SCOC 
overexpres
sion 
constructs 
it knocks 
down 
Effect on 
GFP-LC3 
spots 
Effect on 
LC3 
lipidation in 
HeLa cells 
Effect on 
p62 
degradation 
Dharm. -
01 
-1, -2, -3, -4, 
AAK01707 
Knocks 
down to 5% 
SCOC-myc, 
SCOC-GFP 
Decreases Increases 
LC3II/I 
Strongly 
inhibits 
Dharm. -
02 
-2, -3 Does not 
knock down 
Does not 
knock down 
Decreases Decreases 
LC3II/I 
Inhibits 
Dharm. -
03 
-1, -2, -3, 
AAK01707 
Knocks 
down to 
20% 
SCOC-myc, 
SCOC-GFP  
Decreases Decreases 
LC3II/I 
Inhibits 
Dharm. -
04 
 Does not 
knock down 
Not tested No effect Not tested Not tested 
Ambion -
41 
-1, -2, -3, 
AAK01707 
Knocks 
down to 
25% 
SCOC-myc, 
SCOC-GFP 
Decreases Decreases 
LC3II/I 
Not tested 
Ambion -
42 
-1, -2, -3 Knocks 
down to 4% 
SCOC-GFP Decreases Decreases 
LC3II/I  
Not tested 
Ambion -
43 
-2, -3 Knocks 
down to 
61% 
SCOC-GFP Decreases 
somewhat 
No effect Not tested 
Table 6.1 Summary of SCOC siRNA duplexes 
Summary of seven SCOC siRNA duplexes. Shown are: the isoforms it is expected to target (see Figure 
4.2); effect of SCOC mRNA in GFP-LC3-HEK cells as measured by qRTPCR; effect on overexpressed 
SCOC constructs (see Figure 4.7); effect on GFP-LC3 spots; effect on LC3 lipidation in HeLa cells; 
effect in the p62 degradation assay in GFP-LC3-HEK cells (see Figure 6.5). 
 
Three of the six siSCOC duplexes target a region outside, or upstream, of the 
region expressed by the SCOC-myc construct.  These duplexes are duplex-02, as 
mentioned before, and Ambion duplexes -42 and -43 and when SCOC-myc is 
overexpressed after knock-down with these duplexes, the SCOC-myc fusion protein is 
detected in these lysates (Figure 6.7).  Of note, the SCOC-myc fusion protein migrates 
by SDS-PAGE in both HEK and HeLa cells as a protein of approximately 14 kDa, 
which is larger than the expected 9 kDa size reported by Van Valkenburgh et al.  
Duplexes -01, -03, and -41 target a region downstream of the SCOC-myc start site and 
are all effective at decreasing SCOC-myc and SCOC-GFP overexpression (Figure 6.7).  
I utilised duplex-42 whose binding sequence lies upstream of the SCOC-myc start 
codon and duplexes -03 and -41 whose binding sequences lie downstream of the SCOC-
myc start codon to perform a rescue experiment.  Knock-down of SCOC with 
downstream duplexes -03 and -41 targets SCOC-myc, inhibits SCOC-myc expression 
and decreases LC3 lipidation after both pcDNA 3.1 empty vector and SCOC-myc 
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overexpression (Figure 6.8).  Knock-down of SCOC with upstream duplex-42 however 
allows for the overexpression of SCOC-myc (Figure 6.6, Figure 6.7 panel c).  After 
siSCOC-42 knockdown, LC3 lipidation is inhibited in starvation conditions but this is 
rescued by the presence of SCOC protein after expression of SCOC-myc.  
Overexpression of SCOC-myc after RISCfree control siRNA knock-down increased 
LC3 lipidation beyond the control and this response is repressed by ULK1 knock-down, 
suggesting that overexpression of SCOC increases autophagy. 
 
Figure 6.8 Inhibition of LC3 lipidation after SCOC knock-down is rescued by 
SCOC overexpression 
a. Anti-Actin and -LC3 blots after indicated siRNA treatment and overexpression construct in HeLa cells 
and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). pcD is 
pcDNA3.1(-). b. Quantification of LC3II/LC3I after indicated siRNA, overexpression and incubation 
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conditions. LC3II/LC3I values for siSCOC-42, siSCOC-03,-41, RISCfree+SCOC-myc, and 
siULK1+SCOC-myc are the averages of duplicates. The experiment was done three times; representative 
blots are shown. c. PonseauS staining and anti-myc blot of HeLa lysates after corresponding siRNA 
treatments and construct expression. S-myc is SCOC-myc. 
 
In HeLa cells, overexpressed SCOC-myc migrates as a distinct doublet of 
approximately 14 kDa (Figure 6.8, panel c); the doublet may result from two 
transcriptional start sites from two methionines at the N-terminal of the SCOC-myc 
construct (Figure 6.2).  Its protein levels do not seem to be altered during starvation 
conditions but knock-down of ULK1 consistently led to a drastic reduction of SCOC-
myc levels. 
6.2.3 Overexpression of SCOC drives autophagy 
I observed in HeLa cells that knock-down of SCOC inhibited LC3 lipidation and 
overexpression of SCOC-myc increased LC3 lipidation and I replicated the experiment 
in HEK cells.  As in HeLa cells, when SCOC is reduced by knock-down with 
Dharmacon siRNA duplex-03, endogenous LC3 lipidation is inhibited (Figure 6.9, 
panel a,b,c).  Overexpression of SCOC-myc increased LC3 lipidation when compared 
to overexpression of empty vector (Figure 6.9, panel d,e,f).  In HEK cells, SCOC-myc 
also appears as a doublet though the bands are less distinct than in HeLa cells.  Also, 
overexpression of SCOC-GFP increases LC3 lipidation compared to overexpression of 
GFP alone (Figure 6.9, panel g,h).  Taken together, these results suggest that SCOC is a 
positive regulator of autophagy in GFP-LC3-HEK cells, HeLa cells and HEK cells. 
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Figure 6.9 SCOC knock-down inhibits autophagy and overexpression augments 
autophagy in HEK cells 
a. Anti-Actin and -LC3 blots after indicated siRNA treatment in HEK cells and incubation in full medium 
(FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). b. Quantification of LC3II/LC3I after 
indicated siRNA and incubation conditions. LC3II/LC3I values for siSCOC-03 are the averages of 
duplicates. The experiment was done twice; representative blots are shown. c. Anti-GFP and -myc blots 
of HEK cells after treatment with RISCfree or SCOC siRNA and overexpression of GFP or SCOC-myc. 
d. Anti-Actin and -LC3 blots after indicated construct overexpression and incubation conditions in HEK 
cells. e. Quantification of LC3II/LC3I after indicated construct overexpression and incubation conditions. 
LC3II/LC3I values for siSCOC-myc are the averages of duplicates. The experiment was done three times; 
representative blots are shown. f. Anti-myc blot of HEK cells after treatment with control vector or 
SCOC-myc. g. Anti-GFP, -Actin and -LC3 blots after indicated construct overexpression and incubation 
conditions in HEK cells. h. Quantification of LC3II/LC3I after indicated construct overexpression and 
incubation conditions. LC3II/LC3I values for SCOC-GFP are the averages of duplicates. The experiment 
was done twice; representative blots are shown. 
 
6.2.4 Characterisation of SCOC by immunofluorescence 
Endogenous SCOC has been previously described in NRK cells using an affinity 
purified rabbit antibody raised against human SCOC (Van Valkenburgh et al., 2001); 
these authors observed a punctate cytoplasmic staining plus a perinuclear staining 
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pattern similar to that of Golgi markers, and some plasma membrane staining.  Using 
the same antibody, I observe very similar staining patterns in HEK cells with the 
presence of juxta nuclear patches of SCOC and a punctate cytoplasmic population, 
though I do not see SCOC at the plasma membrane (Figure 6.10, panel a).  SCOC is not 
reported to reside in the nucleus but its small size would allow it to diffuse into the 
nucleus and I sometimes note SCOC labelling in the nucleus.  After co-labelling with 
SCOC and the Golgi markers GM130 and TGN46, I observe extensive overlap in 
clusters around the nucleus.  Unlike Atg9, which has been shown to disperse from a 
juxta-nuclear Golgi pool to an endosomal cytoplasmic pool upon starvation (Young et 
al., 2006), SCOC labelling appears similar in full medium and EBSS (Figure 6.10, panel 
a).  After siRNA-mediated knock-down of SCOC, less signal is seen and the vast 
majority of the pool that remains colocalises with the trans-Golgi network protein 
TGN46 (Figure 6.10, panel b). 
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Figure 6.10 SCOC colocalises with Golgi markers and its signal is depleted by 
siRNA knock-down 
a. HEK cells show SCOC and GM130 co-labelling or SCOC and TGN46 co-labelling after indicated 
incubation conditions for two hours, fixation and immunostaining with anti-SCOC and anti-GM130 or 
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anti-TGN46 antibodies. b. HEK cells show SCOC and TGN46 co-labelling after indicated siRNA 
treatment (siSCOC is siSCOC duplex-03) and incubation in EBSS for two hours, fixation and 
immunostaining with anti-SCOC and anti-TGN46 antibodies. 
 
I next asked whether SCOC colocalises with known autophagy markers, the 
most obvious of which being the Golgi-resident protein Atg9.  SCOC and endogenous 
Atg9 show extensive overlap in the juxta-nuclear Golgi region in both full medium and 
EBSS and while Atg9 disperses after starvation, SCOC does not (Figure 6.11, panel 
a,b).  There is also occasional colocalisation on cytoplasmic vesicular structures in 
EBSS.  More colocalisation on these cytoplasmic vesicular structures is seen between 
SCOC and Atg12 whose staining is wholly punctate and presumably marks the sites of 
autophagosomal assembly (Figure 6.11, panel c).  SCOC also colocalises with GFP-
LC3 spots and endogenous LC3 structures that appear to emerge from the juxta-nuclear 
region (Figure 6.11, panel d,e).  SCOC also displays overlap with GFP-DFCP1, a 
protein that has been shown to localise to the Golgi in full medium (Axe et al., 2008) 
(Figure 6.11, panel f).  In EBSS, a large amount of overlap is seen in a juxta-nuclear 
region and SCOC is occasional seen to decorate GFP-DFCP1-positive punctate 
structures.  Of note, SCOC does not colocalise with LAMP2, a marker of lysosomes 
(data not shown).  Taken together, these results suggest that SCOC is a bone fide 
autophagy protein that appears to be acting at the site of autophagosome formation.  As 
the majority of the structure of SCOC is comprised of a coiled-coil protein-binding 
domain, it is possible that SCOC acts at this site as a scaffold, recruiting and binding 
critical autophagic machinery proteins such as Atg12. 
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Figure 6.11 Endogenous SCOC colocalises with known autophagy proteins 
a. SCOC and mAtg9 in HEK cells after incubation for two hours in full medium. b. SCOC and mAtg9 in 
HEK cells after incubation for two hours in EBSS (arrowheads show co-localisation). c. SCOC and 
Atg12 in HEK cells after incubation for two hours in EBSS (arrowheads show co-localisation). d. SCOC 
and LC3 staining as indicated in HEK cells after incubation for two hours in EBSS. a.-d. Scale bars equal 
5µm. e. SCOC staining in GFP-LC3-HEK cells after incubation for two hours in EBSS (arrowheads show 
co-localisation). Scale bar equals 10µm. f. SCOC staining in GFP-DFCP1 cells (arrowhead shows co-
localisation). Scale bar equals 10µm. b,f. Enlarged inset shown in merge panels. 
 
I next asked what cellular distribution was displayed by overexpressed SCOC 
and whether overexpressed SCOC colocalise with other autophagy markers for which 
we have only rabbit polyclonal antibodies and therefore cannot be used with the anti-
SCOC polyclonal antibody.  SCOC-myc and SCOC-GFP do not appear as endogenous 
SCOC in HEK cells (Figure 6.12).  There are very few small cytoplasmic punctate 
structures and instead, more diffuse cytoplasmic staining.  There are larger, rounded 
SCOC-myc structures and even larger patches of both overexpressed SCOC-myc and 
SCOC-GFP that are usually found somewhat close to the nucleus.  It should be said 
however that these staining patterns could be artefacts of the overexpression of the 
SCOC constructs.  Nonetheless, these areas of more-intense SCOC-myc staining are 
seen to colocalise with endogenous ULK1 and endogenous Atg16.  Interestingly, when 
examining endogenous Atg16 in SCOC-GFP-overexpressing cells, Atg16-positive 
puncta are seen to congregate close to juxta-nuclear concentrations of SCOC-GFP.  The 
Atg16 structures here are reminiscent of the endogenous LC3 and GFP-DFCP1 
structures seen above that also appear to emerge from a Golgi-like pool of SCOC.  I 
have shown that overexpression of both SCOC-myc and SCOC-GFP increases 
autophagy as measured by LC3 lipidation and it would be interesting to test whether 
overexpression of SCOC increases Atg12 or Atg16 puncta.  Again, these 
immunofluorescence experiments place SCOC in the cell with early autophagy proteins. 
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Figure 6.12 Overexpressed SCOC displays different staining than endogenous but 
also colocalises with autophagy markers 
a. HEK cells are transfected with SCOC-myc, incubated for 2 hours in EBSS and fixed. Endogenous 
ULK1 staining (boxes show co-localisation). b. HEK cells are transfected with SCOC-myc, incubated for 
2 hours in EBSS and fixed. Endogenous Atg16 staining (with polyclonal antibody) (arrowheads show co-
localisation). c. HEK cells are transfected with GFP-SCOC, incubated for 2 hours in EBSS and fixed. 
Endogenous Atg16 staining (with monoclonal antibody). Enlarged inset shown in merge panels. 
 
6.3 Regulation of SCOC by ULK1 and the effect of SCOC-
interacting proteins on autophagy 
6.3.1 Regulation of SCOC by ULK1 
I have shown above that knock-down of ULK1 leads to a decrease in the amount 
of overexpressed SCOC protein in HeLa cells (Figure 6.8).  I repeated this experiment 
and in addition, also overexpressed ULK1 and ULK1 kinase-dead mutant ULK1KI 
together with SCOC-myc.  As before, a significant reduction of the SCOC-myc doublet 
is seen after siRNA depletion of ULK1 (Figure 6.13, panel a).  This reduction, however, 
cannot be rescued by the overexpression of ULK1 as a marked loss of SCOC-myc is 
also seen after co-overexpression with both ULK1 wild-type and ULK1 kinase-dead 
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proteins.  The ULK1KI mutant however does not appear to repress the SCOC 
expression as much as the wild-type in this experiment (performed only once), 
suggesting that the kinase activity of ULK1 is partially required for the reduction of 
SCOC (Figure 6.13, panel b).  Co-overexpression of SCOC-myc with wild-type ULK1 
does slightly increases the lipidation of endogenous LC3 but overexpression of the 
kinase-dead ULK1 inhibited LC3 lipidation as expected (Chan et al., 2009) (Figure 
6.13, panel c). 
 
Figure 6.13 SCOC protein levels are regulated by ULK1 
a. Anti-ULK1, -Actin, and -myc blots after indicated siRNA treatment, transfection with indicated DNA 
constructs, and incubation in full medium (FM), EBSS (ES), and EBSS plus 0.25mg/mL leupeptin (ES) 
in HeLa cells. b. Anti-ULK1, -Actin, -myc, and -LC3 blots after transfection with indicated DNA 
constructs and incubation in full medium (FM), EBSS (ES), and EBSS plus 0.25mg/mL leupeptin (ES) in 
HEK cells. c. Quantification of LC3II/LC3I after indicated construct overexpression and incubation 
conditions. LC3II/LC3I values for all bars are the averages of duplicates.  
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6.3.2 SCOC and FEZ1 interact and FEZ1 regulates autophagy 
The C. elegans homologues of FEZ1 and SCOC have been shown to physically 
interact and co-ordinately control axonal development (Su et al., 2006) and this has also 
been shown for the C. elegans homologues of FEZ1 and ULK1 (Toda et al., 2008).  
Though mammalian ULK1 and FEZ1 have not been reported to interact, SCOC and 
FEZ1 have been shown to interact by yeast-two-hybrid in human cells (Assmann et al., 
2006).  I tested the SCOC-FEZ1 interaction in HEK cells and could demonstrate co-
immunoprecipitation of SCOC-myc with GFP-FEZ1 (Figure 6.14, panel a).  A large 
amount of SCOC-myc is pulled down by beads loaded with GFP antibody and an 
almost complete reduction of SCOC-myc is seen after the IP.  There is a marked 
depletion of GFP-FEZ1 in the unbound lysate after IP and a band of approximately the 
right size, though slightly bigger, for endogenous FEZ1 that is also pulled down after 
co-IP.  There is an unspecific band in the lysate lanes that is not decreased after co-IP 
and also not depleted after FEZ1 siRNA knock-down (Figure 2.2).  Of interest, the 
amount of SCOC-myc pulled down by the GFP IP is not changed in HEK cells after 
incubation in EBSS starvation medium for two hours.  By immunofluorescence 
examination, overexpressed GFP-FEZ1 appears cytoplasmic with some accumulation 
around the nucleus with some punctate and ring-like structures that partially colocalise 
with endogenous SCOC (Figure 1.14, panel b).  From these experiments, I can confirm 
that SCOC and FEZ1 are binding partners in human cells. 
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Figure 6.14 Overexpressed SCOC and FEZ1 co-immunoprecipitate and GFP-
FEZ1 and SCOC colocalise to structures 
a. Anti-SCOC and -FEZ1 blot after co-expression in HEK cells, incubation in full medium or EBSS for 
two hours, and co-immunoprecipitation of SCOC-myc and FEZ1-GFP with anti-GFP antibody. Input 
lysate (Inp), unbound supernatant (Unb). Asterix indicates non-specific band, arrow denotes co-
precipitating band of similar size to endogenous FEZ1. b. HEK cells are transfected with GFP-FEZ1, 
incubated for two hours in EBSS and fixed. Endogenous SCOC staining as indicated (arrowheads show 
co-localisation). Enlarged inset shown in merge panels. 
 
During the primary screen, GFP-LC3-HEK cells treated with an siRNA 
Smartpool against FEZ1 exhibited increased SCPO, STIPO and STAPO.  FEZ1 ranked 
2790th as an increaser, placing it in the 13th percentile of all hits.  In order to further 
characterise the effect of FEZ1 knock-down on autophagy, I treated HEK cells with a 
specialised pool of FEZ1 siRNA duplexes previously deconvoluted to confirm that the 
individual duplexes reduced FEZ1 mRNA levels (Figure 6.15).  After incubation in 
starvation medium and starvation medium with leupeptin, LC3 lipidation was increased 
compared to RISCfree control in cells treated with FEZ1 siRNA, comparable to the 
increase seen with the positive control NRBP2.  FEZ1 appears to play a role in 
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autophagy, acting as a negative regulator of GFP-LC3 spot formation and LC3 
lipidation. 
 
Figure 6.15 FEZ1 is a negative regulator of autophagy 
a. Anti-Actin and -LC3 blot after indicated siRNA treatment in HEK cells and incubation in full medium 
(FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). b. Quantification of LC3II/LC3I after 
indicated siRNA and incubation conditions. LC3II/LC3I values for siFEZ1 are the averages of duplicates. 
The experiment was done three times; representative blots are shown. c. Quantification of FEZ1 mRNA 
levels in HEK cells as determined by qRTPCR. Error bars represent the standard deviation derived from 
triplicate wells. 
 
Besides SCOC, three other hits from the starvation-induced autophagy screen in 
GFP-LC3-HEK cells are reported as binding FEZ1 by yeast-two-hybrid: TLK2, 
TBC1D25 and TOMM20 (Assmann et al., 2006), (Stelzl et al., 2005).  TLK2 has been 
discussed above and its knock-down was confirmed to increase autophagy by 
deconvolution and validation by an alternate autophagy assay, LC3 lipidation in HeLa 
cells.  The binding of TLK2 to FEZ1 was shown to require the coiled-coil region of 
FEZ1, also a requirement of FEZ1 binding to another increaser hit from the screen, 
TBC1D25, or OATL1.  Treatment with an siRNA Smartpool against TBC1D25 
increased GFP-LC3 spot parameters in the primary and repeat screen but only one of 
the individual siRNA duplexes repeated this phenotype and thus was not validated by 
deconvolution (Appendix Table 8.5).  TBC1D25 contains a TBC domain and thus could 
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act as a Rab GTPase activating protein though its Rab GTPase partner and function is 
unknown.  A large-scale yeast-two hybrid screen showed that the translocase 
TOMM20, thought to be a member of the complex that controls cytoplasmic precursor 
proteins’ import across the mitochondrial outer membrane, also binds FEZ1 (Stelzl et 
al., 2005).  After knock-down of TOMM20, GFP-LC3 spot parameters were decreased 
and one of the individual siRNA duplexes led to a very large decrease of GFP-LC3 
spots in the deconvolution screen while a second siRNA duplex narrowly missed the 
cut-off for decreasing SCPO and STAPO (Appendix Table 8.5). 
6.3.3 SCOC and TLK2 interact 
TLK2 was shown above to be a validated negative regulator of autophagy and 
has been shown to bind the SCOC-binding partner FEZ1 (Assmann et al., 2006) so I 
asked whether TLK2 and SCOC could interact in HEK cells.  After co-transfection with 
HA-tagged TLK2 and SCOC-myc, HEK cells were incubated with beads and anti-HA 
antibody, and then probed for SCOC after immunoprecipitation.  SCOC-myc was 
detected in the IP-specific lane suggesting that the two proteins do indeed interact 
(Figure 6.16, panel a).  Of interest, overexpression of TLK2 appeared to increase the 
amount of SCOC-myc in HEK cells as demonstrated by the presence of more SCOC-
myc in the input and unbound supernatant lanes compared to those after overexpression 
of GFP-FEZ1.  I examined the cellular distribution of HA-TLK2 in HEK cells and 
found it on cytoplasmic punctate structures, a small number of which were also stained 
with endogenous SCOC (Figure 6.16, panel b).  Mirroring the effect of TLK2 
overexpression on SCOC protein levels by western blot, it appears by 
immunofluorescence that there is more endogenous SCOC in HEK cells overexpressing 
TLK2, especially in the peripheral non-Golgi pool, though this has not been quantified. 
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Figure 6.16 Overexpressed TLK2 and SCOC co-IP and partially colocalise 
a. Anti-SCOC and -HA blot after indicated co-expression in HEK cells, incubation in full medium or 
EBSS for two hours, and co-immunoprecipitation of SCOC-myc and HA-TLK2 with anti-HA antibody 
and co-immunoprecipitation of SCOC-myc and GFP-FEZ1 with anti-GFP antibody. Input lysate (Inp), 
unbound supernatant (Unb). b. HEK cells are transfected with HA-TLK2, incubated for two hours in 
EBSS and fixed. Endogenous SCOC staining as indicated (arrowheads show co-localisation) 
 
6.3.4 ARL1 regulates autophagy 
Like FEZ1, the reported SCOC-binding protein ARL1 increased GFP-LC3 spots 
in the primary screen.  As an increaser, it was ranked 2923rd also placing it in the 13th 
percentile of all genes tested in the primary screen.  In order to confirm this finding I 
knocked down ARL1 with a customised pool of siRNA duplexes derived from the 
Smartpool used in the primary screen that I had determined decreased ARL1 mRNA 
levels.  An increase of LC3 lipidation was seen in full medium and starvation conditions 
after ARL1 knock-down compared to the negative control.  Thus, ARL1 acts as a 
negative regulator of autophagy. 
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Figure 6.17 ARL1 is a negative regulator of autophagy 
a. Anti-Actin and -LC3 blot after indicated siRNA treatment in HEK cells and incubation in full medium 
(FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). (Note: this is the same blot but has been cut). 
b. Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
siARL1 are the averages of duplicates. The experiment was done three times; representative blots are 
shown. c. Quantification of ARL1 mRNA levels in HEK cells as determined by qRTPCR. Error bars 
represent the standard deviation derived from triplicate wells. 
 
6.4 Discussion of SCOC 
SCOC is a bone fide positive regulator of autophagy.  Knock-down of the gene 
with a targeting siRNA decreases GFP-LC3 spot formation, p62 degradation and LC3 
lipidation and overexpression of SCOC increases LC3 lipidation.  SCOC also 
colocalises with multiple autophagy markers including Atg12.  SCOC is found in a 
juxta-nuclear pool that is positive for Golgi markers and is also seen on peripheral 
punctate structures.  These pools do not seem to change upon starvation like the Golgi-
resident transmembrane autophagy protein Atg9, which disperses.  The cytoplasmic 
SCOC structures can be Atg9-, Atg12- or GFP-LC3-positive.  In addition, endogenous 
LC3 and GFP-DFCP1 structures were seen possibly budding off of SCOC-positive 
juxta-nuclear regions.  SCOC does not colocalise with LAMP2; taken together, these 
results suggest that SCOC acts during autophagosome formation possibly by binding 
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autophagy proteins via its coiled-coil domain, thus serving as a platform or scaffold for 
autophagosome assembly. 
As mentioned, SCOC does not seem to alter its cellular localisation during 
starvation and similarly, we have previously illustrated that ULK1 appears to be 
constitutively associated with membrane fractions (Chan et al., 2009).  I have shown 
that overexpressed SCOC colocalises with endogenous ULK1 on cytoplasmic structures 
(Figure 6.12) and have attempted to co-immunoprecipitate the two proteins.  
Overexpressing the short SCOC-myc construct together with HA-tagged ULK1 and IP-
ing with anti-HA antibody, I can occasionally see a very faint band of SCOC-myc 
pulled down and a depletion of HA-ULK1 and SCOC-myc after co-
immunoprecipitation.  I have also seen overexpressed HA-ULK1 pulled down with anti-
SCOC antibody.  In general, SCOC and ULK1 do not readily co-IP and their interaction 
may be transient.  I would however like to test whether a longer form of SCOC such as 
the SCOC-GFP fusion protein could co-immunoprecipitate ULK1; perhaps the N-
terminal of SCOC is required for SCOC binding to ULK1.  It would also be of 
interested to ask whether SCOC interacts with Atg13 or FIP200.  Nonetheless, I have 
shown that overexpressed SCOC protein levels are regulated by ULK1 (Figure 6.13) 
and perhaps SCOC receives signals from the ULK1 kinase complex upon initiation of 
autophagy and assembles the autophagy machinery downstream of that signal. 
I show above that overexpressed SCOC and FEZ1 physically interact (Figure 
6.14) and it has been reported that the C. elegans homologues of these proteins also 
interact and together, they control axonal trafficking (Su et al., 2006).  The C. elegans 
homologues of FEZ1 and ULK1 have also been reported to bind and it would be of 
interest to know if mammalian FEZ1 and ULK1 are binding partners.  Perhaps SCOC, 
FEZ1 and ULK1 form some sort of autophagy regulatory complex, for I have shown 
that FEZ1 is a negative regulator of autophagy.  One way that FEZ1 might negatively 
regulate autophagy is by physically keeping SCOC, a positive regulator, away from its 
potential function as a scaffold for autophagosome formation.  Conversely, I have seen 
that overexpression of FEZ1 inhibits LC3 lipidation (data not shown) reiterating that 
FEZ1 is a negative regulator of autophagy and I would like to ask whether FEZ1, like 
SCOC, colocalises with autophagy markers such as LC3 or DFCP-1.  Although the 
binding of SCOC and FEZ1 did not appear to change in cells that had been incubated in 
EBSS for two hours, one theory could be that FEZ1 binding to SCOC may alter slightly 
Chapter 6. SCOC 
 209 
during starvation so that ULK1 may phosphorylate SCOC.  It would be interesting to 
know if SCOC or FEZ1 are kinase substrates of ULK1.   
Another potential regulator of SCOC is the kinase TLK2.  I have shown that 
TLK2 is a potential negative regulator of autophagy as its knock-down increases 
autophagy (Figure 5.15) and I have also shown that overexpressed SCOC and TLK2 co-
immunoprecipitate and partially colocalise on cytoplasmic puncta (Figure 6.16).  
Interestingly, overexpression of TLK2 seemed increase SCOC-myc expression levels 
and though the experiment has only been performed once, overexpression of a myc-
tagged TLK2 construct seemed to increase LC3 lipidation possibly by stabilising SCOC 
and I have shown that increasing SCOC protein levels increases autophagy.  TLK2 
could also regulate SCOC and/or autophagy itself through its interaction with FEZ1, 
which has been shown by yeast-two-hybrid (Assmann et al., 2006).  Perhaps TLK2, 
FEZ1 and SCOC form a complex together and it would be important to test whether 
knock-down of TLK2 disrupts SCOC-FEZ1 binding and vice versa.  Last, TLK2 could 
potentially regulate SCOC on a transcriptional level.  I have discussed that knock-down 
of TLK2 may increase the mRNA levels of autophagy proteins, potentially explaining 
how it is a negative regulator of autophagy.  I would like to see if knock-down of TLK2 
increases SCOC mRNA levels. 
Taken together, the experiments discussed above, though preliminary, point to 
SCOC as a scaffold for autophagosome formation.  Through its coiled-coil domain, 
SCOC has the potential to bind many proteins.  Beclin 1 and Atg16 both possess coiled-
coil domains as well and SCOC may recruit the PI(3)-kinase complex and members of 
the critical conjugation reactions.  SCOC interacts with a coiled-coil protein that has not 
until now been implicated in autophagy, FEZ1.  FEZ1 itself has many interactors, three 
of which, TLK2, TBC1D25 and TOMM20 were found to be regulators of starvation-
induced autophagy in my screen.  Perhaps SCOC sits between an initiation signal from 
the ULK1 kinase complex or other signalling molecules and the proteins of the 
autophagic machinery.  In this way, SCOC could mark a pre-isolation membrane 
structure that acts as a hub between initiation and autophagosome formation in 
mammalian cells. 
Another possible way that SCOC could influence autophagy is through its 
interacting partner ARL1.  This GTPase has important functions in Golgi for regulating 
the membrane trafficking of endosomes (Burd et al., 2004), (Nishimoto-Morita et al., 
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2009).  I have shown that ARL1 is a potential negative regulator of autophagy in that 
knockdown of ARL1 increased LC3 lipidation.  As ARL1 and SCOC have been shown 
to directly bind (Van Valkenburgh et al., 2001), it is possible that ARL1 holds SCOC on 
the Golgi when autophagy is inactivated and releases SCOC when autophagy is 
induced.  It would be important to test whether the binding of SCOC to ARL1 is 
modulated by amino acid levels in the cell and if so, what signals mediate the response. 
Of interest, alterations of SCOC have been linked to disease.  SCOC is 
significantly down-regulated in Huntington’s disease (Hodges et al., 2006) suggesting 
that SCOC is required for the autophagic clearance of aggregated proteins.  An SNP 
mutation (C to T) in SCOC has also been associated to hypertension in humans 
(Wellcome Trust Case Control Consortium, 2007).  These links to disease highlight the 
importance of SCOC in mammalian cells and it will be important in the future to dissect 
its role as a positive regulator of autophagy. 
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Chapter 7. WAC 
 
7.1 Introduction to WAC 
WAC, WW domain containing adaptor with coiled-coil, was a strong candidate to 
investigate further because both siRNA duplexes were consistently successful in 
decreasing GFP-LC3 spots and WAC mRNA levels as well as in inhibiting endogenous 
LC3 lipidation.  The presence of a WW and a coiled-coil domain suggests that it has the 
potential, like SCOC, for autophagy binding partners.  Two already known and 
interesting binding partners, ubiquilin 4 and huntingtin potentially link WAC to the 
ubiquitin-proteasome system (UPS) and aggrephagy respectively.  Last, WAC has been 
implicated in two diseases that affect a large percentage of the human population, 
Huntington’s disease and diabetes. 
7.1.1 WAC is described as a splicing factor interactor 
WAC is largely uncharacterised and to this date, only one publication describes 
it (Xu and Arnaout, 2002).  It was discovered as a protein that interacted by yeast-two-
hybrid with polycystin 1, or PKD1, a membrane protein that is mutated in Polycystic 
kidney disease.  A WW domain is defined by two tryptophans and an asparagine 
residue separated by 20-23 amino acids and characteristically binds proline-rich regions 
that often contain phosphoserine and phosphotyrosine; proteins that contain WWs have 
a wide variety of functions.  Using computational sequence analysis Xu et al establish 
Drosophila WAC as a Rosetta stone protein that is the result of fusion of two proteins 
or domains.  They found that the N-terminal of WAC is similar to the pre-mRNA 
splicing factor SNRP70 and therefore suggest WAC is involved in mRNA processing.  
They went on to show that, like the pre-mRNA splicing complex marker SC35, over-
expressed WAC appears in punctate speckles within subdomain boundaries in the 
nucleus.  WAC was also found to interact with keratin 15 by yeast-two-hybrid (Rual et 
al., 2005). 
7.1.2  WAC interacts with UBQLN4 
Ubiquilin 4, also known as ataxin-1 ubiquitin-like interacting protein, was used 
as a bait in a large-scale yeast-two-hybrid screen searching for interactors of proteins 
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associated with proteins known to cause ataxias, such as ataxin 1 (Lim et al., 2006).  
This study identified WAC as an ubiquilin 4 or UBQLN4 interactor.  UBQLN4 contains 
a UBQ or ubiquitin homologue domain and a UBA or ubiquitin association domain.  
Through these shared domains one of which binds proteasomal compartments and the 
other of which binds polyubiquitin, ubiquilins regulate protein degradation via the UPS 
most likely by targeting ubiquitinated proteins to the proteasome.  Ubiquilins were first 
linked to autophagy when it was shown that UBQLN1 is a negative regulator of 
starvation-induced cell death in that its overexpression suppresses and knock-down 
enhances this process (Wang et al., 2006).  More recently ubiquilin 1, also known as 
PLIC-1, has been shown to colocalise with LC3 and positively regulate autophagosome 
degradation (N'Diaye et al., 2009).  Following on, Rothenberg et al found that ubiquilin 
1 is enriched in purified autophagosomes and co-immunoprecipitates with LC3 
(Rothenberg et al., 2010).  They show that ubiquilin 1 regulates autophagy in a slightly 
unusual way in that knock-down of UBQLN1 increases LC3I and decreases LC3II but 
also reduces autophagosome number, suggesting it is required for the maturation of 
LC3I to LC3II.   Ubiquilin 1, like p62, is taken up and degraded by autophagy but it is 
also an active substrate of CMA.  As it regulates autophagy but is also a substrate of 
CMA, the authors speculate that ubiquilin 1 may act as a switch between CMA and its 
levels may control which degradative pathway a protein follows (Rothenberg and 
Monteiro, 2010). 
Ataxin-1 ubiquitin-like interacting protein (A1Up) localises to the cytoplasm 
and nucleus and was discovered to interact with both wild-type and mutant ataxin-1 
(Davidson et al., 2000).  A mutation in ataxin-1 causes an expanded trinucleotide repeat 
in the protein, which is linked to spinocerebellar ataxia 1, and it was recently shown that 
the mutation leads to a gain-of-function and also a partial loss-of-function that both 
contribute to the disease (Zoghbi and Orr, 2009).  The function of wild-type ataxin-1 is 
not known.  In their recent publication describing the nucleo-cytoplasmic shuttling of 
p62, Pankiv et al show that p62 can facilitate the recruitment of proteosomes to 
polyglutamine-expanded ataxin-1 and is specifically recruited to nuclear aggregates of 
expanded ataxin-1 (Pankiv et al., 2010).  Though autophagy has not been shown to 
degrade mutant ataxin-1 aggregates, p62 is a regulator of both the autophagy and 
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proteasome pathways.  It is therefore a possibility that ataxin-1 may be connected to 
autophagy through both ubiquilins and p62. 
7.1.3 The role of WAC in disease 
As discussed above, Huntington’s disease (HD) is a genetic disease in which 
defects in autophagy have been implicated.  Interestingly, WAC was found to be 
upregulated in the symptomatic stages of HD as determined with mRNA from human 
blood samples collected from HD patients that were analysed by microarray (Borovecki 
et al., 2005).  WAC was also found to be slightly upregulated in three brain regions of 
HD patients compared with control individuals, as also assessed by microarray (Hodges 
et al., 2006).  In addition, WAC was identified as binding to huntingtin protein in a 
high-throughput yeast-two-hybrid screen (Kaltenbach et al., 2007).  WAC was a strong 
hit in this screen in that 95 out of 97 htt-fragment baits bound to WAC expressed in 
human brain or mouse brain or muscle tissue, though the interaction was not confirmed. 
WAC is also associated with diabetes; a SNP in the human WAC sequence was 
one of 78 found to be associated with was Non-insulin-dependent diabetes mellitus, 
otherwise known as type 2 diabetes (Florez et al., 2007).  This A to T change had a p-
value of 0.00164. 
7.2 Characterisation of WAC’s role in autophagy 
WAC is highly conserved through vertebrates to the Danio rerio or zebrafish and 
the human protein sequence is 94% similar to the mouse (Xu and Arnaout, 2002).  
There are two invertebrate homologues known, one in Brugia malayi (nematode) and 
one in Ciona intestinalis, an urochordata or sea squirt.  
There are multiple isoforms of WAC that are predicted to exist either as the result 
of alternative splicing (isoform Q9BTA9.2) or polymorphism (Q9BTA9.3 and 
Q9BTA9.4, Q9BTA9.5) or both (Q9BTA9.3) (Figure 7.1).  The canonical sequence 
represented by isoform 1, NM_016628, is 647 amino acids long with a predicted 
molecular weight of 71 kDa.  It contains an N-terminal WW domain and less-well 
conserved C-terminal coiled-coil domain. 
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Figure 7.1 WAC isoforms and siRNA- and peptide antibody-targeting regions 
Schematic depicting different isoforms of WAC. The amino acid sequence and predicted molecular 
weights of the protein is shown. The magenta box is the WW domain; the yellow box is the coiled-coil 
domain. The orange polka-dotted boxes and contained grey box show areas of alternate sequences. Green 
boxes show Dharmacon siGenome duplex targeting areas; blue boxes show Ambion siRNA targeting 
areas (note: the region targeted by duplex-54 is upstream of the start of isoforms 2 and 3). Duplexes -01, -
02, -04 and -55 target the sequence of isoform 1, 2, and 5 not 3 and 4. Rainbow box shows the region that 
is suggested to contain the Qiagen QuantiTect WAC primer. The purple boxes show the peptide against 
which the various polyclonal antibodies were raised. For a larger version of this diagram, see Appendix 
Figure 9.2) 
 
During the deconvolution screen, three of the four siRNA duplexes against 
WAC decreased SCPO below 80% of RISCfree control (Figure 7.2, panel a).  This 
response in GFP-LC3-HEK cells corresponds to the degree of knock-down as measured 
by WAC mRNA levels in that duplex-01 is least efficient as reducing WAC mRNA and 
also least efficient as decreasing GFP-LC3 spot number (Figure 7.2, panel b).  In the 
second, more directed deconvolution screen all four siRNA duplexes against WAC 
caused a significant decrease in SCPO.  After the deconvolution screen, WAC was a 
three-out-of-four to four-out-of-four validated-by-deconvolution hit and I confirmed 
that the reduction of WAC mRNA levels corresponded to these effects. 
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Figure 7.2 All four Dharmacon duplexes against WAC decrease WAC mRNA 
levels and decrease GFP-LC3 spot count 
a. SCPO after knock-down of WAC with four individual siRNA duplexes during the primary 
deconvolution screen and secondary deconvolution screen of GFP-LC3-HEK in starvation conditions.  
The blue line marks the 80% of control cut-off for decreasers of GFP-LC3 spots; the red line marks the 
120% of control, the cut-off for increasers of spots. RF is RISCfree control, siW is siWAC. b. 
Quantification of WAC relative mRNA levels after indicated siRNA treatment in GFP-LC3-HEK cells as 
measured by qRTPCR. 
 
As shown in Chapter 5, Figure 5.12, knock-down of WAC with duplex-03 and -
04 led to an inhibition of LC3 lipidation in HeLa cells and I show again here that these 
two duplexes also decrease GFP-LC3 spots and WAC message levels in GFP-LC3-
HEK cells (Figure 7.3, part a,b,e,f).  As duplex-01 and duplex-02 also reduced GFP-
LC3 spots and WAC mRNA levels (Figure 7.2), I ordered these two duplexes and tested 
them along side duplex-03 and -04.  Duplex-02 was as efficient at decreasing GFP-LC3 
spots, WAC mRNA and LC3 lipidation in HeLa cells but again duplex-01 was least 
able to inhibit GFP-LC3 spots and LC3 lipidation (Figure 7.3, part a,b,c,d), most likely 
as a result of its inability to reduce WAC mRNA levels to the extent of the other three 
Dharmacon siRNA duplexes.  
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Figure 7.3 All four Dharmacon WAC siRNA duplexes reduce autophagy and do so 
in an mRNA dose-dependent manner 
a. GFP-LC3 confocal images at 63x after knock-down with indicated siRNA duplex and induction of 
autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. Images were captured with the same laser 
settings and levels were changed in Photoshop using the same adjustments. b. Quantification of WAC 
mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. Error bars represent the standard 
deviation derived from triplicate wells. c. Anti-Actin and -LC3 blot after indicated siRNA treatment in 
HeLa cells and incubation in full medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). d. 
Quantification of LC3II/LC3I after indicated siRNA and incubation conditions. LC3II/LC3I values for 
siWAC-01 and siWAC-02 are the averages of duplicates. The experiment was done twice; representative 
blots are shown. e. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and 
incubation in FM ES or EL. f. Quantification of LC3II/LC3I after indicated siRNA and incubation 
conditions. LC3II/LC3I values for siWAC-03 and siWAC-04 are the averages of duplicates. The 
experiment was done four times; representative blots are shown. 
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Next I asked whether WAC could be shown to be a positive regulator of 
autophagy using an alternate assay, p62 degradation.  As discussed previously, p62 is 
specifically degraded by autophagosomes and its lack of degradation during starvation 
indicates a defect of autophagy.  After starvation the levels of p62 decrease in RISCfree 
control siRNA-treated cells (Figure 7.4, panel a).  Knock-down of ULK1 or WAC 
inhibits p62 degradation and the protein accumulates.  Interestingly, the levels of p62, 
when normalised to actin loading, are higher in siWAC-treated cells as opposed to 
siULK1 treated cells perhaps suggesting that WAC is also required for the non-
autophagic degradation of p62 by ubiquitin-proteasome system (Figure 7.4, panel b).  I 
confirmed that WAC mRNA levels were depleted in this experiment (data not shown) 
but also wished to confirm that the increase in p62 levels after WAC knock-down was 
not due to an transcriptional upregulation of the p62 gene.  To these ends, I plated GFP-
LC3-HEK cells at the same density as those used in the p62 degradation assay described 
here and measured p62 mRNA levels by qRTPCR.  Unexpectedly, knock-down of 
WAC decreased p62 mRNA levels (Figure 7.4, panel c) confirming that the 
accumulation of p62 after knock-down is due to a post-translational event. 
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Figure 7.4 Knock-down of WAC leads to an accumulation of p62 
a. Anti-p62 and -actin blot after indicated siRNA treatment in GFP-LC3-HEK cells and incubation in full 
medium (FM) or EBSS (ES) for 4 hours. b. Quantification of p62/actin after indicated siRNA in 
starvation conditions (EBSS for 4 hours). The experiment was done twice; representative blots are shown. 
c. Quantification of p62 mRNA levels in GFP-LC3-HEK cells after RISCfree or WAC knock-down as 
determined by qRTPCR. This experiment was done once. 
 
Three siRNA duplexes against WAC manufactured by Ambion were also tested 
for their ability to knock-down WAC and modulate autophagy.  All three siRNA 
duplexes reduced GFP-LC3 spots and WAC mRNA levels (Figure 7.5, panel a,b).  
Duplex-55 was best at decreasing GFP-LC3 spots and endogenous LC3 lipidation in 
HeLa cells.  Duplex-53 did not inhibit LC3 lipidation perhaps because Duplex-53 does 
not target WAC isoforms Q9BTA9.2 and Q9BTA9.3 (Figure 7.1).  It should, however 
be noted that the effectiveness of knock-down is questionable in this experiment 
because ULK1 knock-down is not having a strong effect on LC3 lipidation.  Of the 
seven WAC siRNA duplexes tested, five greatly reduce WAC mRNA levels and inhibit 
autophagy as measured by LC3 lipidation. 
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Figure 7.5 Ambion siRNA duplexes against WAC decrease GFP-LC3 spots, WAC 
mRNA levels and LC3 lipidation to various extents 
a. GFP-LC3 confocal images at 63x after knock-down with indicated siRNA duplex and induction of 
autophagy by incubation in EBSS plus 0.25mg/mL leupeptin. Images were captured with the same laser 
settings. b. Quantification of WAC mRNA levels in GFP-LC3-HEK cells as determined by qRTPCR. 
Amb siC1 is Ambion siControl pool 1. Error bars represent the standard deviation derived from triplicate 
wells. c. Anti-Actin and -LC3 blot after indicated siRNA treatment in HeLa cells and incubation in full 
medium (FM), EBSS (ES) or EBSS plus 0.25mg/mL leupeptin (EL). d. Quantification of LC3II/LC3I 
after indicated siRNA and incubation conditions. Amb siC2 is Ambion siControl pool 2. LC3II/LC3I 
values for siWAC-53, siWAC-54, and siWAC-55 are the averages of duplicates. The experiment was 
done twice; representative blots are shown. 
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I next attempted to clone WAC into a mammalian expression vector in order to 
measure the effect on autophagy after WAC overexpression.  I obtained the open 
reading frame corresponding to the canonical isoform, NM_016628, and cloned WAC 
into pcDNA3.1(-) adding a myc tag to either the N- and C-terminals or a FLAG tag to 
the C-terminal of the WAC ORF.  None of these three constructs expressed in HEK 
cells after transfection, as measured by anti-myc or anti-FLAG blotting.  Xu and 
Arnaout also attempted to overexpress a FLAG-tagged WAC construct but could not 
detect the fusion protein in three cell-lines tested including HEK and HeLa cells (Xu 
and Arnaout, 2002).  After overexpression followed by immuno-concentration and 
western blotting, the authors did detect a band of 93 kDa that they conclude is a 
tyrosine-phosphorylated form of the protein. 
We generated rabbit polyclonal antibodies against two N-terminal peptides and a 
C-terminal peptide of WAC.  We affinity purified the serum of a rabbit immunised 
against NT2 (Figure 7.1) and I probed HEK cell lysates treated with either RISCfree 
control siRNA or WAC Dharmacon siRNA duplexes -01 through -04 with this anti-
WAC antibody.  In RISCfree knock-down cell lysates, WAC appears as a doublet band 
with the upper band migrating at approximately 81 kDa and the lower band at 72 kDa 
(Figure 7.6, panel a).  These two bands could represent WAC isoforms 1 and 2 though 
they are migrating slower by SDS-PAGE than their predicted molecular weights of 71.5 
and 65.5 kDa respectively.  One possibility is that both isoforms are post-translationally 
modified.  Another possibility is that the major, upper band is a post-translationally 
modified version of isoform 1.  For instance, the addition of ubiquitin would add 8.5 
kDa to the molecular weight of WAC, though it is unusual that this modified form 
would make up such a large percentage of the overall protein pool.  Both protein bands 
are however specific to WAC, as their levels are reduced after knock-down with the 
four WAC siRNA duplexes.  The extent of reduction correlates with the decrease of 
WAC mRNA levels of corresponding lysates (Figure 7.6, panel b).  The amount of 
WAC protein does not appear to change after cells were incubated in starvation 
medium. 
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Figure 7.6 WAC antibody by western blot 
a. Anti-WAC and -Actin blots after HEK cells are treated with the indicated siRNA and incubated in full 
medium (FM) or EBSS (ES) for 2 hours. siW is siWAC. b. Relative WAC mRNA levels after indicated 
siRNA treatment in HEK cells corresponding to a. 
 
When examined by immunofluorescence, endogenous WAC displays both a 
nuclear and cytoplasmic staining pattern though the majority of the protein appears to 
be nuclear and reside in subdomains, similar to the FLAG-tagged WAC expression 
pattern seen previously (Xu and Arnaout, 2002) (Figure 7.7, panel a,b).  Indeed, WAC 
has a predicted nuclear localisation signal (NLS) in the middle of its protein sequence.  I 
do not observe WAC on the plasma membrane suggesting that it does not interact with 
polycystin 1 as it did by yeast-two-hybrid (Xu and Arnaout, 2002).  But I do observe 
cytoplasmic WAC found on punctate structures that, when present, occur throughout 
the non-nuclear cell area.  Strangely, not every cell displays this punctate WAC 
staining.  The levels of WAC protein, the percentage of cells that display the punctate 
WAC staining, and the number of WAC puncta do not change after the cells are 
incubated in EBSS (Figure 7.7, panel a).  After knock-down of WAC, the nuclear pool 
of the protein is drastically reduced, and some reduction in the number of cytoplasmic 
vesicular structures is observed. 
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Figure 7.7 WAC is seen in the nucleus and cytoplasm of HEK cells, in the nucleus 
of GFP-LC3-HEK cells and is depleted by siRNA knock-down 
a. HEK cells are incubated in full medium or EBSS, fixed, and labelled with anti-WAC antibody.  Images 
were captured at 63X magnification or a zoomed area, indicated by boxes. b. HEK cells are treated with 
RISCfree siRNA or a pool of siWAC duplexes -02,-03, and -04, incubated in EBSS for 2 hours, fixed, 
and labelled with anti-WAC antibody. c. GFP-LC3-HEK cells are incubated EBSS, fixed, and labelled 
with anti-WAC antibody. 
 
I next asked whether the punctate cytoplasmic WAC structures colocalise with 
GFP-LC3 spots in GFP-LC3-HEK cells.  Such colocalisation was not seen (Figure 1.7, 
panel c) and surprisingly, the occurrence of cytoplasmic WAC structures seemed to be 
decreased in the GFP-LC3-HEK cell line compared to HEK293s, though this has not 
Chapter 7. WAC 
 223 
been quantified.  Of note, WAC does not contain a LIR domain, or LC3 interacting 
region, thought to comprise of the amino acids sequence DWxxL (Kirkin et al., 2009). 
I determined that cytoplasmic WAC did not colocalise with GFP-LC3 but asked 
with what other autophagy markers it could be found together in HEK cells.  As I 
showed that WAC is required for the degradation of p62, I double-labelled cells with 
WAC and p62 and saw that WAC could be found on a small number of p62-positive 
puncta though a vast amount of colocalisation was not seen (Figure 1.8, panel a, b).  I 
triple-labelled HEK cells with p62 and GABARAP in order to determine whether WAC 
punctate structures are positive for an alternate mammalian Atg8 family member, 
GABARAP.  Again, one or two WAC and p62 double positive vesicular structures were 
seen and also, GABARAP is seen to colocalise with WAC on small and large 
cytoplasmic structures (Figure 7.8, panel b).  I next asked whether WAC was found 
together with the early autophagosome marker Atg12 and saw that though GABARAP 
does colocalise with Atg12 and WAC again is seen together with GABARAP on 
vesicular structures these puncta are mutually exclusive for WAC and Atg12 and no 
triple-staining of WAC, GABARAP and Atg12 is seen (Figure 7.8, panel c). 
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Figure 7.8 WAC can be found on p62-positive puncta and colocalises with 
GABARAP, but not with Atg12 
a. HEK cells were incubated in EBSS for two hours, fixed, and labelled with anti-WAC and anti-p62 
antibodies. Enlarged inset shown in merge panel. Scale bar equals 5µm. b. HEK cells were treated with 
RISCfree control siRNA, incubated in EBSS for two hours, fixed, and labelled with anti-WAC, anti-
GABARAP and anti-p62 antibodies. Yellow arrows represent WAC and GABARAP colocalisation. Cyan 
arrows show WAC- and p62-positive structures. Purple arrows show GABARAP- and p62-positive 
structures. c. HEK cells were treated with RISCfree control siRNA, incubated in full medium plus 
0.25mg/mL leupeptin for 24 hours, fixed, and labelled with anti-WAC, anti-GABARAP and anti-Atg12 
antibodies. Yellow arrows represent WAC and GABARAP colocalisation. Purple arrows represent 
GABARAP- and Atg12-positive structures. 
 
Unlike SCOC, WAC does not overlap with the markers of early autophagosome 
formation events, Atg12 and LC3.  Instead, WAC is occasionally found on p62-positive 
structures and shows more extensive overlap with GABARAP.  Though both LC3-like 
and GABARAP-like Atg8 family members have been shown to be present in cells and 
are required for mammalian autophagy to properly occur, recent research suggests that 
the two proteins perform functions at different stages (Weidberg et al., 2010).  
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Specifically, Weidberg et al propose that LC3s act at the earlier stages of 
autophagosome membrane elongation while GABARAPs act slightly later and are 
perhaps required for the closing or sealing the autophagosome.  One possibility 
therefore is that WAC is also required for the sealing of the autophagosome and 
cooperates with GABARAP to do so.  Of note, WAC does not colocalise with the 
lysosomal marker LAMP2 suggesting that WAC is not acting on autophagosomes at the 
stage where they fuse with lysosomes. 
Because I know that WAC is required for LC3 lipidation and have seen that 
WAC and GABARAP colocalise, I assessed GABARAP lipidation by western blotting 
after knock-down of WAC.  Knock-down of WAC decreased the amount of 
GABARAPII seen in starvation conditions (EBSS and EBSS plus leupeptin) as knock-
down of ULK1 did.  However, knock-down of WAC did not appear to decrease 
GABARAP lipidation in full medium as ULK1 knock-down did (this experiment was 
done once, data not shown). 
In order to show that WAC can be found together in the cell with proteins 
suggested to be WAC binders by yeast-two-hybrid I performed immunofluorescence 
experiments with UBQLN4 and an overexpressed huntingtin fusion protein.  
Endogenous UBQLN4 appears in the nucleus and cytoplasm of HEK cells and 
extensive overlap of the two proteins is seen in the nucleus of the cell and occasional 
overlap in seen in cytoplasmic structures (Figure 7.9, panel a).  I have not, however, 
determined if the UBQLN4 staining is specific, for instance by knocking down 
UBQLN4 and comparing the endogenous UBQLN4 staining to a control.  In order to 
visualise the degree to which WAC overlaps with huntingtin protein, I overexpressed a 
mutant form of Htt in which exon 1 contained an abnormally expanded stretch of 80 
glutamine repeats which was fused to GFP which has been shown to provide a cellular 
model for Huntington’s disease (Tower et al., 2010).  After transfection of HEK cells 
with this GFP-HttQ80 construct, I observed cells with various degrees of 
overexpression of the fusion protein and also various degrees of its aggregation.  In a 
cell with some GFP-HttQ80 aggregation I saw some WAC staining on these 
cytoplasmic structures (Figure 7.9, panel b).  Although, as discussed above, WAC 
expression has been shown to be altered in Huntington’s disease and its upregulation 
perhaps suggests that WAC and mutant Htt do interact.  It would also be interesting to 
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ask whether WAC colocalises with wild-type huntingtin fragments, replicating the 
yeast-two-hybrid data (Kaltenbach et al., 2007). 
 
Figure 7.9 WAC shows partial co-occurrence with endogenous UBQLN4 and 
overexpressed, mutant Htt 
a. HEK cells were fixed and labelled with anti-WAC and anti-p62 antibodies. Arrows show instances of 
co-occurrence b. HEK cells were transfected with GFP-HttQ80, fixed and labelled with anti-WAC 
antibodies. Arrows show instances of co-occurrence. 
 
7.3 Regulation of WAC by ULK1 
While analysing multiple experiments involving WAC knock-down and knock-
down of ULK1 as a control, I noticed that WAC protein levels were decreased when 
ULK1 was knocked down.  After HEK cells are treated with an siRNA duplex targeting 
ULK1, both the upper a lower molecular weight bands of WAC are less (Figure 7.10, 
panel a).  Additionally, knock-down of WAC also appears to decrease the amount of 
ULK1 protein seen by western blot (Figure 7.10, panel b).  Taken together, these results 
suggest that ULK1 is regulating WAC protein levels and reciprocally, WAC is 
regulating ULK1 protein levels though I have not investigated whether this is occurring 
by destabilisation or some other mechanism.  In order to visualise this decrease in HEK 
cells and ascertain whether this ULK1-mediated decrease was affecting the nuclear or 
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cytoplasmic pool of WAC, I examined endogenous WAC staining by 
immunofluorescence after ULK1 knock-down.  Though the overall amount of WAC 
protein seemed to be slightly diminished after ULK1 siRNA treatment, what was more 
striking was the reduction of cytoplasmic WAC vesicular structures (Figure 7.10, panel 
c).  This was quantified using large panels of cells and IMARIS software. 
 
Figure 7.10 Knock-down of ULK1 decreases WAC protein levels and the 
occurrence of WAC-positive cytoplasmic puncta 
a. Anti-WAC and -Actin blots after knock-down with an ULK1 or WAC siRNA duplex or RISCfree 
control. This experiment was done four times, a representative blot is shown.  b. Anti-ULK1 and -Actin 
blots after knock-down with an ULK1 or WAC siRNA duplex or RISCfree control. This experiment was 
done twice. c. Two confocal images at 63x per condition of HEK cells treated with RISCfree control or 
ULK1 siRNA, starved for two hours, fixed and labelled with anti-WAC antibody. This experiment was 
done once. 
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As ULK1 is a kinase, one way that ULK1 could potentially regulate WAC is 
through phosphorylation.  Xu and Arnaout propose that WAC has a great potential for 
regulation by other proteins because it is enriched for proline, serine and threonine 
residues (Xu and Arnaout, 2002).  9.4% of its amino acid sequence consists of proline 
residues, which are possible binding sites for other proteins.  But also, WAC is rich in 
serines and threonines (15.8% and 7.1% respectively) and these amino acids are 
potential phosphorylation sites.  In fact, WAC has 25 listed phosphorylation sites and 
one potential acetylation site at site 302 (Figure 7.11).  WAC could be signalled to 
move in or out of the nucleus by phosphorylation, possibly by ULK1, and WAC’s 
cellular distribution and translocation to or exclusion from the nucleus could control 
autophagy initiation. 
 
Figure 7.11 Putative post-translation modifications of WAC 
Schematic obtained from HPRD of WAC protein sequence with potential sites of post-translational 
modifications. WW is the WW domain. Red-tipped lines represent phosphorylation sites; the green-
tipped line represents a potential acetylation site. 
 
7.4 WAC and the Ubiquitin-Proteasome system 
WAC is reported to bind ubiquilin 4, the UBQ- and UBA-domain containing 
ubiquitin-specific protease and I have shown that WAC can be found together with 
UBQLN4 and p62, the ubiquitin-binding autophagy and proteasome substrate (Figure 
7.9a, Figure 7.8a, respectively).  I have also shown that WAC is required for the 
degradation of p62 perhaps beyond that of a protein that is merely required for 
autophagy.  In turn, I wished to examine the role of WAC in the ubiquitin-proteasome 
system (UPS) and determine whether WAC is required for this degradation system.  To 
these ends, I measured the effect of WAC knock-down on two UPS reporter cell lines 
stably over-expressing the ubiquitin mutant UbG76V fused to GFP or YFP.  This fusion 
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protein is properly folded and soluble but the mutation prevents cleavage of the Ub 
from the GFP, targeting the fluorescent protein to the proteasome and thus serves a 
read-out for the efficiency of the UPS (Dantuma et al., 2000), (Menendez-Benito et al., 
2005).  When the UPS is compromised, for example after treatment with the 
proteasome inhibitor MG132, the UbG76V-GFP or UbG76V-YFP accumulates in the cell 
and can be quantified by western blotting or immunofluorescence.  First I tested the 
effect of WAC and ULK1 knock-down HeLa UbG76V-GFP cell line.  In RISCfree-
treated cells, the fusion protein, which runs at approximately 39 kDa, is detected in full 
medium, its amounts decrease during starvation and starvation in the presence of 
leupeptin and drastically increases when the proteasome is inhibited with MG132 
(Figure 7.12, panel a).  Treatment with WAC and ULK1 siRNA did not alter the 
amount of UbG76V-GFP detected in full medium.  This contrasts recent work by 
Korolchuk et al who show that inhibition of autophagy with siRNA against ATG7 and 
ATG12 impaired proteasomal degradation, which they determine is due to the 
autophagy deficiency-specific accumulation of p62 (Korolchuk et al., 2009).  As before, 
I observed that ULK1 knock-down slightly decreased cellular WAC levels and vice 
versa.  Surprisingly, I noticed a significant decrease in p62 levels after WAC 
knockdown as detected by western blot, even in starvation conditions when I had 
previously seen an accumulation of p62, though in a different cell line, GFP-LC3-HEK 
cells and after a longer starvation period.  As before, I performed qRTPCR to determine 
the effect of WAC knock-down on p62 mRNA levels and again observed a decrease in 
p62 transcription (Figure 7.12, panel b). 
I again employed the UPS reporter system but in a different cell line, the MelJuSo 
melanoma, that the authors claim are easy to transfect, accumulate reporter very well 
upon inhibition of the UPS and are excellent for imaging purposes (Menendez-Benito et 
al., 2005).  This time I observed a decrease in the amount of UbG76V-YFP after WAC 
knock-down suggesting that degradation via the proteasome was proceeding at a greater 
rate.  I observed that the cell line contained vastly more amounts of LC3II compared to 
LC3I suggesting a very high rate of basal autophagy (data not shown).  I also examined 
endogenous WAC staining in these cells and did not see colocalisation of WAC and 
UbG76V-YFP in full medium or starvation conditions (data not shown). 
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Figure 7.12 The effect of WAC knock-down on UPS reporter cell lines 
a. Anti-ULK1, -WAC, -p62, -Actin, and -GFP blots after HeLa UbG76V-GFP cells were knocked down 
with ULK1 or WAC siRNA or RISCfree control.  Cells were incubated in full medium (FM), EBSS (ES), 
EBSS plus 0.25mg/mL leupeptin (EL) or 10µM MG132 (MG) for two hours. This experiment was done 
once. b. Relative p62 mRNA levels after HeLa UbG76V-GFP cells were knocked down with WAC siRNA 
or RISCfree control as measured by qRTPCR with p62 primers. c. Anti-WAC, -Actin and -GFP blots 
after MelJuSo UbG76V-YFP cells were knocked down with WAC siRNA or RISCfree control.  Cells were 
incubated in full medium (FM), EBSS (ES), EBSS plus 0.25mg/mL leupeptin (EL) for two hours. This 
experiment was done once. 
 
To summarise, WAC is very thoroughly validated in that the siRNAs have a 
reliable effect on autophagy assays consistent with WAC being a positive regulator of 
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autophagy.  Though I was unable to overexpress tagged versions of the protein, we have 
made an affinity purified antibody that detects endogenous WAC by western blot and in 
the cell by indirect immunofluorescence.  WAC colocalises with autophagy markers, 
GABARAP and p62 but not Atg12 and LAMP2.  Its protein levels may influence 
ULK1 and conversely, in the absence of ULK1, WAC may be destabilised.  WAC is 
also required for p62 degradation and its knock-down possibly affects the ubiquitin-
proteasome system. 
7.5 WAC discussion 
In HEK cells, endogenous WAC is seen mostly in the nucleus of the cell but also 
in the cytoplasm.  Often, cytoplasmic puncta are seen and when a cell does have these 
puncta there seem to be quite a lot of them, but their occurrence does not seem to 
increase upon starvation (Figure 7.7).  Occasionally, these puncta overlap with 
GABARAP and p62 but WAC is not found with a marker for the isolation membrane, 
Atg12 (Figure 7.8).  It has been suggested that GABARAP is required for the sealing of 
the autophagosome (Weidberg et al., 2010) and it would be interesting to ask whether 
WAC is also required for sealing autophagosomes.  It would also be interesting to ask 
whether WAC directly interacts with GABARAP.  Though WAC does not possess a 
canonical LIR (DWxxL), there is an amino acid stretch towards the C-terminal of WAC 
with the sequence FSENL.  Recently, it has been suggested that the sequence FxxL, 
when the first x is acidic, can also serve as an LC3 interacting region (Terje Johansen, 
Autophagy GRC, 2010) and the sequence FSENL, with Glutamate (E) being an acidic 
residue, could fit that model.  If it were determined that WAC and GABARAP interact 
it could be asked whether this interaction requires the FSENL region and if the 
interaction is in turn required for WAC’s positive regulation of autophagy.  
Interestingly, GABARAP has been crystallised (Bavro et al., 2002), so perhaps the 
potential binding region could be visualised and drug targets that disrupt this binding 
could be found. 
Only a subset of WAC puncta colocalise with GABARAP and it would be 
interesting to ask whether WAC colocalises with other vesicular markers such as those 
of endosomes (APPL1, EEA1, and Rab5 for early endosomes, Rab11 for recycling 
endosomes or VAC14 and LBPA for MVBs).  ULK1 is also found on vesicular 
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structures and as I have shown that ULK1 seems to regulate WAC levels, I would like 
to know if WAC and ULK1 interact in the cell.  Though I cannot test this endogenously 
(both antibodies are polyclonal) I could overexpress ULK1 and see if it colocalises with 
endogenous WAC.  One way that ULK1 could regulate WAC is by phosphorylation.  
Xu and Arnaout state that when they immunoprecipitate tagged WAC they visualise a 
band of approximately 93 kDa that is phospho-tyrosine positive (Xu and Arnaout, 
2002).  I performed a fractionation experiment in which cytosolic, membrane-bound 
and nuclear portions of HEK cells were separated and probed for WAC.  Surprisingly, a 
band of higher molecular weight (about 93 kDa) was seen in the nuclear fraction.  
Usually a post-nuclear supernatant (after a five minute spin at 12,000 rpm) is run when 
probing for WAC as in Figure 7.6.  But when the nuclear fraction is run, this higher 
band appears and interestingly, there appears to be less of this higher band when the 
cells are starved.  Like FOXO3 whose retention in the cytoplasm is the result of its 
phosphorylation by AKT1 (Brunet et al., 1999), WAC’s cellular distribution and 
translocation to or exclusion from the nucleus could similarly be controlled by ULK1 
and possibly as the result of autophagy initiation. 
As discussed above, there are many potential sites of phosphorylation on WAC 
(Figure 7.11) and another kinase that has the potential to regulate WAC is dystrophia 
myotonica-protein kinase (DMPK).  DMPK has been shown to interact with 
GABARAP (Stelzl et al., 2005) and both ubiquilin 4 and ataxin 1 (Lim et al., 2006).  A 
mutation in DMPK that leads to a repeat expansion of a region of the protein is linked 
to myotonic dystrophy (Boucher et al., 1995), and recently it was shown that 
overexpression of an isoform of DMPK with a long tail anchor led to fragmentation and 
clustering of mitochondria in a perinuclear region as well as increased autophagy (Oude 
Ophuis et al., 2009).  In my screen, knock-down of DMPK led to an increase in GFP-
LC3 spot parameters though only one of the four siRNA duplexes increased spots in the 
deconvolution screen (Appendix Table 9.5).  I observed an interesting cellular 
phenotype when examining DMPK knock-down cells after the repeat screen; the cells 
were large and multinuclear, suggesting a defect in cytokinesis.  Perhaps DMPK 
regulates autophagy by phosphorylating WAC or through interactions with WAC-
interacting proteins. 
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The data that I have presented regarding WAC and p62 is puzzling.  I have shown 
that knock-down of WAC inhibits p62 degradation and the increased amount of p62 is 
not due to an increased amount of p62 transcription because WAC knock-down actually 
decreases p62 mRNA levels (Figure 7.4).  I have shown that WAC is present in the 
nucleus and it was originally characterised as potentially involved in pre-mRNA 
splicing machinery and colocalises with a marker of the splicing complex (Xu and 
Arnaout, 2002).  Thus, WAC has the potential to regulate p62 mRNA levels but also its 
post-translational degradation.  Recently it was shown that p62 shuttles to the nucleus 
and upon treatment of cells with the nuclear export inhibitor leptomycin B (LMB), p62 
stays in the nucleus where it colocalises with PML bodies (Pankiv et al., 2010).  I asked 
whether WAC is also retained in the nucleus like p62 but found that it was not; after 
LMB treatment I did see p62 congregate in the nucleus and form aggregates similar to 
the PML bodies shown by Pankiv et al but nuclear WAC, did not visibly increase 
(though most WAC is in the nucleus of the cell normally) and did not colocalise with 
the p62 aggregates.  WAC is however seen to occasionally colocalise with p62 in the 
cytoplasm of the cell (Figure 7.8). 
WAC is also potentially linked to the UPS through another ubiquitin-interacting 
protein, ubiquilin 4.  WAC is reported to bind to ubiquilin 4 (Lim et al., 2006) and I see 
some colocalisation between the endogenous ubiquilin 4 and cytoplasmic WAC puncta 
(Figure 7.9).  I would like to perform a co-immunoprecipitation in HEK cells to 
determine if I can find the proteins together.  Recently, Rothenberg et al showed that 
LC3 and ubiquilin 1 co-immunoprecipitate; they could not, however, detect an 
interaction between their purified proteins, suggesting that there may be a common 
interacting partner that stabilises the interaction (Rothenberg and Monteiro, 2010).  
Perhaps WAC could bridge the interaction between ubiquilin 4 and GABARAP, for 
instance, thus aiding in the regulation of both the UPS and autophagy pathway by 
ubiquilins and helping ubiquilin to switch between the two.  Consequently, WAC may 
also serve as a switch between the two pathways.  Because WAC has a WW and a 
coiled-coil domain it may perform these functions by acting as an adaptor, bringing 
together components of the autophagy an UPS systems, such as ubiquilin 4.  Another 
WW-domain-containing protein, salvador homolog 1 which contains two WWs, 
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provides a scaffold for the kinases and other proteins that direct the Hippo pathway of 
growth regulation (Tapon et al., 2002). 
Preliminary experiments show that WAC may not be required for the UPS as its 
knock-down did not hinder the pathway (Figure 7.12).  Instead, knock-down of WAC 
seemed to increase the degradation of the UbG76V-YFP reporter in MelJuSo cells.  
Perhaps WAC inhibits the UPS, favouring autophagic degradation and when WAC is 
removed from the cell autophagy is inhibited but ubiquitin-mediated degradation is 
increased.  In this way, WAC may serve as an emergency brake for the UPS and this is 
how WAC toggles between the two pathways. 
WAC may also regulate aggrephagy; WAC and huntingtin were shown to 
interact through a yeast-two-hybrid experiment (Kaltenbach et al., 2007) and I have 
shown that WAC colocalises with aggregated HttQ80 (Figure 7.9).  I would like to 
confirm this interaction by co-IP and also ask whether WAC interacts with wild-type 
huntingtin as well as other aggregate-prone proteins.  WAC may be required for 
aggrephagy and this may explain why WAC is upregulated in the symptomatic stages of 
Huntington’s disease.  A recently study showed that a failure in cargo-recognition is 
responsible for the inability for autophagy to degrade huntingtin aggregates, causing 
them to accumulate and become more toxic (Martinez-Vicente et al., 2010).  The 
authors propose that there is an unknown factor, x, that recognises the cargo and allows 
it to be degraded by autophagy and perhaps WAC is this ‘x factor.’ 
WAC is an interesting new regulator of autophagy with additional ties to the 
ubiquitin-proteasome system and aggrephagy.  It is potentially highly regulated through 
multiple phosphorylation sites and may move in and out of the nucleus where it may 
affect transcription of autophagy proteins.  I have shown that cytoplasmic WAC 
structures colocalise with autophagy markers and also with ubiquilin 4, a protein with 
links to both autophagy and the UPS.  Perhaps through these functions and interactions, 
WAC is switch between autophagy, the UPS and a modulator of the degradation of 
aggregated proteins. 
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Chapter 8. Discussion 
 
In the preceding pages I have described a genome-wide screen for mammalian 
autophagy.  HEK cells stably expressing GFP-LC3 were knocked down with siRNA 
pools from the Dharmacon siGenome library and their ability to form GFP-LC3 tagged 
autophagosomes following amino acid starvation was assessed.  The strongest 
candidates from the primary screen (both ‘increasers’ and ‘decreasers’ of spots) were 
re-assayed in a secondary screen and 190 robust hits were taken forward to a 
deconvolution screen.  Of these, 20 genes had three out of four duplexes that repeated 
the primary spot phenotype and these were passed on for further validation.  During this 
more-labour-intensive screen I quantified mRNA levels of the target protein after 
knock-down, visualised the effect of knock-down on GFP-LC3-HEK cells by confocal 
microscopy and analysed LC3 lipidation in full medium, starvation medium and 
starvation medium plus a lysosomal inhibitor in a different cell line. 
siRNA for five genes targeted efficiently and decreased both GFP-LC3 spots and 
LC3 lipidation: LARP1, PAFAH1B2, SCOC, SUPT5H, and WAC.  Experiments with 
two of these genes, SCOC and WAC, prove that they are true positive regulators of 
autophagy and through directed experiments, possible mechanisms for their positive 
regulation of autophagy were uncovered.  These results confirm that the screen was 
successful in discovering bone fide autophagy proteins.  siRNA for four genes targeted 
efficiently and increased both GFP-LC3 spots and LC3 lipidation: KIF25, TLK2, 
RASIP1, and WDR6.  Though some of the results from the LC3 lipidation experiments 
should be repeated in order to confirm these findings, the seven genes that passed this 
further validation but not investigated further transcribe proteins with interesting 
binding partners and biological activities including a motor protein (KIF25) and a 
kinase (TLK2).  Of the seven proteins not investigated further, SUPT5H, KIF25, WDR6 
and TLK2 are potential drug targets and these drugs could become useful tools in the 
lab or even possible therapeutic agents in the clinic. 
I discussed in Chapter 4 how the screens could have been improved, but overall the 
data generated from the primary, secondary and deconvolution screens were robust.  All 
the data could be revisited or reanalysed and the information from the deconvolution 
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screen is especially valuable because individual siRNA duplexes were used.  When 
combined with data regarding the ability of that individual siRNA to decrease its 
target’s mRNA the GFP-LC3 spot data for all 190 genes is a valuable resource. 
In summary, with a genome-wide screen, I have identified a number of known and 
novel components of autophagy including SCOC, a Golgi protein, and WAC, an 
uncharacterised protein.  The proteins discovered may fill gaps in our knowledge of 
vesicle formation, regulation and even the source of the autophagosome membrane.  
Manipulation of autophagy in order to prevent and treat disease is a realistic goal and 
this work contributes towards that end. 
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Chapter 9. Appendix 
9.1 Further explanation of screen data normalisation 
9.1.1 B-score normalisation 
Since the distribution of the raw values of each plate differed, the GFP-LC3 spot 
parameters SCPO, STAPO and STIPO were normalised to a reference point on each 
plate (Fig. 4.2 A).  A B-score normalisation was performed in order to not only consider 
effects between plates, but also to account for any possible row or column effects.  B-
score normalisation is calculated for each well (W) in row i and column j on plate p by 
subtracting the estimated average of that plate (µp), the estimated offset of the well row 
(Rip) and the estimated offset of the well column (Cjp):  
Wijp = raw data value – (µp + Rip + Cjp ) 
 
The estimated row and column offsets are calculated by a two-way median polish 
(Tukey, 1960).  By applying the B-score normalization, edge and row effects were 
reduced and as a consequence comparison of values amongst the plates was now more 
accurate. 
 
9.1.2 Z-score normalisation 
In order to produce a ranked list of all screened genes, Z-scores for each well 
(Zijp) were calculated.  Z-scores represent the number of standard deviations away from 
a population mean and were calculated by dividing the well B-score (Wijp) by the 
median absolute deviation of the plate (MADp):  
Zijp  = Wijp /  MADp 
 
9.2 Screen data tables 
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Table 9.1 500plus genes whose siRNA knock-down increased GFP-LC3 spots in the 
primary screen 
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Table of approximately 500 best ‘increasers’. Rank based on rank product (RP); GeneID; Gene name; Dharmacon Smartpool catalogue number; SCPO for 3 replicates; STAPO for 3 replicates; STIPO for 3 replicates; Object count (OC) for three replicates; and rank product are shown. ND is not determined, as less than 50 valid objects were counted. Genes highlighted in blue are of interest and spoken of in the text. Genes highlighted in yellow were contained on plate 10 and not processed with screen plates. 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Table 9.2 500plus genes whose siRNA knock-down decreased GFP-LC3 spots in 
the primary screen 
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Table of approximately 500 best ‘increasers’. Rank based on rank product (RP); GeneID; Gene name; Dharmacon Smartpool catalogue number; SCPO for 3 replicates; STAPO for 3 replicates; STIPO for 3 replicates; Object count (OC) for three replicates; and rank product are shown. ND is not determined, as less than 50 valid objects were counted. Genes highlighted in blue are of interest and spoken of in the text. Genes highlighted in yellow were contained on plate 10 and not processed with screen plates. 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Table 9.3 Results of the repeat screen for a subset of Smartpools that cause an 
increase in GFP-LC3 spots 227 Smartpools are listed in order of primary and repeat screen combined rank product (not all 500 increasers are shown). Whether their images were examined, whether they were included in the subsequent deconvolution screen and whether I scored it as a non‐toxic, non‐off‐target repeat hit as a result of visual analysis are indicated. Toxicity and availability of a deconvoluted set of siGenome siRNA duplexes for that given Smartpool are indicated. It is noted whether the gene is annotated as a psudogene. Gene ID, current gene symbol and full name are given. The rank product that combines the primary and repeat screen rank products, and the primary screen rank product and repeat screen rank product as increasers is shown. The repeat screen SCPO, STAPO, and STIPO ranks (as increasers) and the repeat screen median SCPO score are shown. The repeat screen rank generated with the second set of 14 images as well as the valid object count (OC) for three replicates in the repeat screen are shown. Genes highlighted in blue are of interest and are referred to in the text. 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Table 9.4 Results of the repeat screen for a subset of Smartpools that cause a 
decrease in GFP-LC3 spots 226 Smartpools are listed in order of primary and repeat screen combined rank product (not all 500 decreasers are shown). Whether their images were examined, whether they were included in the subsequent deconvolution screen and whether I scored it as a non‐toxic, non‐off‐target repeat hit as a result of visual analysis are indicated. Toxicity and availability of a deconvoluted set of siGenome siRNA duplexes for that given Smartpool are indicated. It is noted whether the gene is annotated as a psudogene. Gene ID, current gene symbol and full name are given. The rank product that combines the primary and repeat screen rank products, and the primary screen rank product and repeat screen rank product as decreasers is shown. The repeat screen SCPO, STAPO, and STIPO ranks (as decreasers) and the repeat screen median SCPO score are shown. The repeat screen rank generated with the second set of 14 images as well as the valid object count (OC) for three replicates in the repeat screen are shown. Genes highlighted in blue are of interest and are referred to in the text. 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Table 9.5 Results of the deconvolution screen Gene ID and Gene symbol for the 190 genes tested in the deconvolution screen. Dharmacon siRNA catalogue number is shown for the 4 individual siRNA duplexes used. The median STIPO, SCPO, and STAPO scores, expressed as a percentage of RISCfree control are shown. If greater than 1.2 it is scored as a positive, if less than 0.8 then it is scored as a negative. The median valid object count (OC) for the three replicates is shown. The GFP‐LC3 spot phenotype from the primary screen (increaser or decreaser) and whether the individual siRNA duplexes, taken together, repeat this phenotype is indicated. If classed as a 2 out of 4 hit a yes is added in that column and if classed as a 3 out of 4 hit a yes is added in that column. (*) indicates a hit that is seen to be a 2 out of 4 here but with an alternate method of normalisation, could be classified as a 3 out of 4. (§) indicates genes with non‐universal expression patterns and were therefore not chosen 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Figure 9.1 SCOC isoforms A larger version of the schematic of SCOC isoforms corresponding to Figure 6.2. 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Figure 9.2 WAC isoforms A larger version of the schematic of WAC isoforms corresponding to Figure 7.1. 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